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Abstract
There is a growing need for synthetic bone graft materials, which is particularly apparent
for procedures requiring impaction bone grafting (IBG), such as revision hip arthroplasty.
Currently allograft bone is used that has limited supply and associated risks of transmission
of infectious agents.
Porous bioresorbable polymeric scaffolds can be created using supercritical carbon diox-
ide (scCO2). This thesis investigated the use of these scaffolds for impaction bone grafting
procedures. Building on previous research within the literature poly(D,L-lactide) (PDLLA)
and poly(D,L-lactide-co-glycolide) (PDLLGA) scaffolds of high molecular weight (≈100 kDa)
were investigated for this use. Scaffolds were milled using a standard bone mill and im-
pacted to create porous milled chips of bioresorbable scaffolds and impacted for mechanical
shear testing and biocompatibilities. The impaction process used forces equivalent to those
experienced during IBG.
In vitro cell experiments were used to assess the proliferation and osteoblastic differ-
entiation of mesenchymal stem cells (MSCs) on impacted scaffolds to identify the most
promising scaffold compositions. These compositions included pure polymer and poly-
mer:HA microparticle composites. Further experiments using animals (murine and ovine)
were then used to investigate the in vivo performance of the scaffolds. A critical sized ovine
femoral condyle defect established the osteoinductive and osteoconductive potentials of
milled scCO2 foamed PDLLA + 10 wt.% hydroxyapatite (HA) microparticle scaffolds in vivo.
The scale-up potential of scCO2 foaming of bioresorbable scaffolds was established using
a 1 L vessel. Scaffolds scCO2 foamed using either a 60 ml autoclave or a 1 L vessel were char-
acterised using scanning electron microscopy and micro computed tomography. Scaffolds
from different batches were characterised and compared to ensure process repeatability was
accounted for.
The final chapter investigated differences in the osteoblastic differentiation of MSCs on
PDLLA and PDLLGA scaffolds observed in experiments at the start of the study. Spincoated
and dipcoated flat films of PDLLA, PDLLGA, and PDLLA:PDLLGA (50:50) were used for
in vitro cell culture to remove the effect of morphological differences that affected scCO2
foamed scaffold experiments. Additionally, this chapter investigated the effect of the form of
iii
HAusing HA nanoparticles andHAmicroparticles in scCO2 foamed PDLLA:HA composites
for in vitro studies.
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1.1 Background
1.1.1 Regenerative medicine, tissue engineering, and biomaterials
Mason and Dunhill succinctly described regenerative medicine as replacing or regenerating
human cells, tissue or organs, to restore or establish normal function [6]. Longer descrip-
tions of the term precededMason and Dunhill’s widely cited paper [7–9]. Tissue engineering
predates regenerative medicine as a term, having first been used to describe the use of pros-
thetic devices and surgical manipulation of tissues [10], and defined more recently as "an
interdisciplinary field that applies the principles of engineering and the life sciences toward
development of biological substitutes that restore, maintain, or improve tissue function"
[11]. Prior to Langer and Vacanti’s paper defining tissue engineering, [11] they undertook
studies to generate functional tissue equivalents utilising biodegradable and biocompatible
polymer scaffolds seeded with viable cells [10, 12]. Published reference to tissue engineering,
as currently understood, can be dated back to 1991 [13]. In literature today the terms "tissue
engineering" and "regenerative medicine" are widely used interchangeably, although typi-
cally a fully regenerative medicine solution will leave no residues within the body, while a
tissue engineered solution requires no such condition be met.
Tissue engineering and regenerative medicine are fields that are relatively new and grow-
ing, and have generated large amounts of research due to high levels of funding in recent
years. A report from the U.S. Department of Health and Human Services in 2004 highlighted
regenerative medicine as an important interdisciplinary field with huge potential to deliver
treatments; bone substitutes along with skin and cartilage substitutes were some of the early
regenerative medicine products to reach the market [14].
The high levels of funding for these research fields that have been observed are due
to the medical need for solutions. Currently, organ failure or tissue loss is treated through
mechanical devices, organ transplantation, or surgical reconstruction and these solutions
savemany lives. Mechanical devices (e.g. dialysis machines) that fail to perform all functions
of the organ they replace merely reduce, rather than halt, patient deterioration. In the case of
organ transplantation, the need outweighs demand and many people die awaiting a donor.
For example over 16,000 people died of liver disease within the U.K. in 2008 [15], and over
33,000 people died of chronic liver disease within the U.S.A in 2011 [16]; both countries have
a rising trend in deaths caused by liver disease, which could be tackled with an abundance
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of suitable donor organs.
Various approaches to regenerating tissue have been investigated. They include: the
implantation of cells of the required function, which may not be retained following im-
plantation or immunologically rejected; the use of signal molecules such as growth factors,
and delivery mechanisms of such factors, to induce tissue growth; and cellular scaffolds to
guide and induce tissue growth within the body. Combinations of such techniques are typi-
cally used with biodegradable scaffolds seeded with cells prior to implantation and signal
molecules embedded or otherwise incorporated within the scaffolds, which act as a targeted
delivery device.
Three-dimensional (3D) constructs, or scaffolds, are typically designed to mimic the ex-
tracellular matrix (ECM) (connective tissue that supports and surrounds cells) of the tissue
to be replaced, either morphologically (form or structure), topographically (surface features),
and/or chemically. Ideal tissue engineering scaffolds should be highly porous with intercon-
nected pores; biocompatible and bioresorbable; have suitable surface chemistry to support
cell attachment, proliferation, and differentiation; and mechanical properties that match
tissues at the implantation site [17]. Interconnected porous networks allow cellular prolifer-
ation throughout entire scaffolds, tissue in-growth where appropriate (such as bone repair),
and transport of nutrients and waste.
The journal, Biomaterials, defined a biomaterial as "a substance that has been engineered
to take a form which, alone or as part of a complex system, is used to direct, by control of
interactions with components of living systems, the course of any therapeutic or diagnostic
procedure". A more simple and commonly used definition, which is subscribed to within
this thesis is "any material that is used to replace or restore function to a body tissue and is
continuously or intermittently in contact with body fluids", taken from Biomaterials science
and engineering by Park [18]. This definition excludes external prostheses (e.g. artificial
limbs, hearing aids) and surgical instruments [19]. Importantly it includes the materials
that form cellular scaffolds implanted within the body to promote regeneration of tissue
and restore function. The majority of biomaterials in use are either metals, ceramic, poly-
mers, or naturally derived materials. All are required to be biocompatible (should not elicit
adverse responses), noncarcinogenic, and nontoxic [19]. Additionally, appropriate mechan-
ical properties are required for the appropriate function (e.g. appropriate strength in a hip
prosthesis).
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In tissue engineering naturally derived materials are desirable for cellular scaffolds be-
cause of their similarity to in vivo ECM. For example collagen, which forms a significant
component of bone and connective tissues, is the major component of mammalian tissue
ECM (25% total protein mass [20]), and has been widely studied for use in various scaffolds
[20–24], which include skin replacements [25–27], and bone substitutes [28, 29]. Variation be-
tween batches and possible immune responses to naturally derivedmaterials are obstacles to
their use in commercially viable products. Despite this collagen is used in Apligraf R©, a com-
mercially available and Food and Drug Administration (FDA) approved skin regeneration
treatment for diabetic ulcers.
Metals are primarily used for their strength in joint prostheses or screws and supports.
Research in coatings for metal prostheses has been reported in the literature with aims to
improve integration with the body by reducing wear, promoting bone in-growth into porous
coatings, and/or providing osteoinductive surfaces [30–32]. Ceramics, such as β-tricalcium
phosphate or hydroxyapatite, are often used for this purpose [30, 31], or to replace bone as
extenders of graft material [33]. The properties of polymers can differ greatly with different
polymer blends, cross-linking, or variations in molecular weight (MW), which suits them to
a wide range of functions. Some examples of which include the use of: ultrahigh-molecular-
weight polyethylene (UHMWPE) as a bearing material in joint prostheses; polylactide and
polyglycolide in biodegradable sutures; polytetrafluoroethylene in stents; polydimethyl
siloxane and polyurethane in facial prostheses; and polymethylmethacrylate as a bone ce-
ment [19].
1.1.2 Hip arthroplasty and revision hip arthroplasty
Sir John Charnley invented the modern hip replacement composing of a metal femoral stem
and head and an acetabular cup in the 1960s; it is one of the most cost-effective surgical pro-
cedures [34], and one of the most successful orthopaedic procedures. Total hip replacement
is predominantly performed in order to treat osteoarthritis, where articular cartilage in the
hip joint has worn away resulting in bone rubbing against bone in the joint, causing pain.
The main aims of the replacement joint are to eliminate the pain osteoarthritis causes and
improve quality of life, function of the joint, and mobility.
The number of hip replacements being performed is increasing annually. In 1996 over
62,000 hip replacements were performed [35] while in 2011 over 88,000 hip procedures were
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carried out in England and Wales according to the National Joint Registry [36]. While the
number of procedures, which includes both primary and secondary replacements, continues
to increase the proportion of revised/secondary replacements is also increasing; from 9% of
total procedures in 2007 to 11% of the total in 2011.
1.1.2.1 Primary hip arthroplasty
In total hip arthroplasty (surgical repair of joint) the articular surfaces of the femur and
acetabulum are replaced. Figure 1.1 shows a typical hip femoral stem and an acetabular cup
prostheses. The socket is replaced with an artificial socket which can either be a polymer
cup that is cemented into place, or a metal socket which can be inserted tightly in to the joint
with no cement and more firmly attached with screws if required. The head of the femur is
replaced with a metal ball attached to a stem either as a complete singular piece or using
modular components. The stem is attached to the femur and this can be donewith orwithout
the use of bone cement. In 2011 in England and Wales 44% of the total number of primary
hip procedures were cementless, 36% were cemented, and 18% were hybrid procedures (the
remain 2% were resurfacing procedures) [36].
Unfortunately, a hip replacement does not last for life and revision surgery may have
to be performed at a later date. Hip replacements currently last approximately 10–15 years
and can fail in a number of ways: loosening of the socket and/or femoral component, infec-
tion, bone loss on socket and/or femoral side, unstable or dislocating hips, or subsidence of
femoral prosthesis. Aseptic loosening is the primary cause of primary hip replacement fail-
ure and of the need for revision surgery. This aseptic loosening is caused by wear particles
from the joint inducing osteolysis (bone matrix resorption by osteoclasts - bone resorbing
cells) [38, 39]. Osteolysis occurred in the absence of identifiable metallic or polymethyl-
methacrylate particles and in the presence of polyethylene particles [40] and the mechanism
by which polyethylene wear particles induced osteolysis is complex [41, 42]. The size, mor-
phology, and concentration of wear particles was shown to have a significant effect on bone
resorbing activity [41, 43]; Green et al. [43], for example, demonstrated polyethylene particles
<2 µm stimulated bone resorption, while particles >8 µm did not, at a range of different con-
centrations. Cellular responses to wear particles entail inflammatory and osteoclastogenic
cytokine secretion, which exacerbate normal osteoclast activity and enhance osteolysis [42].
Bone resorption by osteoclasts is a normal process in healthy bone as bone is remodelled nat-
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Figure 1.1: The stem, socket and centraliser of an Exeter Universal hip joint prosthesis (A)
and an x-ray radiograph of an Exeter prosthesis cemented in place (B) [37].
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urally; a balance is maintained between bone formation by osteoblasts and bone resorption
by osteoclasts. Enhanced osteoclast activity leads to loss of bone around the implant and
subsequent loosening leading to failure of the prosthesis; hip replacement failure results in
the need for revision surgery.
1.1.2.2 Revision hip arthroplasty
Revision hip arthroplasty is more complicated than primary total hip arthroplasty because
each patient brings individual causes for prosthesis failure. In a retrospective review of
reasons for revision hip surgery, Clohisy et al. [44] reported that of 439 revision procedures
carried out in 1996 55% were for aseptic loosening, 14% were for instability, 13% were for
osteolysis, 7% were due to infection, and the remaining were for fractures of the implant or
around the prosthesis (periprosthetic), conversion of hemiarthroplasty, and loose implants.
Additionally, safe removal of the previous prosthesis and ensuring a stable base for the new
prosthesis complicates the procedure. The number of hip revisions performed is growing
annually, as is the percentage of these that are revised surgeries; figure 1.2 shows the trend
across England and Wales.
In the case of loosening of the socket, shields can be used in the instance of bone loss
and a new replacement socket attached in to the shield using bone cement. In the case of
femoral components, however, impaction bone grafting (IBG) is used to rebuild damage to
the femur before inserting the prosthesis in a similar way to primary surgery. With bone
loss in the femur, a stable base needs to be created to support the prosthesis to be inserted.
Currently allogeneic cancellous bone graft (i.e. from the same species) is the ’gold standard’
material used for this application. A stable outline scaffold is created to ensure a stable rigid
base: wires, wire meshes, metal plates or donated bone can be used for this. In the stable
femoral tube cancellous bone graft can be inserted and impacted to create a stable base before
implantation of the femoral component. The concept of IBG to reconstruct bone stock in the
femur with allogeneic bone was introduced by Slooff et al. [45] where they also used cement,
and the procedure became more common with introduction of instruments specifically for
revision operations by Gie et al. [46–48]. Various procedures exist for hip revision surgery;
a common method, the Exeter X-change bone-impaction technique introduced by Gie et al.
[46] is shown in Figure 1.3, taken from [37].
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Figure 1.3: Figures of the X-change revision instruments system for A) femoral revision and
B) socket revision [37].
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1.1.3 Bone grafts
Cortical and cancellous (explained in Section 1.2) bone harvested from the iliac crest forms
viable autologous bone graft, autograft (i.e. from the same person), and is the traditional stan-
dard for treating conditions requiring bone graft [49–51]. However, its drawbacks include
donor site morbidity; increased operative time [49, 50]; and, for application in rebuilding of
the femur to provide a stable base for prosthesis, the volume of bone required is too large to
be obtained through autograft alone [49, 52].
While blood is themost common transplant tissue, bone graft is the secondmost common
[53]. Allogeneic bone graft, allograft (i.e. from the same species), as mentioned previously,
is the clinical ’gold standard’ graft material for application in rebuilding bone stock in re-
vision hip surgery [54, 55]. The use of fresh frozen morsellised allograft eliminates donor
site morbidity associated with autograft and shortens surgical time [56]. However, it does
present the risk of transmission of infectious agents [56–58], including a reported case of
transmission of human immunodeficiency virus type 1 (HIV-1) from an organ donor to
seven recipients, two of which received femoral head donations [57]. Furthermore, cost and
risk of immunological rejection remain disadvantages to allograft use [59, 60]. Tissue process-
ing, and irradiation sterilization much reduce the risk of transmission of infectious agents
however the processing steps affect structural strength [58].
Three main characteristics used to describe the capabilities and nature of different bone
graft materials and bone graft substitutes are:
• Osteogenesis - which refers to the ability of a graft material to form new bone, a capa-
bility present in autograft alone [50].
• Osteoinduction - which leads to osteogenesis through the recruitment of undifferenti-
ated pluripotent cells that are stimulated to differentiate down the osteoblastic lineage
into cells capable of forming bone [50, 58, 61].
• Osteoconduction - which refers to the process of providing scaffolding for new bone
growth due to the ability of bone to grow on the surface and/or penetrate pores of a
material.
Autograft bone tends to be the benchmark against which bone graft substitutes are
compared. Cancellous and, to a lesser extent, cortical autograft contain osteogenic,
osteoinductive and osteoconductive properties, hence they are the regular benchmarks
11
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used to compare the in vivo performance of alternative graft materials to [58].
A comparison and qualitative rating of various properties of bone graft materials was re-
ported by Greenwald et al. [58] and is shown in Figure 1.4. Allograft, while not osteogenic, is
osteoinductive to a lesser degree than autograft [49, 51, 56]. Allograft is still a highly success-
ful viable alternative to autograft in many surgical settings, which extend to impaction bone
graft procedures a majority of which constitute revision hip surgery. This is an indicator that,
while striving to achieve the ideal substitute bone graft material with osteogenic, osteoin-
ductive, and osteoconductive properties, there is need for a material that improves on these
qualities compared to current benchmarks, while simultaneously meeting or improving
required mechanical properties, and remaining cost-effective. If improved osteoinduction
over allograft and osteogenic properties were displayed in a bone graft substitute while
meeting other specifications, this would be sufficient to outperform allograft. Additional
specifications an ideal bone graft substitute would be required to meet include: biocompati-
bility, bioresorbability, and ease-of-use. Bioresorbability of substitute graft material should
be matched to the growth rate of new bone for an ideal regenerative medical solution [17].
Hutmacher’s review of scaffolds in tissue engineering bone and cartilage [17] is widely cited
for the illustration of interdependence of MW loss, mass loss, and tissue remodelling rate for
tissue engineering bone transplants shown in Figure 1.5. The comparability of mechanical
properties between allograft and a bone graft substitute is particularly apt in hip revision
surgery due to the load bearing nature; mechanical strength required of a substitute bone
graft material for non-load bearing applications can be much less [58].
It is important to define the words biodegradable, bioresorbable, bioerodable, and bioab-
sorbable, which are widely used within literature to describe the properties of bone graft
substitutes and tissue engineering scaffolds (and the materials used to form both) to ensure
comprehension of differences between the terms. Hutmacher [17] used the definitions of
Vert et al. [62] and these are the definitions used within this thesis (although not restricted to
purely polymeric materials):
• Biodegradable - materials which break down due to degradation and dispersion in
vivowith no proof of later elimination from the body.
• Bioresorbable - materials which show bulk degradation and elimination from the body
due to filtration of degradation by-products through natural pathways with no resid-
ual effects. Elimination is assumed to have been shown conclusively.
12
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Figure 1.4: Comparative properties of various bone grafts [58].
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Figure 1.5: Figure demonstrating the complex interdependence of molecular weight loss
and mass loss of a 3D scaffold plotted against the time frame for a bone trans-
plant. A) Fabrication of a bioresorbable scaffold, B) seeding of osteoblast pop-
ulations onto the scaffold in vitro, C) growth of premature tissue in a dynamic
environment (e.g. spinner flask), D) growth of mature tissue in a physiologic en-
vironment (bioreactor), E) surgical transplantation, F) tissue-engineering trans-
plant remodeling [17]
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• Bioerodable - materials which show surface degradation, in contrast to bulk degrada-
tion of bioresorbable materials, and also show elimination of degradation by-products
from the body through natural pathways with no residual effects.
• Bioabsorbable - materials which can dissolve in body fluids without molecular mass
decrease or degradation into by-products.
Given the extended surgery time, donor site morbidity, and patient pain associated with
autograft, and the impracticality for surgeries requiring large volumes of graft material, allo-
graft is used. However, due to the drawbacks of allograft and the large demand for suitable
bone graft materials to meet supply, alternative solutions are sought. The market size for
bone graft and substitutes exceeded $250 million in 1999 in the U.S.A alone [58]. Current
commercially available products, are osteoconductive and bioresorbable but have limited os-
teoinductive potential and no osteogenic capabilities; these products include OrthoBlastTM,
DynaGraft R©, ProOsteon R©500R, Grafton R©, OSTEOSET R©, AlloMatrixTM, CollagraftTM[58].
These commercially available products and other methods of bone repair currently being
researched are discussed in Section 1.3.
1.2 Bone physiology
Bones are rigid organs of the body that provide mechanical function in skeletal rigidity,
protective roles, sound transduction and transfer forces allowing movement, in addition to
providing physiological functions. These functions include: haematopoiesis (formation of
blood cellular components), medullary canals in long bones host mesenchymal stem cell
populations fromwhich haemopoietic precursors andmature blood cells originate; acid-base
balance, bone acts as a reservoir of carbonate and phosphate buffers, particularly calcium
carbonate, required when the body has an accumulation of acid (acidosis) causing an imbal-
ance; and acting as a mineral reserve. The majority of the body’s phosphorus and calcium is
stored within bone, and calcium levels within the body are closely regulated [63].
The long bones of the body, of which the femur is one particularly relevant to hip arthro-
plasty and impaction bone grafting, have a central long shaft, or diaphysis, which ends with
rounded ends, or epiphyses. In a long bone the epiphysis closest to the main body is termed
the proximal epiphysis, while the ephysis furthest from the main body is the distal epiphysis.
Bone comprises two types of tissue: cortical or compact bone, and cancellous or trabec-
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ular/spongy bone. Both form lamellar bone, where collagen within the architecture forms
parallel configurations that give bone strength. Cortical tissue is dense and forms the exterior
of bone, while cancellous tissue forms a porous reticular network within the interior of bone
[64]. A membrane adheres to the surface of bones, except where cartilage coats extremities,
and encloses them; it is through this membrane, the periosteum, that a multitude of small
blood vessels permeate into bone tissue.
An osteon is the name of the basic unit of bone, which has a central canal, referred to as
Haversian canals, within which mainly blood vessels are contained; they can also contain
nerves and lymphatic vessels. These canals run parallel to the longitudinal axis of the bone,
while blood vessels running perpendicular to the length of the bone are contained within
Volkmann’s canals. The Haversian canals are contained within rings of concentrically ar-
ranged thin plates of mineralised bone tissue, called lamellae. Also, arranged concentrically
around the central Haversian canals are lacunae, which are spaces occupied by star-shaped
bone cells named osteocytes. Lacunae are linked by microscopic canals, canaliculi, through
which osteocytes form cytoplasmic extensions and form intercellular connections called gap
junctions through which nutrients and waste are exchanged. The structure of bone is shown
in Figure 1.6, taken from Bayliss et al. [63].
Approximately 95% of the organic matrix comprising bone tissue is collagen type-1,
which provides (tensile strength) tensional resistance, particularly in lamellar bone where
collagen fibres are aligned parallel to each other. No such alignment is observed in woven
bone, formed in response to fracture healing and much weaker mechanically. Proteoglycans,
osteonectin, osteocalcin, osteopontin, and other non-collagenous proteins form the remain-
der of the organicmatrix, or osteoid [63]. The inorganic/mineral matrix of bone that provides
compressive strength constitutes approximately 67% of total bone matrix [63] and is formed
from calcium and phosphate ions as hydroxyapatite (Ca10(PO4)6(OH)2, not the empirical
formula to denote the crystal form).
1.2.1 Bone remodelling
Remodelling of bone is a consistent process that ensures repair of fractures and adaptation
to mechanical stimuli, in addition to allowingfor bone growth. Approximately 10% of bone
is remodelled annually within the adult skeleton [63]. Three main cell types are involved in
bone remodelling - osteoblasts, osteocytes, and osteoclasts. Figure 1.7 depicts the develop-
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Figure 1.6: The internal structure of bone [63].
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ment of these cells and some of their markers and differentiation factors. Figure 1.8A depicts
some of the typical characteristics of these cells.
Osteoblasts are cuboid mononuclear cells, which secrete the proteins that form osteoid
(primarily collagen-1, osteocalcin, osteopontin, osteonectin, and bone-sialoprotein) [65]. They
originate from pluripotent mesenchymal stem cells through a conversion to osteoprogenitor
cells, pre-osteoblasts and then mature osteoblasts. This conversion involves interactions be-
tween transcriptional regulators, growth factors, hormones, and signalling molecules, which
include bone morphogenic protein (BMP), platelet-derived growth factor, and transforming
growth factor beta [63]. The majority of osteoblasts become trapped in mineralised bone ma-
trix and further transform to become osteocytes, which make up the majority of bone cells
(ten times more numerous than osteoblasts [63]). Also, osteoblasts may undergo apoptosis
or become bone-lining cells.
Osteocytes are star-shaped, terminally differentiated osteoblasts entrapped within the
mineralised matrix of bone in lacunae, as previously mentioned. Primarily they act as
mechano-sensors within the bone and express biochemical signals based on mechanical
stimuli [63]. They are recognised as regulating osteoblast:osteoclast activity (bone form-
ing:bone resorbing), and hence bone remodelling rate [63].
Osteoclasts are large multinucleated cells, which stimulate resorption of bone matrix.
They derive from the monocyte/macrophage lineage and form a ruffled border that is the
active site of bone resorption, underneath which forms a resorptive pit. Their activity is re-
duced by osteoprotegerin, secreted in the thyroid gland when calcium ion and gastrin levels
rise [63]. Osteoblasts also secrete osteoprotegerin which binds to a key differentiator of osteo-
clast function, RANKL (receptor activator of nuclear factor kappa-B ligand) [63]. Osteoclasts
are located in resorption bays called Howship’s lacunae. Within resorptive pits evidence
has shown areas of low pH form, conducive to resorption of mineralised bone matrix [66].
Cathepsin K, a protease optimal in acidic conditions, is secreted into the resorptive pits and
is believed responsible for the degradation of the proteins that form the organic matrix of
bone, particularly collagen-1 [67].
Bone not undergoing remodelling (quiescent bone) is activated when lining cells sepa-
rate, exposing the bone, and osteoclast precursors are recruited. Cytokines and hormones
regulate the subsequent osteoclast bone degradation. Osteocytes line the Howship’s lacu-
nae that are formed and osteoclasts undergo apoptosis. Formation of osteoid by osteoblasts
18
CHAPTER 1 : INTRODUCT ION
Figure 1.7: The development pathway of A) osteoblasts and osteocytes, and B) osteoclasts
with factors affecting their differentiation. [63].19
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Figure 1.8: A) The typical features of main bones cells. B) The bone remodelling cycle. [63].
20
CHAPTER 1 : INTRODUCT ION
follows, which is then mineralised. The whole remodelling cycle ends with the creation of a
new osteon. The arrangement of osteoclasts, osteocytes, and osteoblasts that complete the
remodelling cycle are called bone remodelling units and are arranged in a conical shape,
the front edge of which sees osteoclast bone resorption trailed by osteoblastic secretion of
osteoid proteins [63]; the cycle is depicted in Figure 1.8B.
1.3 Approaches to bone repair
A range of different approaches to addressing bone repair are under continuing investigation.
Some of these can be categorised into factor, cell, ceramic, or polymer-based approaches.
Expander/extender materials for use with autograft or allograft can be used both to improve
treatment/bone repair, and to reduce the volume of bone graft required for treatment, but
are not discussed here.
1.3.1 Factor-based
Bone repair is controlled by a large number of cytokines, growth factors (GFs), and hormones
that provide cellular signals to trigger healing responses and promote both migration of
osteoprogenitor cells and specific lineage differentiation [68]. A growing body of research
investigates the use of growth factors to promote bone regeneration. Results vary due to
differing potency and efficacy of GFs used, physiological system variety, in addition to bone
type and function, and bone defect type studied [69].
Bioactive molecules investigated include:
• Bone morphogenetic proteins, BMPs. BMPs are widely used osteoinductive factors
in bone tissue engineering for a variety of roles that include acting as an osteoblastic
differentiation factor for mesenchymal stem cells, MSCs.
• Insulin-like Growth Factors, IGFs. IGFs are a group of autocrine, endocrine, and paracrine
polypeptide growth factors that play a role in bone metabolism and are known to stim-
ulate proliferation and chemotactic migration of cells originating from periodontal
ligaments [69, 70].
• Fibroblast growth factor-2, FGF-2. FGF-2 has been shown to have a positive effect on
bone healing [71, 72] and to inhibit osteogenesis of stromal cells while maintaining
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osteogenic potential state [73].
• Vascular endothelial growth factor, VEGF. VEGF plays an important role in bone an-
giogenesis (development of new blood vessels) and its administration has been shown
to enhance blood vessel formation and ossification in bone damage models [74].
Studies investigating a variety of deliverymechanisms have been carried out and include
investigation of a variety of polymer materials acting as carriers to deliver these bioactive
molecules in 3D scaffolds, microparticles, or hydrogels. A review by Lee et al. [69] provides
a more detailed overview of the role of bioactive molecules in bone regeneration.
1.3.2 Cell-based
Preclinical in vivo studies have been carried out investigating the use of various cell types as
potential methods to improve bone regeneration with generally positive findings. Evidence
that showed thatMSCs, periosteal cells, and osteoblasts are capable of enhancing bone repair
was reported [75, 76]. Osseous tissue reconstruction involves cells undergoing a progression
from undifferentiated progenitors to fully differentiated adult cells which explains how a
tissue engineering approach for improving osseous healing can be approached through
different stages of the bone healing process [77].
MSCs are of particular interest for a cell-based approach to bone healing as they can be
harvested easily through the iliac crest and expanded to produce a large enough population
for a clinical therapy. Additionally, their ability to differentiate down different cell lineages
and the presence of research and evidence demonstrating control of the differentiation paths
down which they mature make MSCs particularly relevant in this field [77].
1.3.3 Ceramic-based
The main inorganic component in bone is HA, a calcium apatite with a crystal form and
chemical formula Ca10(PO4)6(OH)2. Ceramic-based bone graft substitutes are formed from
calcium phosphates, calcium sulphates and/or Bioglass R©(a range of bioactive glass ceram-
ics, commercially available, with different compositions of SiO2, Na2O, CaO, and P2O5 [78])
due to the similarity with a large part of the natural components found in bone. These
materials are both osteoconductive and biocompatible [79], both of which are important
in scaffolds for this application. Similarity to natural hydroxyapatite and their ability to
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act as sources of calcium and phosphate ions for bone remodelling and mineralisation are
drivers for their use. Additionally researchers have shown bonding of new bone to synthetic
hydroxyapatite [80]. A large number of bone graft substitutes are commercially available
that are based on calcium sulphates, calcium phosphates and bioactive glasses: Osteograf R©
(Dentsply Friadent, Germany), Norian SRS R© (Synthes, USA), Pro Osteron R© 200R and 500R
(Biomet, USA), Osteoset R© (Wright Medical Technology, USA), Chronos R© (Synthes, USA),
Actifuse ABX R© (Apatech, Germany), Vitoss R© (Othovita, USA), Tutoplast R© (Tutogen Medi-
cal, Germany).
1.3.4 Polymer-based
A range of different polymeric materials have been used in some form for bone repair. A
wide array of polymeric materials with many different properties allow for tailoring of
scaffolds for different applications. Polymeric materials that have been investigated in this
field vary from natural to synthetic. Those of natural origins include collagen, silk fibroin,
chitosan, hyaluronic acid, alginates, cellulose, and dextrans. A review of polymers of natural
origins and their role as scaffolds in tissue engineering was carried out byMalafaya et al. [81].
These roles include commercially available bone graft replacements such as Healos R©Bone
Graft Replacement (DePuy Orthopaedics, USA). Healos R©is a matrix of cross-linked collagen
fibres coated with HA and has been approved for clinical use as a bone graft substitute in
spinal fusions [81].
Synthetic polymers used in this field include poly (α-hydroxyacids), poly (ǫ-caprolactone),
poly (urethane)s, poly (propylene fumarate), poly (phosphazenes), and poly (1,4-butylene
succinate). Poly (α-hydroxyacids) include poly (glycolide) (PGA), poly (lactide) (PLA), and
poly (ǫ-caprolactone) (PCL), and there is a large body of knowledge about these polymers.
These polymers and their copolymers have FDA approval for a variety of clinical applica-
tions, and as such are the most commonly used polymers for investigation within the tissue
engineering and regenerative medicine field [82]. Various reviews of the many different
porous scaffolds under investigation for the application of bone tissue engineering have
been reported within the literature [17, 82]. The use of a polymeric based scaffold for bone
tissue engineering provides great opportunity to incorporate bioactive molecules, cells, and
ceramic materials to form a composite tissue engineering solution that combines benefits of
each approach. The innovative combination of the most promising technologies will build
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towards optimum solutions for different problems within this field.
1.4 PLA, PGA, and PLGA
Lactide is a dimer of lactic acid. Lactide, the monomer unit for PLA, has three stereoisomers
(Figure 1.9A) which lead to three different possible forms of PLA: poly (L-lactide), PLLA;
poly (D-lactide), PDLA; and poly (D, L-lactide), PDLLA. PLLA is a semi-crystalline polymer
with a melting transition around 180 ◦C and a glass transition temperature, Tg, at approx-
imately 67 ◦C [83] that is reported to vary between 63 ◦C and 71 ◦C [84]. Crystallinity of
PLLA varies between 10–69% [85, 86]. Amorphous polymers are formed from polymerisa-
tion of a racemic mixture of D-lactide and L-lactide and have lower Tgs in comparison to
the semicrystalline forms. A value of 62.5 ◦C was reported for the Tg of PDLLA [84]. PDLA
is used much less than PLLA and PDLLA for tissue engineering scaffolds.
Glycolide is the dimer of glycolic acid. Glycolide (shown in Figure 1.9B) is the monomer
of PGA (shown in Figure 1.9B), a widely used biodegradable polymer. Poly (lactide-co-
glycolide), PLGA, is a copolymer formed from glycolide and lactide monomer units. PLGA
with different ratios of glycolide:lactide can be produced; the ratios of the different monomer
units result in PLGA with different properties; these include a variation in the degradation
rate which allows tailoring of the biodegradation rate of scaffolds formed of this polymer
based on lactide:glycolide ratios.
A review by Södergård et al. [87] was published that provides a comprehensive review
of the properties (thermophysical, mechanical, solubility, stability) of a wide number of
lactide based polymers and includes a discussion of the preparation of the polymers by
polycondensation and ring-opening polymerisation. The ring-opening polymerization is
more common for PLA and is also used for PGA; the reaction is commonly catalysed by tin,
zinc, or aluminium [85, 88].
L-lactic acid is the enantiomer of lactic acid found in mammalian systems [87]; as such
lactic acid is a chemical found within the body for which natural processes for removal
already exist (respiratory and renal filtration routes). The polymer eventually degrades to
monomeric acids and then to carbon dioxide and water through de-esterification [89]. PLA,
PGA, and PLGA degrade within the body through random bulk hydrolysis of ester bonds in
the polymer chain; water attacks the polymer chains and through hydrolytic cleavage breaks
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Figure 1.9: A) The chemical structures of lactide stereoisomers, from left to right -D-Lactide,
L-Lactide, and meso-lactide; and polylactide (below). B) The chemical stuctures
of, from left to right, glycolide, and polyglycolide.
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them in to oligomers [89]. The degradation rate has been found to be heterogeneous in cases
where oligomers within the polymer cannot diffuse away as quickly as oligomers formed
at the surface. In these cases the oligomers increase the concentration of carboxylic acid
end groups, which results in autocatalytic degradation of the polymer [90, 91]. The acidic
degradation products of PLA and PGA can cause inflammation/adverse tissue reactions
which can be detrimental to tissue repair. The degradation of the polymers will result in
reduced mechanical properties and hence understanding and control of the degradation
rates of materials offering structural support in vivo is required.
PLA, PGA, and their copolymers are bioresorbable. The degradation rate of these poly-
mers varies with MW , degree of crystallinity of the polymers, as well as through the previ-
ously mentioned copolymer ratios. All of these can be used to target specific degradation
rates. The shape of implanted scaffolds formed from these polymers will also affect the degra-
dation rate based on surface area, and diffusion rates of acidic degradation by-products.
However, tissue engineering scaffold morphologies are typically optimised for function,
hence, the inherent polymer properties such as MW are preferred for tailoring degradation
rates. Blends rather than copolymers can also be utilised to affect the degradation rates of
scaffolds formed of these and other polymers.
1.5 Polymer scaffold production methods
There are many methods for producing polymeric scaffolds for tissue engineering with a
variety of advantages and disadvantages. Some of the main polymer processing methods
are briefly overviewed in this subsection.
Solvent casting/particulate leaching
Solvent casting scaffold production involves the dissolution of a polymer in a solvent to
create a solution that is thenmixedwithwater-soluble particles (salt primarily). This mixture
is cast in a mould (if a 3D structure is desired) and the solvent removed through vacuum
or freeze drying. Water can then be used to leach the particles from the structure creating a
porous structure. Porosity and pore size can be controlled through variation of the amount
and size of water-soluble particles used.
Downsides to this process include the use of organic solvent and difficulty in removing
particles from the internal structure. Thin films (500–2000 µm) which are then layered to
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create a laminated structure overcome this difficulty [79, 92].
Emulsion freeze drying
Polymer is dissolved in a solvent and a second immiscible liquid is added to form a stable
emulsion using a homogeniser. The emulsion is cast into a mould, frozen in liquid nitrogen,
and then freeze dried to remove both liquids. Porous scaffolds (up to 95% porosity) with
small pores (13–15 µm) can be formed using this technique [93]. The small pore sizes and use
of solvents limit the application of this technique to create scaffolds for tissue engineering
applications.
Thermally induced phase separation
Polymer is dissolved completely in solvent with a low boiling point. The solution is then
fast cooled moving the solution from a homogeneous single-phase region into its spinodal
region (on and beyond the limit of stability of the solution). This leads to a break down in
the stability of the solution resulting in liquid-liquid phase separation with polymer rich
and polymer poor regions [94]. Liquid nitrogen quenching and subsequent freeze-drying
to remove solvent obtains interconnected porous structures. The presence of solvent limits
biocompatibility of scaffolds produced by this method.
Solid freeform fabrication
Solid freeform or rapid prototyping technologies build a 3D scaffold up in layers and can
use a variety of different processes to achieve this such as: 3D printing, stereolithography,
selective laser sintering, and extrusion-based systems [89]. Computer aided design (CAD)
software is used to design the 3D model that is produced through the layering process. The
advantages of scaffolds produced this way lie in extremely good reproducibility [82, 89] and
control of porosity and structure. However, high temperatures and organic solvents may
be required in processing and the processes often trap monomer within the scaffolds. The
high level of control over structure is such that x-ray or MRI images of defects can be used
to allow design of scaffolds to fill the defects using CAD software.
Various forms of 3D printing exist that use a computer controlled head to eject a binder
into a bed of powder particles, joining them. In the case of stereolithography a liquid pho-
tocurable monomer is polymerised using a laser beam and a scaffold is built up from layers
of selective polymerisation. Selective laser sintering utilises a computer controlled infrared
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laser to heat a fine polymer powder above its Tg in localised areas allowing particle bonding
to occur. In extrusion based systems, or fused deposition modelling, melted polymer fibres
are deposited on a stage from a computer controlled nozzle, where they cool and solidify
to form a layer; this layer is then deposited on and a 3D scaffold/structure is created from
the multiple layers. While computer controlled, rough edges and trailing solidified polymer
connections require user removal.
1.6 Supercritical fluids
This section is taken and adapted from a published review on "Supercritical fluid processing
of materials for regenerative medicine" [1] authored by the author of this thesis.
Supercritical fluids, SCFs, are substances at or above their critical temperature, Tc, and
critical pressure, Pc. On a phase diagram for a substance the point at the Tc and Pc is called
the critical point and marks the end of the phase boundary between the gas phase and the
liquid phase; the other end of this line marks the triple point, the temperature and pressure
at which the substance may exist in all three phases (for water this is 0 ◦C at atmospheric
pressure); both points can be seen in the typical phase diagram shown in Figure 1.10. The
critical point for water is 374.2 ◦C and 2.2 MPa.
Baron Cagniard de La Tour is credited with the discovery of SCFs. His experiments in
1822 involved rolling a steel ball within a sealed gun barrel containing ethanol that was
heated [96]. He observed acoustic differences in the sound of the ball rolling within the
barrel that appeared to signify the absence of a liquid phase after appropriate heating. The
point at which this occurred, the critical point, was previously known as the Baron Cagniard
de La Tour point.
Above the critical point the distinction between a gas phase and a liquid phase vanishes
and the resultant SCF has properties of both phases - solvating and density properties similar
to liquids, and diffusivity and viscosity properties similar to gases. Large density changes
can be effected through small changes in temperature and/or pressure at, or around the
critical point. The properties of SCFs have been exploited in various processes, such as dry
cleaning and decaffeination, in the place of organic solvents. The most commonly used SCF
is supercritical carbon dioxide (scCO2), which has a comparatively low critical temperature
(31.1 ◦C), and a critical pressure of 7.38 MPa). Carbon dioxide is readily available, considered
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Figure 1.10: A typical substance phase diagram displaying phase boundaries, the triple
point, and critical point. [95]
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a green solvent due to its reclamation from other processes, where it would otherwise be
vented to atmosphere, nonflammable, and has a low toxicity and cost. The value of SCFs,
particularly scCO2 has begun to be realised in creation of regenerative medicine scaffolds.
Supercritical CO2 processing of polymers does not require the use of organic solvents, offer-
ing advantages over many of the alternative polymer processing methods mentioned due
to the final application of the polymer scaffolds: use as a biomedical product.
Polymer exposed to scCO2 for a period of time becomes saturatedwith the fluid. The SCF
plasticises the polymer, reducing the glass transition temperature, Tg. As operating pressure
is lowered to below the critical value for CO2, areas of CO2 gas nucleate and grow within
the polymer forming pores; additionally, as CO2 diffuses out of the polymer the plasticis-
ing effect reduces and the Tg rises. When the Tg of the polymer rises above the processing
temperature the porous polymer structure sets [97, 98]. The rate of growth and structure of
the pores formed within various polymers can be controlled by varying operating condi-
tions such as temperature, venting time, and operating pressure. Work reported in literature
demonstrated the effect of these conditions on the porosity and pore size of resultant PDLLA
and PDLLGA foams [97]. The ability of a polymer to be foamed using scCO2 is dependent
on the CO2 absorption. A crystalline polymer or crystalline region requires harsher foaming
conditions (higher temperature and/or pressure) in comparison to amorphous polymers
to enable scCO2 to penetrate the crystalline regions. The MW of polymers also affects the
foamed structure achieved under identical foaming conditions due to the effect MW has on
inherent polymer viscosity, Tg, and Tm.
Supercritical fluids have been utilised to fabricate regenerative medicine scaffolds since
1990, when De Ponti et al. [99] patented the creation of porous sponges of biodegradable
polymers such as PLA and PLGA. Although high pressure gases had previously been used
to produce bubble nucleation in polymers [100, 101], the foams produced contained closed
pores. The advent of the De Ponti patent and a patent by Cha et al. [102] in 1991 demonstrated
that SCFs could produce open pore foams, suitable for tissue engineering applications. This
novel technique removed the need for organic solvents or high operating temperatures in
scaffold production through the use of suitable SCFs, such as scCO2.
Figures 1.11 and 1.12 provide a timeline of key patents and papers in the development
of SCF formed scaffolds suitable for regenerative medicine applications. Fundamental work
published by Goel and Beckman in the 1990s [103–106] demonstrated not only that scCO2
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could be used to foam discs of poly(methylmethacrylate) (PMMA) but also that process
conditions could significantly affect the pore structure of the foamed construct. Mooney et al.
[107] published a pivotal paper on the use of a high pressure gas to produce porous sponges
and demonstrated that amorphous polymers or copolymers such as PDLLGA foamed more
easily than semi-crystalline polymers such as PLLA. The combination of growth factors
(GFs) in foamed constructs was achieved with high pressure gas foaming [108–110] with the
addition of salt particle leaching required to achieve internal porosity [109, 110]. Howdle
et al. [111] demonstrated that scCO2 alone, without the use of co-solvents, could be utilised
for mixing active molecules with polymers to form composite materials; the low operating
temperatures also enabled thermolabile bioactive materials, such as enzymes, to be incorpo-
rated into polymer scaffolds. A schematic diagram of scCO2 foaming is provided in Figure
1.13.
In addition to the production of solvent free porous scaffolds, SCFs were also utilised
as ’clean’ solvents for therapeutic molecules [112, 113], which eliminated the need to re-
move residual solvents. Sterile filtered SCFs as solvents for pharmaceutical ingredients were
patented as early as 1979 [114]. Combining SCFs as solvents with their penetrative ability led
to patents for therapeutic or biofunctionally loaded polymer production methods [115–117],
where SCFs, active agents, and polymers were contacted or mixed to form composites. These
methods were also applied to produce therapeutic loaded coatings for medical devices [118].
Supercritical fluids have also been utilised in the formation of other scaffold types, most
notably, electrospun scaffolds. Traditionally, electrospinning has involved the use of a poly-
mer dissolved in an organic solvent pumped through a charged needle to an oppositely
charged collection plate. McHugh et al. [119] patented a process whereby a high pressure
gas (subcritical or supercritical) could replace the organic solvent in electrospinning. Recent
developments in scCO2-assisted electrospinning have been reported in scientific literature
[120].
Another application of SCFs has been in the field of sterilization, where Dillow et al.
[121] patented a method using scCO2 above 14 MPa and 30 ◦C that sterilised materials by
altering the internal pH of microorganisms, inactivating them. The attraction over tradi-
tional techniques such as steam or ultraviolet sterilization, was that it could be performed
at low temperatures and could also clean surfaces [21]. The alteration of internal pH of cells
placed time restrictions upon the processing of mammalian cells using scCO2 but a method
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Figure 1.11: Timeline showing the pivotal patent and scientific literature that contributed to the advancement of supercritical fluids for the manu-
facture of regenerative medicine scaffolds.[1]
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Figure 1.12: Timeline showing the pivotal patent and scientific literature that contributed to the advancement of supercritical fluids for the manu-
facture of regenerative medicine scaffolds.[1]
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Figure 1.13: Overview of scCO2 foaming whereby A) polymer or polymer and porogen are
placed into a foaming vessel, B) scCO2 plasticises the polymer and C) controlled
depressurisation produces an interconnected porous foam. The use of a poro-
gen is optional is later leached to improve the interconnectivity of scaffolds
produced. Image taken from [1].
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to load polymeric tissue engineering scaffolds with cells was patented [122] and studies
demonstrated the viability of cells post-processing [123].
1.6.1 Supercritical fluid foaming
Porous matrices require a high degree of interconnectivity for use in regenerative medicine
applications; interconnectivity is crucial for cell migration and nutrient transfer within the
matrix [124]. To improve interconnectivity, porogens have been included in polymer melts
and leached post-foaming [125, 126]. In a recent development, Turng et al. [127] patented the
novel use of a water-soluble polymer, such as poly(vinyl alcohol), in an extrusion polymer
melt and in combination with the use of porogens, to form scaffolds with greater intercon-
nectivity and porosity. This method complemented injection moulding processes and was
combined with the use of foaming agents (such as an SCF) to produce foamed complex
scaffold shapes. An operator skilled in the art could further adapt this method to include the
plasticisation effect of scCO2 to operate at lower temperatures and incorporate thermolabile
molecules into the scaffolds.
Chattopadhyay et al. [128] developed a method that replaced organic solvents with
SCFs for removal of soluble components from traditionally produced (melt extrusion, co-
precipitation, spray drying, lyophilisation, emulsion formation) composites. This method
both reduced residual solvent and impurities which would diminish the need for down-
stream purification steps and provided a high level of porosity and pore size control.
In addition to porosity requirements, it is important that mechanical strengths (compres-
sive and tensile) of scaffolds are matched to their function [129]. The strength of polymers
varies with stereoisomer concentration, e.g., PLLA or PDLA contain more crystalline regions
and therefore greater strength than amorphous PDLLA. Stereocomplexes (where interac-
tion of polymers with different tacticities prevails over those of identical tacticity [130])
of two homopolymers (e.g. PLLA and PDLA) formed by solvent casting or melt blending,
have different crystalline structures with different mechanical properties than those of the
homopolymers alone. Kim et al. [131] established the use of scCO2 as a solvent to form
stereocomplexes and to produce them in a foamed form.
An alternative method used to increase scaffold mechanical strength has been to utilise
reinforcement from nanopowders such as smectite clays or calcium phosphates [132]. Super-
critical fluid foaming has been shown to increase the interactions between polymer and clay
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to increase bonding strength and this method was patented by Kannan et al. [133].
In combination with scaffold porosity and strength requirements, the incorporation of
bioactive molecules and materials (e.g. hydroxyapatite and dexamethasone) has improved
scaffold function through guided cell differentiation or localised drug delivery [134, 135].
Duarte et al. [136] successfully impregnated chitosan scaffolds with dexamethasone using
scCO2 for guided osteogenic differentiation of stem cells. Koltzenburg et al. [137] recently
developed a method with foamed amphiphilic copolymers (such as polyether). These were
combined with biodegradable polymers and active ingredients (such as chitin), that are spar-
ingly soluble in water, to produce active ingredient containing polymers. Polymers such
as this were extruded in the presence of SCFs to produce foams and the authors claimed
improved mechanical properties although this was not shown. Howdle et al. [138] had previ-
ously demonstrated that biofunctional materials such as hydroxyapatite could be physically
mixed with polymers in SCF environments to create composite biofunctional polymers
irrespective of material solubility. An alternative method to include bioactive molecules
was invented by Chatziniko-laidou et al. [139], where dry polymer powders were mixed
with aqueous GF solutions to the hygroscopic limit of the powder; this created "slurries" of
polymer and GF that were capable of being shaped and utilised in extrusion and foaming
processes to create GF containing scaffolds.
Recent patents in the application of polymer foams include their use as hemostatic
sponges (used to apply pressure and stop deep bleeding in minimally invasive surgery)
and delivery devices [140, 141]. Chang et al. formed blends of biodegradable polymer and
moisture-absorbent material, such as collagen, that when foamed were suitable to act as
degradable hemostatic sponges, eliminating the need for their removal. Sandler et al. [140]
produced stable nanoporous foams using rapid depressurisation (15,000–2,000,000 MPa s−1)
of polymer melts in SCFs; these foams contained a nanoscale open cell network that would
not allow cellular ingress but did make them suitable for delivery of incorporated active
compounds (e.g. albumin).
1.6.2 Microparticles by supercritical fluid processing
Polymer microparticles can join together to form 3D scaffolds [142], alternatively they can
be incorporated as particle components of composite scaffolds - the benefit imparted by the
microparticles to the scaffold may be release of bioactive signalling molecules (e.g. BMP-2
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[143] or antibiotics to reduce risk of infection post-implantation. There is an abundance of
literature surrounding SCF based methods for producing particles (see for example [144–
146]). Many papers deal with production of polymer microparticles while others deal with
production of active molecule based nanoparticles, with little cross-over between the two.
Most recently polymer-based microparticles in regenerative medicine were reviewed by
Oliveira and Mano [147], although with limited discussion of SCF based methods. Sheth et
al. [148] provided a recent and comprehensive review of SCF technologies for nanoparticle
production in the pharmaceutical industry.
There are three established techniques for particle production using SCFs. These are:
• Rapid expansion of supercritical solutions (RESS), where an SCF is saturated with a
substrate and rapidly depressurised through a heated nozzle to form small particles
[146].
• Particles from gas-saturated solutions (PGSS), where a liquid or polymer is saturated
with an SCF which is then expanded through a nozzle to produce particles.
• Supercritical antisolvent precipitation (SAS), where a liquid solution is contacted with
an SCF in which the solvent is miscible and the solute is insoluble, causing supersatu-
ration and precipitation of the solute [146].
A schematic overview is provided in Figure 1.14
Many innovative adaptations to these techniques have recently been patented. Fulton
et al. [149] transformed the RESS method of producing nanoparticles into a novel coating
process. A stream of charged ions was generated that interacted with the RESS produced
nanoparticles, which enabled electrostatic deposition. Previous work from the same group
had shown that it was extremely difficult to deposit particles in the range 10–500 nm on to
a surface from the RESS technique due to their low mass [150]. This transformed process
overcame these coating difficulties, avoided the use of organic solvents, and provided a
more uniform coating compared to those prepared by a cloud-point precipitation technique.
Recently patented adaptations to the RESS method tackle the challenge of producing
aqueous solutions of insoluble materials [151, 152]. For example, Sun et al. [151] patented
the use of stabilizing agents (that do not form micelles in aqueous solution), mixed with
biologically activematerial (that has little or no solubility in water) in a solvent such as scCO2
to form a non-aqueous solution. Then, using RESS, an aqueous suspension of particles was
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Figure 1.14: Established techniques for SCF particle production utilising scCO2. (P = Vessel
pressure and Pc = Critical pressure of CO2). [1]
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achieved where the particles had an average diameter <100 nm. Suspensions of nanoscale
materials are treated as equivalent to solutions of the materials when considered for medical
applications [153]. Suspensions of nanoparticles were created using established processes
such as SCF spray drying, or precipitation by directly collecting the particles created in
a media that formed the final formulation [152]. Importantly, this reduced the number of
processing steps.
Innovative advances have been made for SAS particle manufacture methods [154–156].
For example, Subramaniam et al. [154] adapted the SAS method to produce coated particles.
A high energy gas stream was used to break up the fluid dispersion into extremely small
droplets which precipitated into small particles (0.1–10 µm) in the SCF anti-solvent. In the
precipitation chamber it was possible to coat a counter current flow of "core" particles with
the precipitating nanoparticles. Conventional methods for producing nanoparticles such
as micronisation are often unsuitable for less brittle materials, like polymers, for which
this method is appropriate. An alternative revision of the SAS process, from a different
research team, was the use of a modulator (such as a polyethylene oxide), with a solubility
inversely proportional to temperature in aqueous solutions [155]. The modulating agent
enabled reduction in particle size and agglomeration, and aqueous solutions of a substrate
to be used in the SAS process with scCO2. Particle size and agglomeration were reduced by
Shekunov et al. [156], who developed a method for utilising growth retardant compounds
for the SAS technique. Compounds with CO2-philic and CO2-phobic groups such as sugar
acetates were shown to reduce the particle growth rate and prevent agglomeration.
An adaptation of PGSS was made by Chattopadhyay et al. [157] where an emulsion
of polymer, wax/lipid, and bioactive compound was created in an SCF environment. The
expanded emulsion provided greater control over particle size, morphology, and size dis-
tribution than expanded polymer melts have achieved. In contrast, Deschamps et al. [158]
produced solid micro or nano particles of active substance by expanding scCO2 solutions
of the active substance into chambers under conditions where liquid CO2 was present con-
taining a divided solid. This process produced a solid dry product in a stable form (such
as a nifedipine/mannitol formulation), avoiding the use of wet size-reducing steps (e.g.
ultrasound) that are common for nanoparticle dispersion production.
The atomisation of substances that are insoluble (or poorly soluble) in scCO2 has previ-
ously been limited to methods that avoided the use of scCO2. However, Osada et al. [159]
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pioneered a method to atomise substances with poor solubility in scCO2 through the com-
bined use of water and scCO2. Compounds or polymers insoluble in scCO2 were reduced to
fine particles with an average size up to one hundred times smaller than their starting size.
This was achieved by exposure to scCO2 and water in a pressure vessel, followed by reduc-
tion of internal pressure. Whilst this method has been proven to be effective, the mechanisms
of the atomisation process have not been fully elucidated by the authors.
A one step purification/harvesting method developed by Tsung et al. [160] used an SCF,
or high pressure gas, to remove a solvent from a microparticle dispersion. This method
removed the need for lyophilisation or evaporation steps to dry the microparticles. Cas-
tor et al. [161] also utilised SCFs as working fluids to purify protein-containing-polymer-
microspheres and avoid use of organic solvents. Kaiso et al. [162] employed scCO2 as a
washing agent in their novel process for forming porous polyamide microparticles. The
polyamide was dissolved in a cyclic amide, then heated and cooled to form particles; these
contained residual cyclic amide that was recovered using scCO2, allowing recycling of the
solvent.
Recent interest has been shown in the use of scCO2 in phase separation processing
[163, 164]. Brown et al. [164] patented the use of a phase-separation enhancing agent (PSEA)
for particle production. The PSEA enhanced or induced liquid-solid phase separation of
active ingredients in aqueous solutions to produce spherical particles. Supercritical fluids
were then utilised to remove residual PSEA from the particles. Day et al. [163] employed
thermally induced phase separation to produce polymer microparticles with radial pores.
Polymer was dissolved in a solvent, such as an SCF, then homogenised, rapidly frozen, and
freeze dried. Microspheres with and without a nonporous skin region were formed by this
method.
1.7 Aims of this study
The focus of this thesis is to establish the potential of scCO2 foamed polymeric scaffolds as
viable substitutes to allograft for impaction bone grafting (IBG), particularly revision hip
arthroplasty. To achieve this scCO2 foamed scaffolds investigated within this thesis were
processed as donated femoral heads would be - utilising a bone mill to create chips that
retain the porosity imparted through scCO2 foaming.
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In the next chapter, Chapter 2, general methods and equipment used for the experimental
work of studies within this thesis are described in detail. This chapter is for reference for
experimental work carried out and deviations from the general methods are described in
the experimental section of the relevant chapter.
In Chapter 3, building on previous work within the literature, melt processed and scCO2
foamed PDLLA and PDLLGA scaffolds were investigated to establish the advantages of
porous scaffolds over non-porous. The performance of different scCO2 scaffolds were then
assessed in in vitro and in vivo models of IBG to establish the most promising scaffold for-
mulation to investigate in a large animal in vivomodel. Hydroxyapatite microparticles were
incorporated into some scaffolds and the effect of these particles on scaffold performance
was also assessed. The performance of different scaffolds were assessed based on cellular
compatibility, cellular differentiation, and resistance to shear forces (a common mechanism
of failure for hip prostheses).
In Chapter 4, having determined themost promising scaffold formulation, scCO2 foamed
PDLLA + HAmicroparticles composite scaffolds were studied using an ovine in vivo femoral
condyle model. The performance of scaffolds in vivo were studied both with and without
pre-seeded autologous MSCs. In this chapter the potential scale-up of production of scCO2
foamed polymeric scaffolds was also investigated. Establishing this potential is important
for determining the viability of scCO2 scaffolds as alternatives to allograft.
The aims of Chapter 5 were to investigate differences in the performances of scaffolds of
PDLLA and PDLLGA scaffolds observed in Chapter 3. Given the similarity of the polymers,
the large differences observed in the osteoblastic differentiation of MSCs cultured on the
scaffolds was unexpected and in vitro experiments with MSCs cultured on thin films were
carried out to remove morphological difference in the scCO2 foamed scaffolds. Additionally,
the incorporation of HAmicroparticles improved the cellular performance of scCO2 foamed
PDLLA and PDLLGA scaffolds in Chapter 3, while having no significant effect on mechanical
properties. The effect of incorporation of HA nanoparticles was studied through in vitro
cell experiments as a promising method to improve formulation performance prior to any
further potential large animal studies.
The final chapter, Chapter 6 gives a final discussion of the significance of the results and
experimental work presented within this thesis.
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Table 2.1: Properties of polymers used in the studies contained within this thesis taken from
the manufacturers (Surmodics Biomaterials) specification sheets.
Polymer MW Polydispersity Tg Inherent viscosity
[kDa] index (PDI) [dL g−1]
PDLLA 126 1.5 50.3 0.80
PDLLA 106 1.9 52.0 0.75
PDLLGA 110 1.5 50.0 0.71
2.1 Supercritical CO2 foaming
Various polymers were purchased from SurModics Biomaterials (Birmingham, U.S.A.) and
used to produce scCO2 foamed scaffolds. Table 2.1 displays the properties of the various
polymers utilised in the studies within this thesis. Polymers, as purchased from manufac-
turer, were ground using a blade grinder (Krups, model F203) prior to scCO2 foaming.
Ground polymer powder was weighed into cylindrical wells (11.2 mm × 10.4 mm)
within a custom-made (School of Chemistry, The University of Nottingham) PTFE mould
(74.2 mm× 27 mm× 12 mm), 300 mg per well, and a stainless-steel lid (with a PTFE insert to
aid removal of the scaffolds) was screwed into place above the wells filled with polymer. The
mould contained vents at the base and top of each well to enable CO2 access. For scaffolds
containing HA particles, these were weighed into the wells of the mould with the ground
polymer powder prior to the lid being screwed into place. Hydroxyapatite microparticles
were purchased from Berkeley Advanced Biomaterials and graded to a size range of 100-300
µm.
Hydroxyapatite nanoparticles (both nanorods and nanoplates) were kindly donated by
Prof. Edward Lester andMiss Selina Tang (Faculty of Engineering, The University of Notting-
ham). For supercritical foaming the sealed mould was placed into a custom-made (School
of Chemistry, The University of Nottingham) 60 ml stainless-steel autoclave (pressure rated
to 35 MPa) and clamp sealed. Swagelok (Ohio, U.S.A.) piping and fittings, and HiP (High
Pressure Equipment Company, Pennsylvania, U.S.A.) high pressure valves connected the
system. A pressure transducer located on the inlet line between the HiP inlet CO2 valve and
the autoclave inlet enabled internal pressure monitoring. The autoclave was fitted with a
heating jacket controlled using a CAL 3000 temperature controller (CAL controls, Brighton
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U.K.). A high pressure PM1010 pump (New Ways of Analytics, Lörrach, Germany) was
used to pressurise CO2 from cylinder pressure (≈5 MPa) to 30 MPa. Pressure within the
autoclave was controlled using a Bronkhorst (Ruurlo, Netherlands) back pressure regulator,
and FLOWDDE version 4.44 and FlowPlot version 3.11 Bronkhorst software.
With the polymer and mould in place the autoclave was jacket heated to 35 ◦C; then
filled with CO2, the pressure increased to 23 MPa over a period of 20 minutes (fill time);
the pressure was held constant for 60 minutes (soak time); the pressure was then reduced
over a period of 30 minutes at a constant rate to ambient conditions (the vent time); heating
was ceased; the mould was removed from the autoclave, and the foamed polymer scaffolds
removed from the mould. Figure 2.1 shows the layout of the scCO2 foaming equipment and
an image of the 60 ml autoclave used. Figure 2.2A and B show images of scCO2 foamed
polymer scaffolds formed through this process.
The standard operating procedure of the high pressure foaming rig is detailed in Ap-
pendix 1.
2.2 Scanning electron microscopy
Scanning electron microscopy (SEM) was carried out on two different machines. Samples for
imaging were prepared using a scalpel to create axial slices across the porous scaffolds (in
line with the diameter). scCO2 foamed scaffold slices were placed on SEM stubs and sputter
coated. Gold sputter coatingwas performed using a Leica EM SCD005 sputter coater; coating
at≤ 4 Pa (in argon) for 180 seconds. A JEOL JSM-6060LV SEMwas used for general imaging
with an accelerating voltage of 15 keV.
Scanning electron microscopy commonly detects secondary electrons emitted by atoms
excited by the electron beam of themicroscope. In themicrographs produced from secondary
electron detection HA particles were difficult to discern from the background PDLLA. Sam-
ples containing HA particles were imaged using both secondary electrons and backscatered
electrons (BSEs).
For samples that required imaging using BSE carbon sputter coating was used. Carbon
sputter coating was performed using a Polaron SC7640 sputter coater at 4 × 10-2 mbar (or
below) for 40 seconds. A Philips FEI XL30 SEM with an accelerating voltage of 15 keV, and
Inca Suite, version 4.14 (Oxford instruments analytical Ltd), were used for imaging.
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Figure 2.1: The layout of scCO2 foaming equipment and the block arrow indicates an image
of the 60 ml autoclave into which PTFE moulds were placed for foaming. A
diptube CO2 cylinder provided a source of CO2 pressurised in the pickel pump
and flowed into the pressure vessel. A back pressure regulator (BPR) controlled
the internal pressure. Internal temperature was recorded via a thermocouple (T)
linked to a PC.
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Figure 2.2: Supercritical CO2 polymer scaffolds are shown in a PTFE mould post-foaming
(A) and removed from the mould (B). Image B) also shows chips of scCO2
foamed polymer scaffolds after processing with a standard bone mill. Image
C) shows an x-ray image of milled chips of scCO2 foamed PDLLA + 10 wt.% HA
microparticles impacted into an impaction chamber, taken using µCT.
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Backscattered electrons arise from the electron beam of the microscope (incident beam)
scattered back at an angle nearly normal to the incident beam without loss of kinetic energy
(elastic scattering). The probability of electrons being elastically scattered increases as the
atomic number of elements in the sample increases due to a larger cross-sectional area. A
proportional relationship exists between the mean atomic number of a sample and the num-
ber of BSEs detected. While PDLLA contains carbon, oxygen, and hydrogen, HA is formed
of calcium and phosphorus, which have larger atomic numbers (20 and 15, respectively).
2.2.1 Elemental mapping
Energy dispersive x-ray spectroscopy (EDX) was performed to identify HA particles within
the scaffolds. Samples were prepared as for SEM prior to sputter coating. Carbon sputter
coating was performed using a Polaron SC7640 sputter coater at 4× 10-2 mbar (or below) for
40 seconds. A Philips FEI XL30 SEM was used for elemental mapping with an accelerating
voltage of 15 keV, and Inca Suite, version 4.14 (Oxford instruments analytical Ltd), was the
software used.
X-rays are emitted when a high energy electron in an outer shell of an atom within a
sample fills a lower shell from which electrons were ejected due to bombardment by the
incident beam in SEM. The emitted x-rays balance the energy difference when the outer
electron drops to a lower shell and the intensity of the x-rays emitted are characteristic of
the atoms they are emitted from.
2.3 Micro x-ray computed tomography
Micro x-ray computed tomography (µCT) was carried out on two different machines. The
details of which machine was used for each study is reported within the individual results
chapters, as well as here. The use of µCT enabled non-destructive imaging and quantitative
analysis of the 3D microstructure and morphology of scCO2 foamed samples. A Skyscan
system was used for all scCO2 foamed scaffolds quantitifed by µCT and for ovine femoral
condyle defect samples. An XTEK System µCT scanner was utilised for murine samples
post-in vivo incubation.
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2.3.1 Skyscan
The µCT system utilised for most samples was a Skyscan 1174 µCT scanner (Skyscan, Bel-
gium). Scaffolds were mounted on a holder and placed in the scanner. The stage was set at
a height of 6.5 mm and the scaffolds were scanned with the following settings: 40 kV volt-
age, 800 µm current, and 12.0 voxel resolution. Image reconstruction was performed using
NRecon (Skyscan, Belgium) and saved as 8 bit bitmaps (BMP). Analysis of the reconstructed
images was performed using CTAn (Skyscan, Belgium) using threshold values of 37 and 255
for scCO2 foamed polymer scaffolds.
2.3.2 XTEK Systems
MicroCT scanning and reconstruction using the XTEK system was carried out at µ-VIS,
Southampton University by Dr. Stuart Lanham and Mr. E. Tayton.
Quantitative 3D analysis of implanted impaction chambers was obtained using a Metris
Xtek HMX ST 225 kV CT scanning system (X-TEK Systems Ltd, Tring, Hertfordshire, U.K.).
Raw data was collected and reconstructed using Next Generation Imaging (NGI) software
package (X-TEK Systems Ltd.) with a 10.6 µm voxel resolution. All voxels were automati-
cally assigned Houndsfield units via calibration against a standard water sample. The im-
ages were visualised and analysed using Volume Graphics Studio Max software (Volume
Graphics, Heidelberg, Germany). The regions of interest (contents of the impaction cham-
bers), thresholds for new bone, polymer, and HAmicroparticles were selected manually, and
the volumes of new bone calculated via the software. From this data, the mean and standard
deviations for bone volume were calculated for each experimental group. Both 2D and 3D
images (saved as TIFFS) were created, with different colour assignments to certain greyscale
value ranges in order to highlight areas of interest.
2.4 Mechanical characterisation
2.4.1 Shear testing
Shear testing was carried out at Southampton University by Mr. E. Tayton.
Shear testing was carried out on milled scCO2 foamed scaffolds. The scaffolds were pro-
cessed using a standard bone mill (Tessier Osseous Microtome, Stryker Leibinger, Freiberg,
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Germany) and impacted into custom-made acrylic rings (School of Engineering Sciences,
University of Southampton) with an internal diameter of 65 mm and 10mm high. The acrylic
rings had removable perforated lids and bases. A custom-made impactor (School of Engi-
neering Sciences, University of Southampton) was used for the impaction process. This was
designed to mimic the forces of impaction bone grafting, which has been shown to be the
equivalent of a 1.98 kg mass dropping 65 mm onto a 60 mm diameter circular base [165].
The impactor was scaled to exert an identical pressure, this was achieved by dropping a 344
g mass a distance of 65 mm onto a 25 mm diameter base. The impaction process involved
filling the rings with milled polymer scaffold and impacting twenty-four times, and this
process was repeated twice more to fill the centre of the rings with impacted, milled, scCO2
foamed polymer scaffolds. The perforated lid and base were applied and the impacted poly-
mer discs were incubated at standard physiological conditions (37 ◦C, 5% CO2) in PBS for 1
week to replicate in vivo conditions. Figure 2.3A shows the impactor and a prepared sample
impacted into an acrylic ring.
After 1 week incubation the impacted polymer discs (65 mm × 10 mm) were removed
whole from the acrylic rings and placed into a custom-made Cam shear tester (School of
Engineering Sciences, University of Southampton) that consisted of two stainless-steel rings,
each 5 mm in height with 65 mm internal diameters. The rings were vertically stacked and
the upper ring was fixed in position, while the lower ring could be moved horizontally. Im-
pacted polymer discs, positioned in the centre of the stainless-steel rings, were placed under
a normal/compressive load; this was achieved through placing weights onto a plunger run-
ning on a linear bearing and resting on the polymer disc. A time of 5 minutes was allowed
for the sample to settle after applying the normal load. The lower ring was then driven by
a hydraulic actuator (Instron Ltd., Bucks, U.K.) at a constant rate of 1.2 mm min−1 .This
movement forced the impacted polymer disc to shear and the force required to move the
lower ring and the distance travelled were recorded using load and displacement sensors
within the actuator. For each polymer scaffold type three compressive loads (50, 150, and
250 N), which gave compressive stresses of 102, 306, and 509 kPa to simulate physiological
stresses [54], were used on different samples (n=4). This method has been used previously
within the literature by Bolland et al. [54].
The resultant stress-strain curves were used to plot the Mohr-Coulomb failure envelope
curves for each scaffold type and shear strength and interlocking particle cohesion were
derived for each. The mean shear strength at 10% strain (standard engineering practice) was
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Figure 2.3: A. Impactor for preparing samples for mechanical shear testing. White arrow in-
dicates the impactor device and the black arrow indicates an impacted sample of
milled scCO2 foamed polymer in an acrylic ring. B. Example Mohr-Coulomb fail-
ure curve for impacted allograft morsels. The inset diagram shows the direction
of the forces applied to impacted rings under test.
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plotted against the normal load and grouped linear regression analysis carried out (Graph-
Pad Prism 6, GraphPad Software Inc., CA, U.S.A.). The Mohr-Coulomb failure criterion is
expressed as τ = σtan(φ) + c, where τ is the shear strength, σ is the normal stress, φ is the
angle of internal friction, and c, the intercept is the interparticulate cohesion. An example
Mohr-Coulomb failure curve is shown in Figure 2.3B.
2.5 General cell culture
Cell culture was performed using aseptic technique in a class II microbiological safety cab-
inet (Envair, Haslington, U.K.). In vitro incubation of cells was in a Sanyo MCO-17AIC
incubator (Sanyo Electric, Biomedical, IL, U.S.A) at 37 ◦C and 5% CO2.
Primary human mesenchymal stem cells were used for the majority of the cell culture
studies within this thesis. Ovine mesenchymal stem cells were utilised for the parallel in vitro
studies that accompanied the ovine femoral condyle defect study in Chapter 4. Immortalised
human mesenchymal stem cells were used for the polymer film experiments in Chapter
5. Protocols for these studies are included in the materials and methods sections of the
appropriate chapters.
For cell expansion and cell seeding basal medium was used which was α-Modified Ea-
gle’s Medium (α-MEM) supplemented with 10 vol.% fetal bovine serum (FBS), and 100 µg
ml−1 penicillin and 100 µg ml−1 streptomycin (Pen-Strep, Invitrogen).
Osteogenic differentiation of MSCs was stimulated utilising osteogenic medium which
was basal medium supplemented with 100 µM ascorbate-2-phosphate and 10 nM dexam-
ethasone.
2.5.1 Primary human mesenchymal stem cells
All culture of primary MSCs was performed at Southampton University by Mr. E. Tayton.
2.5.1.1 Isolation of cells
Mesenchymal stem cells were harvested from the bone marrow of a 66 year-old male un-
dergoing routine hip replacement surgery with the approval of the local hospital ethics
committee (LREC 194/99/w, 21/10/10). They were then expanded in vitro in T150 flasks in
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basal medium (α-MEM with 10% FBS and 1% penicillin and streptomycin) at 37 ◦C and 5%
CO2 until confluent. Media changes were performed every 3 days during culture. At con-
fluence the cells were washed in phosphate buffered saline (PBS) and treated with trypsin
in ethylenediaminetetraacteic acid (EDTA) for 2 minutes to detach cells from tissue culture
plastic (TCP). An equal volume of serum-containing medium was used to deactivate the
trypsin and the cell suspension transferred to a universal tube and centrifuged for 5 minutes
at 180 g. Supernatant was aspirated and cells resuspended in FBS + 10% dimethyl sulfoxide
(DMSO) to a concentration of 1 million cells ml−1. Cells were stored in 1 ml cryo-vials at -80
◦C for one week and then transferred to liquid N2 storage.
2.5.1.2 Cell culture
For each study an appropriate number of cryo-vials of cells (passage 1, P1) were reanimated
by thawing and suspension in 10 ml of basal medium. Then they were centrifuged for 5
minutes at 180 g. The supernatant was aspirated and the cells re-suspended in basal medium.
Cell concentration was determined using a haemocytometer and appropriate dilution with
basal medium to reach a final concentration of 5 × 105 cells ml−1.
2.5.1.3 Preparation of scaffolds
Polymer scaffolds were milled in a standard bone mill (Tessier Osseous Microtome, Stryker
Leibinger, Freiberg, Germany) to produce small chips of porous scaffold. These chips were
sterilised in 5% antibiotic/antimycotic solution (Sigma-Aldrich, U.K.), placed under ultravi-
olet (UV) light for 24 hours and submerged in basal medium for a further 24 hours prior to
cell seeding. Figure 2.2B shows an image of milled chips of polymer scaffolds.
2.5.1.4 Cell seeding
Sterilised milled chips of polymer scaffolds were placed in sterile universal tubes and 20 ml
of cell suspension (5 × 105 cells ml−1 in basal medium) was added to each. The universal
tubes were placed in an incubator under standard conditions (35 ◦C, 5% CO2) for 2 hour
with gentle agitation every 30 minutes.
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2.5.1.5 Impaction of seeded scaffolds
A smaller scale impaction device to the one described in Section 2.4.1 was sterilised in an
autoclave. The design of the device was such that it applies equal pressure upon impaction
to the larger device to simulate the forces experienced during IBG. Approximately 1 ml of
milled polymer chips seeded with cells was loaded into an open ended plastic impaction
chamber in three equal portions and the impaction device was used to give 24 impactions
between each addition. The open ended impaction chambers were placed in non-TCP six
well plates (1 sample per well) and cultured in osteogenic conditions (basal medium + 100
µM ascorbate-2-phosphate and 10 nM dexamethasone) at 37 ◦C and in 5% CO2. Cell culture
medium was changed every 3 days. Figure 2.2C shows an x-ray image of chips of polymer
scaffold impacted into an impaction chamber.
2.6 Cellular assays
2.6.1 WST-1 proliferation assay
TheWST-1 (Water soluble tetrazolium salt-1 (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disul-
fophenyl)-2H-tetrazolium)) metabolic assay (Roche Ltd, Welwyn Garden City, U.K.) was
used to assess cell viability and proliferation. WST-1 is reduced by metabolically active cells
to a water-soluble formazan dye that then allows a colorimetric measurement of metabolic
activity that can be correlated to number of viable cells. This reduction is dependent on
reduced pyridine nucleotides NADH (reduced nicotinamide adenine dinucleotide) and
NADPH (reduced nicotinamide adenine dinucleotide phosphate) and occures primarily at
the extracellular surface of the plasma membrane [166].
The protocol varied for each study and deviations are detailed in individual chapters. An
example protocol follows for milled, seeded, and impacted polymer scaffolds in impaction
chambers. For each scaffold type three samples (and one control without cells) were sub-
merged in 2.5 ml of 1:10 dilution WST-1 substrate. At 2 and 4 hr, 400 µl of substrate was
removed and read in triplicate via a Bio-Tek KC4 microplate fluorescent reader (Bio-Tek,
USA) at 450 nm. Mean and standard deviation values for each sample at both time points
were calculated and mean control values subtracted.
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2.6.2 Alkaline phosphatase activity assay
Alkaline phosphatase (ALP) is a membrane bound enzyme utilised as an early indicator
for osteoblastic differentiation [167, 168]. Its expression is not entirely specific to osteoblas-
tic cells and other indicators are required to confirm osteoblastic differentiation [169]. The
levels of alkaline phosphatase expression were determined through a colorimetric assay.
para-Nitrophenylphosphate and water react in the presence of alkaline phosphatase to phos-
phate and para-nitrophenol; para-nitrophenol has a yellow appearance and the concentra-
tion can be determined through optical absorbance reading at 405 nm. The concentration
of para-nitrophenol is proportional to the concentration of alkaline phosphatase in each
sample if read at the same time point, under the same conditions, and if the same starting
concentration of para-nitrophenylphosphate is used.
The protocol varied for each study and deviations are detailed in individual chapters. An
example protocol follows for milled, seeded, and impacted polymer scaffolds in impaction
chambers. The contents of three impaction chambers and one control from each group were
washed in PBS and fixed in 90% ethanol prior to air drying; then rewashed with PBS and
suspended in 2 ml of 0.5% Triton X-100. Three freeze thaw cycles were carried out with vig-
orous agitation between cycles. p-Nitrophenyl phosphate (1 mg ml−1) was used as substrate
in 2-amine-2-methyl-1-propanol alkaline buffer solution (Sigma-Aldrich, U.K.) for lysate
measurements for ALP activity. Cell lysate samples has ALP substrate solution added and
were incubated at room temperature for 30 minutes. Cell lysate (10 µl) was run in triplicate
for three impacted cell seeded samples and a single control sample of each scaffold type on
a plate against ×2 standards, read on a Bio-Tek KC4 and FLX-800 microplate fluorescent
reader (Bio-Tek, USA) at 405 nm and the mean and standard deviations were calculated. The
standards were used to calculate a standard curve from which ALP concentration within
cell lysate samples could be calculated. Mean ALP activity was calculated for each polymer
scaffold type by dividing the mean ALP concentration by the mean DNA concentration for
each group, which gave the specific ALP activity in units of nanomoles of para-nitrophenyl
phosphate per hour per nanograms of DNA [nmols pNPP h−1 ng DNA−1].
2.6.3 DNA assay
The protocol varied for each study and deviations are detailed in individual chapters. The
cell lysate used for ALP assays was also used for DNA assays. An example protocol fol-
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lows for milled, seeded, and impacted polymer scaffolds in impaction chambers. PicoGreen
(Molecular Probes, U.K.) was used to quantify deoxyribonucleic acid (DNA) concentration
as per manufacturer protocol. Triplicate measurements of 10 µl of lysate for each sample
were measured against ×2 standards on a Bio-Tek KC4 and FLX-800 microplate fluorescent
reader. Calf thalmus DNAwas used for the standards. Means for each groupwere calculated
and the means of controls subtracted (for the appropriate group). The standards were used
to calculate a standard curve from which DNA concentration within cell lysate samples
could be calculated.
The PicoGreen assay uses a fluorescent nucleic acid stain that has a linear detection
range over three orders of magnitude (500 pg ml−1 - 500 ng ml−1. The dye bonds to double-
stranded DNA, although it will also bond to RNA and single-stranded DNA. When bonded
to double-stranded DNA it excites at a wavelength of 480 nm and fluoresces at 520 nm with
minimal interference from single-stranded DNA and RNA bound dye.
2.7 Immunohistochemical staining
Immunostaining of primary MSCs and ovine MSCs was performed at Southampton Univer-
sity by Mr. E Tayton. Confocal microscopy of these samples was performed at Southampton
University by Dr. David Johnston. Immunostaining and fluorescent microscopy of immor-
talised human MSCs (Chapter 5) was performed at The University of Nottingham by the
author.
The protocol varied for each study and deviations are detailed in individual chapters. An
example protocol follows for milled, seeded, and impacted polymer scaffolds in impaction
chambers. The contents of an impaction chamber for each scaffold type was washed in PBS
and fixed for 24 hours in 4% paraformaldehyde. Samples were kept in PBS until immunohis-
tochemically stained, which involved 10 min incubation in 1% bovine serum albumin (BSA)
followed by incubation overnight in 1 ml primary antibodies for collagen-1 (LF68, whole
rabbit serum; 1:3000 diultion), osteocalcin (OC; monoclonal antibody OS 35; 1:100 dilution),
and bone sialoprotein (BSP; anti-human BSP; 1:100 dilution). Then three washes with 0.1%
PBS Tween were carried out. The appropriate secondary antibody was added for an hour
at ambient conditions followed by three 0.1% PBS Tween washes. DAPI (1:100) was added
as a nuclear counter stain via 10 min incubation. Specificity was confirmed by treating a
portion of each sample with secondary antibody only. Samples were stored in PBS and kept
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away from light until imaged via confocal microscopy (Leica SP5 Laser Scanning Confocal
Microscope and software, Leica, Germany).
2.8 Statistical analysis
GraphPad Prism 6 software (GraphPad Software Inc., CA, U.S.A.) was used to carry out sta-
tistical analysis on quantitative results. One way analysis of variance with Tukey’s multiple
comparison test was carried out to assess statistical significance of results.
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CHAPTER 3
Supercritical CO2 foamed polymeric
scaffolds for impaction bone grafting
applications
In this chapter the difference between non-porous and porous polymer scaffolds produced
through scCO2 is highlighted. Both PDLLA and PDLLGA scaffolds are used to demonstrate
improved cell compatibility and shear resistance of foamed scaffolds over nonfoamed scaf-
folds. Given that both PDLLA and PDLLGA compare favourably against allograft in mechani-
cal shear tests polymer choice was left to cellular responses. MSCs were shown to proliferate
well on both types of polymer but osteoblastic differentiation was demonstrably greater in
the time period on PDLLA scaffolds. This was shown to be improved with the inclusion
of hyrdoxyapatite and mechanical strength remained unaffected by the composite scaffold.
A small scale in vivomodel demonstrated the same results and additionally demonstrated
vascularisation of the scaffolds and cell staining was used to confirm cells seeded on the
scaffolds remained.
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3.1 Introduction
In Chapter 1 the increasing need for bone graft materials was established, particularly for im-
paction bone grafting (IBG). Various biomaterials used to produce bone tissue engineering
scaffolds including bioresorbable polymers were described. Methods of producing porous
bioresorbable polymeric scaffolds were also described. Supercritical CO2 foaming is one
such method that holds particular promise due to the low operating temperature and no
requirement to utilise organic solvents. High operating temperatures limit the use of thermo-
labile, bioactive molecules that can enhance scaffold performance such as BMP-2. Organic
solvents leave residues that are harmful to cells and limit the cellular compatibility of scaf-
folds, or add the need for a solvent extraction step which can decrease the economic viability
of a process.
A large volume of scientific research has been generated on the subject of bone tissue
engineering/regeneration. Bone properties (modulus, porosity, tensile strength, and com-
pressive strength) vary widely with function which has led to a diverse range of studies for
different application of scaffolds in bone tissue engineering. Where a scaffold may be perfect
for maxillofacial [170] or dental applications, a different scaffold may perform better in load
bearing applications such as spinal [171] or long bone repair. Targeted scaffold application
and well-designed studies demonstrate the capabilities of this field more strongly.
The studies described in this chapter were undertaken to determine the most favourable
polymeric scaffolds to use, in conjunction with MSCs, as osteogenic alternatives to allograft
bone in IBG procedures. The scaffolds tested with the most promising results were then used
in a large animal model as detailed in Chapter 4. The number of scaffolds that could be in-
vestigated in the large animal model were severely restricted because of the associated costs
and time investment. Therefore, the studies within this chapter were required to identify the
most promising scaffolds worthy of this investment.
Previous work demonstrated enhanced MSC survival and proliferation on high molec-
ular weight, MW (>80 kDa) PDLLA, PDLLGA, and PCL over low MW (<35 kDa) forms of
the same polymers [4]. Tayton et al. [4] studied the proliferation of MSCs on melt processed
polymer scaffolds. These melt processed scaffolds were milled using a standard bone mill,
sterilised, and seeded with MSCs. After seeding, the milled chips were aseptically impacted
in a process to mimic the forces of an IBG procedure and cultured for 8 days. A metabolic
assay (WST-1) and live/dead fluorescent staining revealed significantly greater proliferation
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(P<0.05) on high MW (126 kDa) PDLLA and high MW (110 kDa) PDLLGA scaffolds, than low
MW (26 kDa for PDLLA and 36 kDa for PDLLGA) scaffolds of the same polymers; the same
trend was observed for MSCs cultured on high MW (85 kDa) PCL scaffolds to those on low
MW (14 kDa) PCL, although this was not significant at the P<0.05 level. In the same study
the authors investigated the resistance to mechanical shear of impacted, milled chips of the
polymers. They reported that both high and low MW PDLLA and PDLLGA outperformed
milled and impacted chips of allograft bone; high and low MW PCL samples did not. These
results provided a basis for the further study of high MW PDLLA and PDLLGA scaffolds.
The importance of porosity in bone regeneration targeted scaffolds has been strongly
established [172]. Kuboki et al. [173] established BMP-induced osteogenesis occurred in vivo
(inside a living organism) (rat ectopicmodel) on porousHA and not on solidHA. Fujibayashi
et al. [174] were the first to report bone induction in a non-osseous site by titanium metal
(a material accepted as being bioinert) attributed purely to the macrostructures (>100 µm)
and microstructures (≤100 µm) of the implants. In contrast to the findings of Fujibayashi
et al., Yuan et al. [175] reported osteoinductive properties of HA (a material generally ac-
cepted as having osteoinductive properties) varied with the microstructure of implants to
such an extent that while in vivo (3 and 6 months in canines) bone formation was found
with macroporous HA implants (average pore size 400 µm, porosity 60–70%) with rough
irregular pore walls (observed by SEM), no bone formation was detected in the same model
in macroporous HA implants (average pore size 200 µm, porosity 70%) with smooth pore
walls. With the importance of porosity established, many investigations in the literature are
published on novel porous scaffolds targeted for bone tissue engineering with the absence
of non-porous controls for comparison [176–178].
In addition to the body of evidence supporting osteoinductive properties of micro poros-
ity within bone tissue engineering scaffolds, the presence of porosity, particularly intercon-
nected porosity, is required for cell migration, cell proliferation, vascularisation, nutrient
transfer, and bony in-growth. Work in 1970 by Hulbert et al. [179] recommended minimum
pore sizes of 100 µm for improved osteogenesis in porous implants. Subsequent work has
demonstrated improved osteogenesis in comparative studies where porous implants with
pores >300 µmwere utilised [180, 181].
The consensus on optimal pore size for bone regeneration scaffolds is not definitive, par-
ticularly given the wide range in bone properties such as porosity and mechanical strength.
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A porosity greater than 100 µm is widely regarded as optimal but ranges from 100–400 µm
are cited [182–184], while other published studies demonstrate no significant difference in
bone growth on scaffolds with different pore sizes [129]. Additionally, it is inappropriate
to use optimal properties for animal in vivomodels and regard the results as definitive for
human application. Karageorgiou et al. [172], in a review of porosity in osteogenic scaffolds,
identified that there are no reports indicating beneficial effects for implants with low poros-
ity in terms of cell behaviour. For scaffolds formed of the same material, mechanical strength
typically decreases as porosity increases.
Additionally optimal porosity is also dependent on the scaffold materials. Degradation
rates andmechanical properties vary between materials and an optimal balance between the
required properties of a bone tissue engineering scaffold is required [17]. Where biodegrad-
able polymers are utilised as scaffold materials degradation rates and mechanical strength
will vary based on MW even for identical polymers e.g. PDLLA MW ≈ 20 kDa will undergo
hydrolytic degradation more quickly than PDLLA MW ≈ 100 kDa.
In IBG a bone mill is utilised to process allograft into mm sized particles for impaction
into the cavity created through loss of bone stock. The milling process imparts additional
macro porosity into the allograft, whereby the milled and impacted particles form a scaffold
to support bone regeneration and the impacted particles do not fit perfectly together when
impacted, that results in macro porosity between particles [185]. Whether this level of poros-
ity is sufficient, or whether greater osteogenic performance can be imparted into polymer
scaffolds undergoing milling and impaction is important. This study provided a comparison
between milled and impacted polymer versus porous milled and impacted polymer.
Previously, supercritical CO2 foaming was utilised to create porous polymeric foams us-
ing biodegradable polymers such as PLA and PLGA [108, 186, 187]. The process is free from
the use of organic solvents which appeals for tissue engineering applications by removing
the need for drying steps and residual entrapped organic solvents within the polymeric scaf-
folds as with other processes e.g. solvent casting/particulate leaching. The supercritical CO2
foaming process was performed at low temperatures (35 ◦C) which favourably compares to
melt extrusion processing or solvent casting/particulate leaching by allowing incorporation
of thermolabile or chemically sensitive bioactive molecules such as BMP-2 that would lose
activity under the more harsh conditions of the alternative processes. Howdle et al. [188]
demonstrated the incorporation of thermolabile molecules into polymers utilising supercrit-
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ical CO2 technology and BMP-2 is a potential molecule of interest that may further enhance
osteogenic performance of these scaffolds [189].
While allograft is the current clinical gold standard for IBG procedures it lacks the os-
teogenic (ability to form new bone) properties of autograft. Allograft is osteoinductive (stim-
ulates pluripotent cells to differentiate down the osteoblastic lineage) and osteoconductive
(provides scaffolding for new bone). A synthetic alternative to allograft would demonstrate
clear advantages by providing osteogenic properties in addition to osteoinductive and os-
teoconductive properties. Cells (osteoblastic or osteoprogenitor) must be incorporated into
a scaffold to impart osteogenic properties. For cells to be incorporated into scaffolds for IBG
applications the cells must be capable of surviving the impaction process.
A study by Bolland et al. [54] established osteogenic potential in allograft when seeded
with MSCs. The work utilised an impaction process to mimic IBG that had previously been
used by Dunlop et al. and Brewster et al. [165, 190]. This experimental model demonstrated
cell survival on allograft through an impaction process. Bolland et al. also demonstrated
improved shear strength in allograft seeded with hBMSCs in comparison to allograft alone.
While this study established improved performance of allograft with hBMSCs the issues
associated with allograft use such as availability and risk of infection transmission remain.
The studies detailed in this chapter demonstrate cell survival on scCO2 foamed scaffolds
through an impaction process that mimics forces used in IBG for the first time. This is an im-
portant initial step in demonstrating the potential of supercritical foamed polymer scaffolds
and MSCs as composite alternatives to bone allograft in IBG. Initial in vitro (outside of a
living organism) experiments are described that were used to determine the most promising
scaffold formulations for a 5 week murine in vivomodel. These were carried out using pro-
liferation assays and osteogenic differentiation assays. The in vitro experiments were carried
out to reduce the number of animals required for in vivo study. The murine in vivo model
was undertaken to establish the in vivo performance of the most promising formulations
to distinguish the most promising to be taken forward in to an ovine in vivo model that is
detailed in Chapter 4.
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3.2 Materials and methods
3.2.1 Reagents
All reagents were obtained from Sigma-Aldrich (U.K.) unless otherwise stated. This in-
cludes α-MEM, FCS, ascorbate-2-phosphate, and dexamethasone. Fluorescent dyes includ-
ing Cell Tracker Green (CMFDA, 5-chloromethylfluorescein diacetate), Vybrant Alexafluor,
and EthidiumHomo-dimer-1 were purchased from Invitrogen (U.K.). Collagen-1 polyclonal
antibodies were obtained as a gift from Dr. Larry Fisher (NIH, MD, U.S.A.).
3.2.2 Importance of supercritical foaming
3.2.2.1 Preparation of polymer scaffolds
Supercritical CO2 foamed PDLLA and PDLLGA scaffolds and melt processed PDLLA and
PDLLGA scaffolds were used for this study. The processes for producing these scaffolds are
detailed below. Once the scaffolds were formed they were milled in a standard bone mill
(Tessier Osseous Microtome, Stryker Leibinger, Freiberf, Germany), sterilised, seeded with
primary human MSCs, and impacted into open ended impaction chambers. The milling and
sterilisation process is detailed in Section 2.5.1.3.
Supercritical carbon dioxide foaming
Supercritical CO2 foamed polymer scaffolds were prepared as detailed in Section 2.1 using
PDLLA and PDLLGA. Briefly, 300 mg of ground polymer powder was loaded into cylindrical
wells of a PTFEmould and foamed in scCO2 at 35 ◦C and 23MPa for 1 hour with a 30 minute
constant rate vent back to atmospheric pressure.
Melt processing of polymer
Melt processed scaffolds were made in the same PTFE moulds used for scCO2 foamed
scaffolds. Polymer powder was heated to 150 ◦C on a PTFE sheet on a hot plate and the
softened polymer transferred into cylindrical wells of the PTFE mould and subsequently
cooled. The polymer scaffolds were then removed from the moulds.
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3.2.2.2 Scanning electron microscopy
Scanning electron microscopy was used on scaffolds prior to the milling process to charac-
terise the internal porous structure. Obtaining SEM images was a destructive process. The
protocol used for SEM is detailed in Section 2.2 .
3.2.2.3 Micro x-ray computed tomography
Like SEM, µCT was used to characterise scaffolds prior to the milling process. Unlike SEM
however, µCT was non-destructive. The protocol used for characterising scaffolds using
µCT is detailed in Section 2.3.1.
3.2.2.4 Mechanical shear testing
Mechanical shear testing was carried out using the protocol detailed in Section 2.4.1. Sam-
ples of allograft were also characterised using this method. Donated fresh femoral heads
were stored at -80 ◦C prior to use. They were retrieved with consent of patients undergo-
ing hip surgery with approval of the local ethics committee (LREC 194/99/w, 27/10/10).
Under sterile conditions femoral heads were defrosted, had the cartilage and cortical bone
removed, and were then milled using a standard bone mill (Tessier Osseous Microtome,
Stryker Leibinger, Freiberf, Germany). Milled bone graft was soaked in 6% hydrogen per-
oxide for 30 min, to remove fat and marrow. The fat and hydrogen peroxide were removed
and allograft was then saline washed ×3, soaked in antibiotic/antimycotic solution and
subjected to UV light for 24 hours. It was then washed in PBS and submerged in basal media
for 24 hours prior to use. It was impacted as polymer scaffolds were impacted, using the
protocol detailed in Section 2.4.1.
3.2.2.5 Cell culture
The isolation of primary human MSCs and their expansion and storage prior to use is de-
tailed in Section 2.5.1.1. The subsequent seeding and impaction of seeded scaffolds is de-
tailed in Sections 2.5.1.4 and 2.5.1.5, respectively. Cells were incubated in vitro for 2 weeks
under standard cell culture conditions (37 ◦C and 5% CO2).
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Live/dead immunocytochemical stain
Cell Tracker Green is a widely usedmarker used to label viable cells. Ethidium homodimer-1
is a widely used marker for nectrotic cells. Together the two stains are used for live/dead
staining and imaging of cellular samples. Following 2 weeks of in vitro incubation the con-
tents of two impaction chambers from each group (melt processed PDLLA, melt processed
PDLLGA, scCO2 foamed PDLLA, and scCO2 foamed PDLLGA) were removed and placed in
six well plates. They were incubated for 90 minutes in 5 ml of standard CTG/EH-1 solution
(10 µg ml−1 CTG, 5 µg ml−1 EH-1). Samples were then fixed in ethanol and stored in PBS
prior to imaging under confocal microscopy (Leica SP5 and software, Leica Microsystens,
Germany).
WST-1 assay
The WST-1 assays were carried out for samples following the protocol described in Section
2.6.1.
ALP/DNA assay
The ALP and DNA assays were carried out using the protocols described in Sections 2.6.2
and 2.6.3, respectively.
3.2.3 Assessing formulation performance
3.2.3.1 Preparation of polymer scaffolds
Supercritical CO2 foamed PDLLA and PDLLGA scaffolds as pure polymer and with 10 wt.%
HA microparticles were used for this study. Supercritical CO2 foamed polymer scaffolds
were prepared as detailed in Section 2.1 using PDLLA and PDLLGA. Briefly, 300mg of ground
polymer powder (or 270 mg ground polymer and 30 mg HA microparticles) was loaded
into cylindrical wells of a PTFE mould and foamed in scCO2 at 35 ◦C and 23 MPa for 1
hour with a 30 minute constant rate vent back to atmospheric pressure. Once the scaffolds
were formed, they were milled in a standard bone mill (Tessier Osseous Microtome, Stryker
Leibinger, Freiberf, Germany), sterilised, seeded with primary human MSCs, and impacted
into open ended impaction chambers. The milling and sterilisation process is detailed in
Section 2.5.1.3.
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3.2.3.2 Mechanical shear testing
Mechanical shear testing was carried out using the protocol detailed in Section 2.4.1.
3.2.3.3 Cell culture
The isolation of primary human MSCs and their expansion and storage prior to use is de-
tailed in Section 2.5.1.1. The subsequent seeding and impaction of seeded scaffolds is de-
tailed in Sections 2.5.1.4 and 2.5.1.5, respectively. Cells were incubated in vitro for 2 weeks
under standard cell culture conditions (37 ◦C and 5% CO2).
Live/dead immunostain
Live/dead immunocytocehmical staining was carried out using the protocol described in
Section 3.2.2.5.
WST-1 assay
The WST-1 assays were carried out for samples following the protocol described in Section
2.6.1.
ALP/DNA assay
The ALP and DNA assays were carried out using the protocols described in Sections 2.6.2
and 2.6.3, respectively.
Collagen-1 immunohistochemical stain
Collagen-1 immunostaining was carried out utilising the protocol described in Section 2.7.
3.2.3.4 Murine in vivo model
The osteogenic capacity of the scCO2 foamed PDLLA scaffolds with and without 10 wt.% HA
microparticles was assessed utilising an in vivo murine subcutaneous model. The PDLLA
scaffolds were chosen over PDLLGA scaffolds due to better performance in in vitro studies
(greater observed osteoblastic differentiation after 2 weeks). It was desirable to reduce the
scaffolds tested in vivo to conform to Good Laboratory Practices (GLP) for animal studies
and reduce the animals required for testing.
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Primary human MSCs were used as described Sections 2.5.1.1 and 2.5.1.4. The polymer
scaffolds used were scCO2 foamed and prepared as described in Sections 2.1 and 2.5.1.3.
The milled polymer scaffolds were then impacted into open ended impaction chambers
as described in Section 2.5.1.5. These scaffolds were then incubated in vitro for 1 week in
osteogenic medium under standard cell culture conditions (35 ◦C and 5% CO2). Impacted
scaffolds with no cells were cultured under the same conditions for 1 week and used in vivo
as controls. On day six the cells in two impaction chambers of both groups (scCO2 foamed
PDLLA and scCO2 foamed PDLLA + 10 wt.% HA microparticles) were immunostained for
long-term tracking by submersion in 8 ml of 1:800 dilution Vybrant:PBS for 15 minutes.
This was followed with a PBS wash and 24 hour incubation in osteogenic medium under
standard culture conditions (35 ◦C and 5% CO2).
After 1 week of in vitro incubation, pre-acclimatised male foxn1numice (Harlan, Lough-
borough, U.K.) were anaesthetised intraperitoneally using fentanyl fluanisone (Janssen-
Cilag Ltd., Bucks, U.K.) and midazolam (Roche Ltd., Welwyn Garden City, U.K.). Small
(1 cm) incisions were made into the subcuticular tissue over the loin area, bilaterally, and
pockets created into which the open ended impaction chambers containing the impacted
polymeric scaffolds were placed. The incisions were closed under aseptic conditions, the
mice allowed to recover, and were subsequently allowed ad libitum access to standard
mouse chow and water.
After 5 weeks the mice were euthanized, and half were perfused with radio-opaque
contrast (a mixture of barium sulfate and 2% laponite solution) via the left ventricle as
detailed in Bolland [191], in order to display the neo-vasculature around and throughout
the open ended impaction chambers.
Micro x-ray computed tomography
The protocol used for characterising scaffolds using µCT is detailed in Section 2.3.2.
Histological analysis
Following µCT analysis, the samples were removed from the impaction chambers and was
used for histological analysis. They were washed and decalcified as detailed by Miao and
Scutt [192], followed by dehydration in a graded series of alcohols, lowmelting point paraffin
wax embedding, and cut into 7 µm sections. Staining included an Alcian Blue (for proteogly-
can rich ECM) and Sirius Red stain (for collagen), and Goldner’s Trichrome stain for bone
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and osteoid. Alcian blue staining required deparaffinizing the samples and hydration with
distilled water; then coating in alcian blue solution (pH2.5, alcian blue 10 mg ml−1, acetic
acid 3%) for 30 minutes; and washing in distilled water. Sirius red staining followed with
submersion in sirius red solution (sirius red 1 mg ml−1, 1.3 % picric acid in water) for 1
hour and ×3 washes in acidified water (acetic acid 5 ml L−1). Goldner’s trichrome staining
required staining in poncea acid fuchsin solution (ponceau 2R 750 µg ml−1, acid fuchsin 250
µg ml−1, azophloxine 100 µg ml−1, acetic acid 0.2%) for 5 minutes, washing in 1% acetic acid,
submersion in phosphomolybdic acid-orange G solution (orange G 20 mg ml−1, phospho-
molybdic acid 40 mg ml−1) to decolourise collagen, washing in 1% acetic acid, staining in
light green stock solution (light green 2 mg ml−1, acetic acid 0.2%), and final washing in 1%
acetic acid.
Immunohistochemical staining
Sections of impacted scaffolds removed from the impaction chambers post-in vivo incuba-
tion underwent immunohistochemical staining for collagen-1, bone sialo protein, osteocalcin,
and von Willebrand factor following the protocol detailed in Section 2.7.
3.3 Results and discussion
3.3.1 Importance of supercritical foaming
The aim of this study was to determine the most favourable polymeric scaffolds for use
with MSCs as an osteogenic alternative to allograft. Previous work demonstrated high MW
PDLLA and PDLLGA as promising scaffold materials over PCL, an alternative widely used
biodegradable polymer [4]. The importance of porosity in bone tissue engineering scaffolds
is widely established [173, 174, 180, 181, 193] and various methods for porous scaffold for-
mation exist which were discussed in chapter 1. To establish the need for microporosity in
scaffolds that are milled using a bone mill, which incorporates macroporosity, scCO2 foamed
scaffolds were compared to non-foamed polymer scaffolds produced through melt process-
ing. These scaffolds were initially characterised by SEM and µCT was used to characterise
the internal structure of porous scaffolds.
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3.3.1.1 Structure characterisation
Scanning electron microscopy
Representative SEM images of milled polymer scaffolds are displayed in Figure 3.1 at x50
and x200 magnification. Figures 3.1A and B demonstrate the lack of porosity throughout the
non-foamed scaffolds for both PDLLA and PDLLGA, respectively, in comparison to the scCO2
foamed scaffolds (Figures 3.1C and D for PDLLA and PDLLGA, respectively). The differences
in porosity and pore size were expected due to the use of identical scCO2 foaming protocols
for both polymers, which interact differently with the scCO2.
Micro x-ray computed tomography
Representative axial µCT slices of scCO2 foamed PDLLA and PDLLGA are shown in Figure
3.2. These images give an indication of the porosity of the foamed polymer scaffolds prior to
milling. µCT analysis of the scaffolds calculated the mean porosity of the scaffolds as: 58.7
± 0.6% and 45.5 ± 0.6% for scCO2 foamed PDLLA and scCO2 foamed PDLLGA, respectively.
The average pore size of the scaffolds was also calculated using micro CT analysis as: 118 ±
3 µm and 85 ± 11 µm for scCO2 foamed PDLLA and scCO2 foamed PDLLGA, respectively.
3.3.1.2 Mechanical characterisation
Scaffolds were then milled using a standard bone mill and impacted in a process that mim-
icked the forces of a surgical IBG process. Milled and impacted polymer scaffolds were tested
for shear resistance under different normal loads and compared to milled and impacted al-
lograft as a control. The mean of the shear resistance for samples under each normal loading
are displayed in Figure 3.3. Linear regression analysis was used to analyse these results and
calculate interparticulate cohesion values for each sample from plotted Mohr-Coulomb fail-
ure curves (example curve shown in Figure 2.3B). The interparticulate cohesion values for
the milled polymer scaffolds were compared to allograft controls for statistical significance
and both the interparticulate cohesion and statistical significance are shown in Table 3.1.
Revision hip allografts are common surgical procedures that utilise allograft for IBG into
the femur and acetabulum. Shear failure has been identified as a common cause of failure
of revision hip allografts through stem subsidence. The mechanical shear tests carried out
were consistent tests reported within the literature [54, 190, 194], and established that PDLLA
and PDLLGA (both scCO2 foamed and non-foamed) had significantly higher interparticulate
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Figure 3.1: Representative SEM images of polymeric scaffolds post-milling (bone mill) to
demonstrate microscale morphological differences between (A) non-foamed
PDLLA, (B) non-foamed PDLLGA, (C) scCO2 foamed PDLLA, and (D) scCO2
foamed PDLLGA . Main images at x200 magnification and inset images at x50
magnification. Scale bars equal 300 µm.
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Figure 3.2: Axial micro CT images of scCO2 foamed scaffolds prior to milling for: (A) scCO2
foamed PDLLGA and (B) scCO2 foamed PDLLA.
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Figure 3.3:Mean shear stress at 10% strain (n=4) for milled and impacted samples at differ-
ent normal loads. Porous refers to scCO2 foamed scaffolds. Both PLA and PLGA
are amorphous. Error bars represent standard deviation.
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Table 3.1:Mohr Coulomb failure curve interparticulate cohesion and R2 values calculated
from Figure 3.3 results (n=4). Statistical significance from linear regression analy-
sis of test materials compared to allograft controls also shown.
Test material Interparticulate Statistical Linear regression
cohesion significance R2 value
Allograft 62.5 N/A 0.990
PDLLA 201.3 P<0.0001 0.852
ScCO2 foamed PDLLA 155.1 P<0.0001 0.998
PDLLGA 111.6 P<0.001 0.987
ScCO2 foamed PDLLGA 228.5 P<0.0001 0.994
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cohesion values than allograft controls. Results between foamed and non-foamed polymer
scaffolds were inconclusive limiting further conclusions.
3.3.1.3 In vitro assessment of biocompatibility
Cellular compatibility
Representative live/dead confocal images of hMSCs seeded onto milled polymer scaffolds
and subsequently impacted and cultured for two weeks in osteogenic medium are shown
in Figure 3.4. Cells (green) are shown to have survived on all samples with few dead cells
(red) showing and a higher rate of proliferation evident on the scCO2 foamed scaffolds.
Visual observation showed a higher density of cells on scCO2 foamed scaffolds compared to
non-foamed scaffolds (Figures 3.4 B & D shows scCO2 foamed scaffolds versus non-foamed
counterparts in Figures 3.4 A & C).
Results fromWST-1 assays demonstrated quantitative evidence of increased metabolic
activity, and hence survivability and proliferation, of cells on scCO2 foamed scaffolds in
comparison to non-foamed scaffolds as can be seen in Figure 3.5. The mean metabolic
activity (n=3) of cells cultured on scCO2 foamed PDLLA is significantly greater than on
non-foamed PDLLA (P<0.01) and similarly the mean metabolic activity of cells cultured on
scCO2 foamed PDLLGA is significantly greater than on non-foamed PDLLGA (P<0.01). WST-
1 assays provide a quantitative measure of cell metabolic activity that can be correlated to
total cell number, but does not provide exact information. There is significant evidence from
the results of these assays, in conjunction with confocal images, that scCO2 foamed scaffolds
support a greater population of cells to corresponding non-foamed scaffolds. This is likely
due to the greater specific surface area of the porous scaffolds.
Figure 3.6 shows live/dead confocal images taken of MSCs cultured in osteogenic media
for 2 weeks on non-milled scCO2 foamed PDLLA (Figure 3.6 A and C) scaffolds and non-
milled scCO2 foamed PDLLGA Figure 3.6 B & D). Figures 3.6 A & B show cells growing on
the outer surface of the porous scaffolds while Figures 3.6 C & D show cells growing in the
pores of the scaffold which demonstrates cell migration into the scaffolds. This evidence that
cells are able to penetrate into non-milled scCO2 scaffolds is also evidence that this would
be possible in milled impacted scCO2 scaffolds.
O’Brien et al. [195] found strong correlation between scaffold specific surface area and
cell attachment for MC3T3 cells (murine osteoblast precursors) over 48 hours. Greater cell
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Figure 3.4: Confocal images of live/dead stained hMSCs cultured on milled polymer scaf-
folds of (A) PDLLA, (B) scCO2 foamed PDLLA, (C) PDLLGA, and (D) scCO2
foamed PDLLGA at x40 magnification. Cells were cultured for two weeks prior
to immunostaining. Inset images are control samples containing no cells. Inset
scale bars equal 200 µm.
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Figure 3.5:WST-1 assay readings showing optical density readings at 450 nm for hMSCs
cultured on milled and impacted polymer scaffolds for two weeks in osteogenic
medium (n=3). Assay readings were taken in triplicate after 2 hour incubation
and statistical significance between scCO2 foamed and non-foamed PDLLA and
PDLLGA is shown (**P<0.01). Other results not significant at p<0.05 level).
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Figure 3.6: Confocal images of live/dead stained hMSCs (bright green) cultured on: (A)
outer surface of scCO2 foamed PDLLA, (B) outer surface of scCO2 foamed
PDLLGA, (C) inner sectioned surface of scCO2 foamed PDLLA, and (D) inner
sectioned surface of scCO2 foamed PLGA. Cells were cultured for two weeks in
osteogenic media. Arrows highlight cells that demonstrate cell growth within
the scaffolds.
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attachment on porous scaffolds and similar population doubling times between porous
and non-porous scaffolds would lead to a larger cell population on porous scaffolds, as
observed, until confluent. With a greater specific surface area, and cells able to penetrate
the porous scaffolds, porous scaffolds would allow a larger cell population. There were
significant (P<0.05) differences in WST-1 assay readings between cells cultured on scCO2
foamed PDLLA and scCO2 foamed PDLLGA which would imply greater proliferation of
cells on scCO2 foamed PDLLA scaffolds. However, given the scCO2 foamed PDLLA scaffolds
were more porous (58.7%) than the scCO2 foamed PDLLGA scaffolds (45.5%), this is likely
due to the difference in specific surface area between the two scaffold types. This porosity
difference is due to the different polymers undergoing an identical supercritical foaming
process and behaving slightly differently under identical conditions.
The porosity in scCO2 foamed scaffolds may provide protective cavities for cells to
reside in during impaction; this could also be attributed to the larger stem cell population
observed on the porous scaffolds. If cells are damaged through the impaction process when
seeded onto non-foamed scaffolds and cells seeded on scCO2 foamed scaffolds are protected
from the impaction forces we would expect a greater cell population on the scCO2 foamed
scaffolds, as observed. Korda et al. [196, 197] previously demonstrated that hMSCs could
survive typically impaction forces when seeded on allograft. Allograft itself is porous and
may provide cavities for cells to reside in during impaction. This makes it difficult to confirm
whether cells are withstanding the force of the impaction or are shielded from the full force
of the impaction through scaffold/allograft porosity.
Osteoblastic differentiation
Specific activity of ALP was measured in triplicate for cells cultured on each of the milled
and impacted polymer scaffolds as an early indicator of osteoblastic differentiation. The
results presented in Figure 3.7 show negligible ALP specific activity for cells cultured on
non-foamed polymer scaffolds and scCO2 foamed PDLLGA. A significantly greater (P<0.001)
ALP specific activity was observed from cells cultured on scCO2 foamed PDLLA scaffolds.
As an additional indicator of osteoblastic differentiation collagen-1 (red) immunostaining
was carried out with DAPI nuclear stains (green) and representative images are shown in
Figure 3.8. Figure 3.8 B shows strong positive staining for collagen-1 for cells cultures on
scCO2 foamed PDLLA while Figure 3.8 A shows some positive collagen-1 staining for cells
cultured on PDLLA and Figures 3.8 C and D show presence of cells but a lack of collagen-1
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for cells cultured on PDLLGA scaffolds, both scCO2 foamed and non-foamed.
Total specific activity of ALP was utilised as an early indicator for osteoblastic differ-
entiation of MSCs on the different scaffolds. Alkaline phosphatase is used as an indicator
for osteoblastic differentiation [167, 168], and while its expression is not entirely specific to
osteoblastic cells, collagen type-1 (col-1) immunohistochemical stains were used to confirm
evidence of osteoblastic differentiation of MSCs in these experiments [169]. From specific
ALP activity there is significant evidence (P<0.001) that MSCs cultured on scCO2 foamed
PDLLA scaffolds differentiated more quickly down the osteoblastic lineage than MSCs cul-
tured on non-foamed PDLLA and both scCO2 foamed and non-foamed PDLLGA (Figure 3.7).
This was supported by confocal imaging showing greater levels of col-1 surrounding cells
on scCO2 foamed PDLLA scaffolds.
3.3.2 Assessing formulation performance
Having established the improved biocompatibility and osteoinductive properties of scCO2
foamed scaffolds over non-foamed scaffolds, further improvements in osteoinductive prop-
erties were investigated through the use of HA microparticles. Polymer:HA composites
were formed using scCO2 foaming and compared to pure polymer scaffolds formed through
scCO2 foaming.
3.3.2.1 Mechanical characterisation
Milled and impacted scCO2 foamed polymer samples (PDLLA and PDLLGA) were prepared
with andwithout 10%HAmicroparticles added prior to foaming. These samples were tested
for shear resistance under different normal loads and compared to allograft as a control. The
mean shear resistance for samples under each normal loading are displayed in Figure 3.9.
Linear regression analysis was used to analyse these results and calculate interparticulate
cohesion values for each sample from Mohr-Coulomb failure curves. The interparticulate
cohesion values for the milled polymer scaffolds were compared to allograft controls for
statistical significance and both the interparticulate cohesion and statistical significance are
shown in Table 3.2.
In this chapter shear testing was performed without cells; similar experiments with
impaction and shear testing of allograft demonstrated that allograft seeded with MSCs in-
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Figure 3.7:Mean ALP specific activity for hMSCs cultured in vitro on both scCO2 foamed
and non-foamed PDLLA and PDLLGA scaffolds for 2 weeks (n=3) (***P<0.001).
Scaffolds were milled and impacted and cultured in osteogenic medium. Error
bars show standard deviation.
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Figure 3.8: Confocal images at x80 magnification of collagen-1 immunostained (Alex-
aFluor 594, red) with DAPI nuclear counterstain (green) of hMSCs cultured on:
(A)PDLLA, (B) scCO2 PDLLA, (C) PDLLGA, and (D) scCO2 PDLLGA. Cells were
cultured for two weeks in osteogenic medium.
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Figure 3.9:Mean shear stress at 10% strain (n=4) for milled and impacted scCO2 foamed
samples at different normal loads. PLA and PLGA are amorphous and sam-
ples containing HA are polymer:HA 90:10 weight loading. Error bars represent
standard deviation.
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Table 3.2:Mohr Coulomb failure curve interparticulate cohesion and R2 values calculated
from Figure 3.9 results (n=4). Statistical significance from linear regression analy-
sis of scCO2 foamed polymer scaffolds and HA composites compared to allograft
controls also shown.
Test material Interparticulate Statistical Linear regression
cohesion significance R2 value
Allograft 62.5 N/A 0.990
PDLLA 155.1 P<0.0001 0.998
PDLLA+ HA 144.2 P<0.0001 0.977
PDLLGA 228.5 P<0.0001 0.994
PDLLA+ HA 311.7 P<0.0001 0.983
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creases the shear strength of the impacted construct [54]. Further published work went on to
demonstrate an enhancement of this effect through functionalising allograft/cell constructs
with HA and collagen [55]. In contrast to this finding, impaction shear testing of milled
scCO2 foamed scaffolds of PDLLA and PDLLGA found no significant difference between
samples with 10% HA and samples without. The enhancement in shear resistance Jones et al.
reported may be due to the enhanced differentiation of MSCs coated in HA nanoparticles;
the ECM the cells produced may have added structural integrity that increased the shear
resistance of the scaffold.
3.3.2.2 In vitro assessment of biocompatibility
Cellular compatibility
Representative live/dead confocal images of MSCs seeded onto milled polymer scaffolds
and subsequently impacted and cultured for 2 weeks in osteogenic medium are shown in
Figure 3.10. Viable cells (green) are shown to have survived on all samples with few dead
cells (red) apparent. Cells were observed to have proliferated to near 100% confluence on
all samples with little observable difference of cell proliferation and viability between cells
cultured on HA containing samples (Figures 3.10 B & D) or polymer type (PDLLA samples in
Figures 3.10 A& B; PDLLGA samples in Figures 3.10 C&D). Figures 3.10 E–H display control
samples with no cells stained and imaged for the corresponding scaffold compositions in
the images above (3.10 A–D), confirming specificity of the stains. Polymer autofluorescence
shows as purple in all images.
Results from WST-1 assays, shown in Figure 3.11, provide quantitative data to substanti-
ate the live/dead images. Cells cultured on non-foamed PDLLA were used as controls and
significantly greater cell viability was observed on scCO2 foamed PDLLA scaffolds (P<0.01
on scCO2 foamed PDLLA and P<0.05 on scCO2 foamed PDLLA + 10%HA). Greater cell viabil-
ity was observed on scCO2 foamed PDLLA scaffolds than scCO2 foamed PDLLGA scaffolds
(P<0.05) but for all other comparisons between samples there was no significant difference
in cell viability following two weeks cell culture in osteogenic medium. The incorporation
of 10 wt.% HA microparticles appeared to have no noticeable effect on the cell population
density on either of the scaffold compositions.
Bolland et al. [194] previously established the survival of hMSCs onmilled scCO2 foamed
PDLLA utilised as a bone graft extender. Osteoprogenitor cells seeded on polymer scaffolds
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Figure 3.10: Confocal images of live (green)/dead (red) hMSCs cultured on milled polymer
scaffolds of (A) scCO2 foamed PDLLA (control image E), (B) scCO2 foamed
PDLLA + 10 wt.% HA (control image F), (C) scCO2 foamed PDLLGA (control
image G), and (D) scCO2 foamed PDLLGA + 10 wt.% HA (control image G) at
x20 magnification. Cells were cultured for two weeks in osteogenic medium
prior to immunostaining. Control samples contained no cells.
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Figure 3.11:WST-1 assay readings showing optical density readings at 450 nm for hMSCs
cultured onmilled and impacted polymer scaffolds for two weeks in osteogenic
medium (n=3). Assay readings were taken in triplicate after 2 hour incubation
and statistical significance between: non-foamed PDLLA and scCO2 foamed
PDLLA ± 10% H, and scCO2 foamed PDLLA and scCO2 foamed PDLLGA
(**P<0.01, *P<0.05).
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were shown to survive an impaction process that mimicked IBG which matches our find-
ings. Live/dead staining, confocal imaging, and tetrazolium salt colorimetric assays (WST-1)
(Figures 3.4, 3.5, 3.10 & 3.11) provide evidence of cell proliferation on such scaffolds post
impaction for both PDLLA and PDLLGA scaffolds. Bone graft extenders reduce, but do not
eliminate the downsides of allograft (cost, risk of infection, and limited availability).
Osteoblastic differentiation
Specific activity of ALPwasmeasured in triplicate for cells cultured for 2 weeks in osteogenic
medium on each of the milled and impacted polymer scaffolds as an early indicator of
osteoblastic differentiation. The results presented in Figure 3.12 show significantly greater
ALP specific activity for cells cultured on scCO2 foamed PDLLA + 10 wt.% HA than on
all the other scaffold types. There was no significant difference between PDLLGA samples,
although greater specific ALP activity was measured for cells cultured on PDLLGA + 10%
HA scaffolds than scaffolds without HA. Cells cultured on PDLLA + 10% HA scaffolds had
significantly higher specific activity than cells cultured on PDLLA scaffolds (P<0.01). Cells
cultured on all PDLLA scaffolds (both with and without HA) expressed significantly higher
ALP specific activity than cells cultured on PDLLGA scaffolds (both with and without HA).
The osteoblastic differentiation of MSCs appeared to have progressed for cells cultured
on scCO2 foamed PDLLA compared to scCO2 foamed PDLLGA again when 10 wt.% HA
microparticles were incorporated. The presence of HA microparticles appeared to further
accelerate the differentiation; significantly higher ALP expression was observed in MSCs
cultured on PDLLA scaffolds with HA than without HA (P<0.01). This trend appeared to
repeat in MSCs cultured on scCO2 foamed PDLLGA with HA than without, although the
results were not significant at the 5% level (Figure 3.12). Hydroxyapatite was incorporated
into the scaffolds to improve the osteoblastic differentiation and these results confirm HA
presence in the scaffolds improved the scaffolds osteoinductive properties as has been found
previously in the literature [131, 198, 199].
3.3.2.3 In vivo assessment of biocompatibility
The performance of PDLLA scaffolds in in vitro experiments was greater than that of PDLLGA
scaffolds in terms of osteoinductive properties. While PDLLGA scaffolds demonstrated
greater resistance to shear both PDLLA and PDLLGA scaffolds showed greater resistance
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Figure 3.12:Mean ALP specific activity for hMSCs cultured on milled and impacted scaf-
folds in osteogenic medium for two weeks (n=3) (****P<0.0001, **P<0.01,
*P<0.05, ns = not significant). Error bars show standard deviation.
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Figure 3.13: Confocal images of collagen-1 immunostained (AlexaFluor 594, red) with DAPI
nuclear counterstains (green) of hMSCs cultured in osteogenic medium for
two weeks on (A) scCO2 foamed PDLLA (control image E), (B) scCO2 foamed
PDLLA + 10 wt.% HA (control image F), (C) scCO2 foamed PDLLGA (control
image G), and (D) scCO2 foamed PDLLGA + 10 wt.% HA (control image H) at
x40 magnification. Negative controls with no primary antibody were used.
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to shear than allograft bone. In line with animal testing principles to reduce the number
of animals tested it was possible to rule out PDLLGA scaffolds; of the scCO2 foamed scaf-
folds the PDLLA scaffolds with and without HA demonstrated greater potential based on
the increased osteoblastic differentiation observed in vitro. For these reasons scCO2 foamed
PDLLA with and without 10 wt.% HA microparticles were taken forward to in vivo testing.
The scaffolds were foamed, milled, sterilised, seeded with MSCs, aseptically impacted, and
then implanted subcutaneously into mice and incubated in vivo for 5 weeks.
Micro x-ray computed tomography
µCT analysis was carried out on samples postmurine incubation and quantitative analysis of
bone-likematrix formation revealed the values presented in Table 3.3. There was a significant
increase in mineralised matrix formation between PDLLA scaffolds implanted with MSCs
and PDLLA scaffold control (P<0.01). An increase in bone formation was observed between
PDLLA + HA scaffolds implanted with MSCs and the control scaffolds but this did not reach
significance. There was a highly significant increase in bone-like matrix formation between
PDLLA + HA scaffolds and 100% PDLLA scaffolds for both samples implanted with MSCs
and controls (P<0.001).
A representative 3D reconstruction of a PDLLA scaffold (implanted with hMSCs) post
murine incubation is shown in Figure 3.14. Figure 3.14 A shows the entire implanted scaffold
contained within a cylindrical pot, open at both ends, and Figure 3.14 B is the same image
with the low density plastic pot and scaffold removed, leaving the higher density bone like
matrix formed visible.
Figure 3.15 shows post murine incubation (five weeks) representative axial and longi-
tudinal µCT slices of PDLLA + 10 wt.% HA scaffolds implanted with (Figures 3.15 A–C)
and without MSCs (Figures 3.15 D–F). Hydroxyapatite particles, as the most dense material
within the samples, are visible as white circular shapes across the slices. Bone like matrix
formed has a lower density than HA and has been coloured red in the images to improve
visible contrast. The newly formed mineralised matrices have a range of densities that ap-
proach that of HA and reduce the overall reliability in absolute values of matrix volumes
formed within the HA containing samples. Comparison of the µCT slices show that for the
scaffolds implanted with hMSCs (Figures 3.15 A–C) bone like matrix has formed across
the scaffold around HA particles and in areas removed from HA particles. For samples im-
planted without hMSCs (Figures 3.15 D–F) the formation of bone like matrix appears more
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focused around HA particles.
Four groups were tested in vivo: PDLLAwithMSCs, andwithoutMSCs; PDLLA + 10 wt.%
HA microparticles with MSCs, and without MSCs. Utilisation of µCT gave quantitative val-
ues formean volumes of mineralisedmatrix within the scaffolds following in vivo incubation
(five weeks). A 10 µm resolution was possible which allowed visualisation of HA particles
and, through contrast agent injection, imaging of vessel formation within and around the
scaffolds. Thresholding is a requirement in µCT analysis and is subjective. Thresholding val-
ues have a major impact on the quantitative results produced through µCT [200–202]. Due to
the density difference between PDLLA andmineralised ECM effective threshold ranges were
assigned for each to ensure accurate volume calculations. Mineralised matrix deposited in
scaffolds during in vivo culture has a similar density to HA, a main constituent of bone. Due
to the defined shape of HA particles incorporated in the scaffolds it was possible to thresh-
old using mineralised matrix formed away from any particles as a guide to minimise the
unavoidable crossover. Exposure of HA to physiological conditions may lead to degradation
of the particles and hence reduction of HA density at the particle periphery. This would lead
to HA volume inclusion with new mineralised matrix volume in µCT analysis. However
HA, as a crystallised form of calcium phosphate, has a low bioresorbability and remains
within the body for some time following implantation [203]. One study demonstrated HA
implants unaffected by biodegradation processes following 22 weeks implantation texitin
vivo[204]. This adds confidence to the µCT image analysis that demonstrated much of the
mineralised matrix formed within the scaffolds surrounding the HA particles and that the
PDLLA + 10% HA scaffolds implanted without MSCs also show mineralised matrix to have
been deposited within the scaffolds, primarily around HA particles, during in vivo incuba-
tion (Figure 3.15). Visualisation of vasculature formed within the scaffolds during five week
murine implantation was possible utilising radiocontrast agent barium sulfate injection and
µCT imaging. Resulting images are shown in Figure 3.16 and provide evidence of neo-vessel
formation in PDLLA (Figure 3.16 B) and PDLLA + 10% HA (Figure 3.16 B) scaffolds.
Implanted cell survival
In two samples per group (scCO2 foamed PDLLA and scCO2 foamed PDLLA + 10 wt.% HA)
MSCs were labelled with fluoromarkers (Vybrant) pre in vivo incubation. Samples recovered
post five week in vivo incubation were imaged using confocal microscopy and images are
shown in Figure 3.17. This provides evidence of sustained implanted cell survival in both
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PDLLA (Figure 3.17 A) and PDLLA + 10 wt.% HA (Figure 3.17 B) scaffolds.
Immunohistochemical staining
In addition to µCT analysis, immunohistochemical stains and histological stains gave com-
parative qualitative results. Immunohistochemical staining was carried out on all samples
post 5 week murine incubation and representative confocal images are shown in Figure 3.18.
Stains for early osteoblastic differentiation markers collagen-1 and bone sialoprotein stained
positive for both PDLLA and PDLLA + 10%HA samples implanted with MSCs, while PDLLA
+ 10% HA control samples also stained positive. PDLLA control samples did not show pos-
itive staining. Osteocalcin immunostains were carried out as late markers of osteoblastic
differentiation but no positive staining was observed on any samples. Von Willebrand factor
immunostains were carried out as a vascularisation indicator and limited positive stains are
shown for samples PDLLA and PDLLA + 10% HA samples implanted with cells and PDLLA
+ 10% HA control samples.
Histological analysis
Post murine implantation samples were stained with Sirius Red and Alcian Blue for col-
lagen and proteoglycan deposition which was evident in both PDLLA and PDLLA + 10%
HA samples implanted with hMSCs as shown in Figures 3.19 A and D, respectively. Some
positive indicators were evident in the PDLLA + 10% HA control samples implanted with-
out cells (Figure 3.19 C) while none were observed on PDLLA control samples (Figure 3.19
A). Goldner’s Trichrome staining of samples for osteoid was also used and showed posi-
tive staining on samples that also stained positive for collagen: PDLLA + hMSCs, PDLLA +
10% HA, and PDLLA + 10% HA + hMSCs (Figures 3.19 F-H, respectively). Control PDLLA
samples implanted without cells showed no positive staining for osteoid (Figure 3.19 E).
The presence of mineralised matrix observed in PDLLA + 10% HA scaffolds implanted
in vivo without MSCs imaged through µCT is substantiated by: the positive staining for
collagen-1 and BSP, which did not stain positively on PDLLA scaffolds implanted without
MSCs; and positive histological staining for osteoid (Goldner’s trichrome in Figure 3.19.
The combined results provide evidence of HA particles improving the performance of the
scCO2 foamed PDLLA scaffolds in vivo by providing osteoinductive properties to host cells
in addition to implanted cells. The osteoinductive properties of HA were expected given
previous published results [205, 206]. Previously, hMSCs cultured on scCO2 foamed PDLLA
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Table 3.3:Mean bone volume (n=4) formed during five week in vivomurine study for scCO2
foamed PDLLA with and without 10% HA implanted with and without hMSCs
Scaffold material Mean bone volume SD
[mm3]
PDLLA + MSCs 0.6575 0.312
PDLLA control 0.0825 0.025
PDLLA+ HA + MSCs 24.6175 3.976
PDLLA + HA control 18.1800 4.627
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Figure 3.14: Reconstructed post murine implantation µCT scan into 3D model of milled
scCO2 foamed PDLLA, seeded with hMSCs, impacted into cylindrical pot (A);
and the same image with the low density pot and PDLLA removed to show
higher density bone like matrix.
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Figure 3.15: Representative micro CT slices of milled scCO2 foamed PDLLA + 10 wt.% HA
scaffolds implanted in Foxn1numice both with (A-C) and without (D-F) hMSCs
and recovered post five week in vivo incubation. White circular shapes show
HA particles while bone like matrix has been coloured red to improve visual
contrast in images B-C and E-F.
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Figure 3.16: Injection of barium sulfate radiocontrast agent (A) enabled visualisation of
neo vessel formation in µCT reconstructed models of post five week in vivo
incubation PDLLA scaffold (B) and PDLLA + 10% HA scaffold (C).
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Figure 3.17: Confocal images of hMSCs stained with Vybrant, incubated subcutaneously in
Foxn1numice for five weeks on PDLLA scaffolds and recovered post implanta-
tion. (A) shows cells survived on PDLLA scaffolds and (B) shows cells survived
on PDLLA + 10% HA scaffolds. Main images at x40 magnification, inset images
at x10 magnification.
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Figure 3.18: Confocal images of samples post five week murine implantation at x20 magni-
fication showing immunostains (red) for: osteoblastic differentiation markers
collagen-1, bone sialoprotein, and osteocalcin; and vascularisation marker von
Willebrand’s factor. DAPI nuclear counterstains (green) are also shown. Nega-
tive controls were stained without the use of primary antibody. Scale bars equal
200 µm.
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Figure 3.19: Histological samples imaged utilising optical microscopy at x20 magnification
(inset images at x5 magnification) post five week murine incubation. Scale bars
= 100 µm. Alcian blue and Sirius red stained for proteoglycan and collagen,
respectively. Goldner’s trichrome stained for osteoid. Control PDLLA samples
implanted without cells stain show no positive staining (A & E) while all other
samples show positive staining.
98
CHAPTER 3 : SUPERCR I T I CAL CO2 FOAMED POLYMER I C SCAF FOLD S FOR
IMPACT ION BONE GRAFT ING APPL I CAT IONS
(12 kDa) were implanted in mice for 11 weeks and bone formation was observed [207],
although in these experiments the PDLLA was a much lower (≈90%) MW and the cells were
not impacted as they were for the experiments detailed in this chapter. Similarly, Wang
et al. [208] prepared composite polyamide/HA scaffolds and implanted them into rabbits
with and without MSCs. Through quantification of histological slides they provide evidence
that MSC/scaffold implants had significantly greater new bone volume than pure scaffold
implants (P<0.05). These findings are in agreement with our µCT analysis which show
significantly greater mineralised matrix formed on scaffolds implanted with cells than those
implanted without.
Hollister [129] points out, answering the question "is there an optimal material for re-
generation of specific tissues?" requires textitin vivo experiments using scaffolds made with
controlled characteristics. While Hollister is referring to carefully controlled porosity, among
other properties scaffold milling imparts macro porosity into the final impacted scaffold.
For IBG providing a viable alternative to the current clinical ’gold standard’ material will
likely require compatibility with current clinical procedures, which include scaffolds being
easy to handle and that can be processed as allograft is now i.e. milled and chips impacted
into defect. In this study scCO2 foamed polymers with similarly high MW (≈100 kDa) were
foamed to produce scaffolds with porosities ≈50%. These scaffolds were found by clinicians
(Southampton collaborators) to be easy to handle and possibly to mill utilising a bone mill,
found in theatres for IBG.
To answer the question "is there an optimal material for IBG?" the scaffolds with the most
potential were studied in vivo. Subcutaneous implantation in a murine model provided ini-
tial promising results. While this model is on a small scale in a non-load bearing application
the study did provide an assessment of both osteoinductive and osteogenic capacity and
vascularisation potential of the scaffolds and scaffold/cell composites. The in vivo study also
provided evidence that inflammation and toxicity of the scaffolds is minimal. Degradation
time in physiological conditions for these scaffolds will be measured in months not days
with no significant degradation observed after five week in vivo incubation. It is important
that scaffolds do not degrade faster than new bone can be formed, and additionally that
acidic degradation products should have time to diffuse and be removed from the site to
prevent both build of acidic products which may cause detrimental inflammation levels,
and autocatalyse the hydrolytic degradation of the polymer. Further study in a larger an-
imal model (ovine) using a condyle defect followed and the results are presented in the
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next chapter. From these results HA inclusion and MSC/scaffold composites both demon-
strated improved performance. Therefore scCO2 foamed PDLLA with 10% HA and MSCs
was taken forward into the large animal model and controls without cells were also used as
a comparison.
3.4 Conclusion
The work described in this chapter has demonstrated that scCO2 foamed biodegradable
polymer scaffolds can withstand shear forces to the same or to a greater extent than allograft
bone chips when both are milled and impacted to simulate IBG. High MW scCO2 foamed
PDLLA and PDLLGAwere shown to support greater numbers of MSCs, which differentiated
toward the osteoblastic lineage more quickly than cells cultured on non-foamed scaffolds of
the same polymers.
Comparison of scCO2 foamed PDLLA and scCO2 foamed PDLLGA scaffolds showed
variation in pore size and porosity under identical foaming conditions (118 µmmean pore
size and 59% porosity for PDLLA, 85 µmmean pore size and 46% porosity for PDLLGA). Both
scaffolds were easily milled and impacted, and while both scaffolds resisted shear PDLLGA
scaffolds were able to resist to a greater extent. Cellular assays demonstrated that, while
cell proliferation was closely matched on both scaffolds, MSCs were capable of osteoblastic
differentiation (observed through ALP assays and collagen-1 immunostaining) on PDLLA
scaffolds over 14 days to a significantly greater extent than was observed for MSCs cultured
on PDLLGA scaffolds. This result was repeatable and observed in the initial study comparing
scCO2 foamed scaffolds to non-foamed scaffolds, and the second study comparing scaffolds
with and without HA.
Hydroxyapatite was utilised to improve scaffold osteoinductive properties and mechani-
cal strength. Shear resistance of milled and impacted scaffolds was not significantly different
with or without HA microparticles at 10 wt.% concentration. The presence of HA did ap-
pear to improve the osteoinductive properties of the scaffolds. The scCO2 foamed PDLLA
scaffolds with HA recruited host cells which formed osteoid and mineralised matrix tex-
titin vivo, observed through histological staining and µCT. Supercritical CO2 foamed PDLLA
scaffolds without HA did not show evidence of recruiting host cells over five weeks with
subcutaneous murine incubation.
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Production of mineralised matrix to form new bone appeared to centre around HA par-
ticles. While mineralised matrix was formed within scCO2 foamed PDLLA scaffolds without
HA,more was formed in the scaffolds with HA particles, demonstrated through quantitative
analysis of µCT scans. Where mineralised matrix had been formed, it was possible to high-
light in µCT reconstructed images newly formed mineralised matrix and HAmicroparticles.
In these images mineralised matrix predominantly surrounded HA particles. By providing
further sites for mineralised matrix to form around, it may be possible to improve the rate at
which new bone might be formed. This could be achieved by using smaller particles (such
as nanoparticles) and increasing the specific surface area available to MSCs.
The significant difference in osteoblastic differentiation between cells cultured on PDLLGA
scaffolds and PDLLA scaffolds was not anticipated. Both polymers used to form scaffolds
had MWs ≈100 kDa and the lactide:glycolide ratio in PDLLGA was 85:15. After two weeks
in vitro culture, the significant amounts of ALP and collagen-1 expressed by cells cultured
on PDLLA scaffolds was a large contrast to the almost negligible amounts expressed by cells
cultured on PDLLGA scaffolds. The morphology of the scaffolds was slightly different, as ob-
served through µCT and SEM, which may contribute to the difference in cell differentiation
between the scaffolds. Further work will be required to investigate this.
The murine model used within this study has provided confirmation that scCO2 foamed
PDLLA scaffolds with HA and MSCs are suitable for impaction and implantation without
observable toxic or detrimental effects in the time frame. The short time frame, non-load
bearing site (subcutaneous implantation), and small scale are limits to the study. Further
investigation of the performance of these scaffolds in a critical sized bone defect in a larger
animal (ovine condyle defect) is detailed in the following chapter. Additionally, scale-up of
scaffold production is also considered within the following chapter.
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CHAPTER 4
Investigation of the scalability of
manufacturing scCO2 foamed
scaffolds and their utilisation in vivo
This chapter investigates in vivo bone regeneration of critical sized condyle defects within
ovine femoral condyles filled with scCO2 foamed scaffolds. Additionally investigation of
the scale-up of production of porous scCO2 foamed scaffolds is performed.
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4.1 Introduction
In Chapter 3, high MW (106 kDa) scCO2 foamed PDLLA scaffolds with 10% HA were iden-
tified as the most promising scaffolds, of those tested, for use in impaction bone grafting
procedures. This was determined by mechanical shear testing of milled and impacted scaf-
folds: a common mechanism of failure in revision hip replacements, which constitute a large
proportion of IBG procedures. Additionally, in vitro cellular compatibility and differentia-
tion, and an in vivo small animal model identified these PDLLA scaffolds as those with the
most potential for this application. Scaffolds were implanted with and without hMSCs in
immunodeficient mice and the presence of implanted MSCs appeared to improve the bone
formation observed.
This chapter describes the in vivo performance of scCO2 foamed PDLLA scaffolds with
10%HA in an ovinemodel. An ovine hemiarthroplasty (hip replacement) modelwas initially
planned to provide a clinically relevant loaded model for later application to human clinical
trials following strong indications of good bone repair. An ovine model appealed for several
reasons: adult sheep have a similar bodyweight (70-90 kg) to adult humans [209], sheep
long bones are large enough to accept human-scale implants [209], and the joint forces in
sheep have been characterized [210–212]. Additionally, in large animals the bone biology,
mineral composition, turnover, and loading environments are similar to human conditions
[211]. The use of large animal models for bone regeneration scaffolds provides high value
data relating to scaffold degradation, resorption, and biomechanical properties [211].
A comparison of key attributes of human and ovine bone that included macrostructure,
microstructure, and remodelling was made by Pearce et al. [213] from a review of literature.
The overall hierarchical structure of bone was described in Chapter 1. Here macrostruc-
ture refers to the overall geometry (e.g. cross sectional area) and properties of bone, such
as bone mineral density and mechanical strength [214], while Pearce et al. separate bone
mineral density and strength into a separate category, bone composition. Microstructure
refers to the structure and shape of bone concentric layers formed around blood vessels
(Haversian systems, osteons, or bone structural units). Bone remodelling refers to the pro-
cess of co-ordinated osteoclast mediated bone resorption, osteoblast mediated bone matrix
formation, and matrix mineralisation [215]. As previously mentioned, dimensionally the
macrostructure of ovine long bones is similar to that of human long bones. However, ovine
bones demonstrate greater apparent density and strength, in comparison to human bones
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[213, 216, 217], but do not show significant differences in mineral composition [218].
Microstructurally, sheep are reported as having predominantly primary bone (woven or
immature bone), which is more irregular than secondary bone and contains osteons with
diameters <100 µm, and lack a cement line. Human bone is predominantly secondary bone
(lamellar/mature bone), which is more organised, contains larger osteons (100 - 300 µm
diameter) with larger vascular channels within the centre than primary osteons. Martin et
al. [219] hypothesized that the smaller vascular channel size in primary bone may result in
greater mechanical strength compared to secondary bone, which may explain the greater
mechanical strength reported between ovine and human bone [216, 217]. Secondary bone
remodelling in sheep does become more prevalent with age and is reported in 7-9 year old
sheep by Newman et al. [209].
While differences between ovine and human bone structures exist, ovine models remain
valuable for remodelling and bony in-growth into porous implants [211, 213, 220, 221]. In a
weight-bearing ovine model for bone in-growth there was no significant difference reported
between the amount of cancellous bone in-growth over time in the ovine model and from
human total bilateral knee replacement data [221]. Additionally, ovine bone metabolic and
remodelling rates are similar to human rates [222, 223], supporting the value of ovine models
for human bone remodelling [220].
Due to insufficient funding for an ovine hemiarthroplasty model a femoral condyle
critical sized defect model was substituted. Critical sized defects have been defined as "the
smallest size intraosseous wound in a particular bone and species of animal that will not heal
spontaneously during the lifetime of the animal" [224, 225]. Ovine femoral condyle models
have previously been used to study the osteoconductivity and bone in-growth of other
scaffold types targeted as either bone graft extenders (scaffolds to be used in conjunction
with allograft to reduce the required volume of allograft) or scaffolds to augment bone
healing [226–230]. This chapter describes the bony in-growth observed within an ovine
femoral condyle model filled with scCO2 foamed PDLLA with 10% HA scaffolds and the
effect MSCs implanted with scaffolds had on the bony in-growth observed. Similar ovine
condyle studies utilising different scaffolds are reported in the literature and extended the
scope of the conclusions that could be drawn from this study. Empty defects were not used
as negative controls to confirm the defects were critically sized, but the limited regenerative
potential of such defects is reported within the literature [230, 231]. Van der Pol et al. [230]
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reported a bone density within the empty defects of 28.4 ± 15.3% after 12 months. This
was an increase of 1.5% from the bone density reported at 4 months; additionally, the bone
formed within the defect was concentrated around the edge. Flautre et al. [231] reported
5.9% and 11.0% new bone formed within empty cavities after 12 and 24 weeks, respectively.
Alternative critical sized defect animal models of bone repair could have been substi-
tuted. Particularly, canine models are reportedly more suitable models of human bone bio-
logically [213, 232]. However, the use of companion animals (e.g. dogs and cats) for medical
research is less desirable from ethical and public perception viewpoints [213]. A canine hemi-
arthroplasty model would be unsuitable in terms of loading environment, animal weight,
and implant design. Clinical translation of scCO2 foamed biodegradable polymer scaffolds
into viable alternatives to allograft will require regulatory approval. For this to occur, com-
prehensive in vitro and in vivo studies need to be performed,which should include a clinically
relevant hemiarthroplastymodel [211]. Reichert et al. state this strongly: "To establish a tissue
engineering concept in a clinical setting, a rigorous demonstration of the level of therapeutic
benefit in clinically relevant animal models is a conditio sine qua non [a condition without
which it could not be]" [211]. In this case a clinically relevant animal model is most likely to
take the form of an ovine hemiarthroplasty model; hence, an ovine condyle defect model
was preferred to viable alternatives (e.g. canine) because it would provide more relevant
data to support the success of a later loaded ovine model.
The manufacturing process of tissue engineering scaffolds must be scalable and commer-
cially viable to be successful. A gap exists whereby the discovery phase of tissue engineering
research receives the majority of funding, while the products resulting from the research
remain few [211, 233]. Hollister et al. [233] claim two reasons for tissue engineering technol-
ogy failure: lack of design for specific application, and inability to be scaled to clinical level
production. The scCO2 foamed scaffolds studied within this thesis have been specifically
targeted at impaction bone grafting as potential replacement to allograft bone. The supercrit-
ical fluid foaming process is scalable and within this chapter scaffolds produced on the small
scale (60 ml autoclave, 1.8 g/six scaffolds per batch) were characterised alongside scaffolds
produced within a larger vessel (1 L autoclave, 54 g/one hundred and eighty scaffolds per
batch). For consistency, scaffolds produced within the larger vessel were not used in the
ovine study.
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4.2 Materials and methods
4.2.1 In vivo ovine study
Supercritical CO2 foamed scaffolds with 10 wt.% HA microparticles performed the most
favourably in previous studies and were investigated in an ovine femoral condyle model.
The in vivo ovine study was carried out at the Royal Veterinary College, Potters Bar, by
Prof. A. Goodship, Mr. E. Tayton, Miss G. Hughes, and Mr J. Smith.
4.2.1.1 Sheep selection
Six healthy skeletally mature (>2 years old) welsh mule ewes weighing between 60 and 90
kg were obtained, vetted, and acclimatised in a barn for 4 weeks prior to the start of the
study, which was initiated with harvesting of ovine MSCs.
4.2.1.2 General anaesthesia
General anaesthesia following a standard protocol was carried out prior to interventional
procedures. Premedication consisted of 0.1 mg kg−1 intramuscular xylazine (Rompun, Bayer
PLC., U.K.) injection and 5 mg of the prophylactic antibiotic sodium cefalexin (Ceporx,
Schering-Plough, U.K.). Anaesthesia was induced using 2.5 mg intravenous midazolam
(Hypnovel, Roche, U.K.) and 2 mg −1kg intravenous ketamine hydrochloride (Ketaset, Fort
Dodge Animal Health Ltd., U.K.). The sheep were then intubated and general anaesthesia
was maintained using inhaled isofluran, oxygen, and nitrous oxide.
4.2.1.3 Harvest and expansion of mesenchymal stem cells
Once fully anaesthetised sheep were placed in the left lateral position (i.e. lying on their
left side) and an area shaved over the iliac crest. This was cleaned using 10% povidine-
iodine (betadine) solution followed by 2% chlorhexidine gluconate solution. A trochar was
then inserted through the cortical bone, and approximately 5-10 ml aspirated. The aspirate
from each sheep was then placed into a separate universal container and into a cool box
for transportation to the laboratory. The sheep were then recovered, and given analgesia as
required. They were housed in the barn, penned, and fed standard food until further use.
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The universal tubes containing the ovine aspirates had 10 ml of basal medium (α-MEM,
10% FBS, 1% penicillin and streptomycin) added and the solutions were then filtered (70
µm filter) into separate universal tubes and centrifuged at 180 g for 4 minutes. The super-
natants were aspirated and cell pellets resuspended in 40 ml basal medium. These solutions
were split equally into four T75 tissue culture flasks and incubated under standard culture
conditions (37 ◦C and 5% CO2) until confluent. Cell media was changed every three days.
When required for scaffold seeding the cell monolayers were released using 10% trypsin in
EDTA for 2 minutes. The trypsin was neutralised with the addition of equal volume of basal
media, and cell pellets obtained via centrifugation (180 g for 4 minutes). The supernatants
were aspirated and the cell pellets resuspended in basal media. Total cell number was ap-
proximated using a haemocytometer. Appropriate dilution with basal media was used to
achieve a concentration of 5×105 cells ml−1.
4.2.1.4 Scaffold seeding
Supercritical CO2 foamed PDLLA scaffolds + 10 wt.% HA microparticles were produced as
described in Section 2.1 (270 mg ground PDLLA, 30 mg HA microparticles). They were then
milled and sterilised as detailed in Section 2.5.1.3. The sterilised milled polymer scaffolds
were placed in universal tubes and 20 ml of the solutions of ovine MSCs were added to each
and incubated for 2 hours with gentle agitation every 30 minutes. The medium was then
aspirated from each universal tube and the seeded scaffolds were placed into individual
wells of six well plates and cultured in osteogenic medium (basal media + 100 µM ascorbate-
2-phosphate, and 10 nM dexamethasone) for 2 weeks. Media was changed every 3 days.
4.2.1.5 Operative procedure
The sheep were given two fentanyl patches (75 mcg hr−1) 12 hours prior to surgery and
were randomised to receive scaffold + MSCs or scaffold alone to either the right or left side.
The sheep again underwent full general anaesthesia as described in Section 4.2.1.2. They
were placed in the supine position (lying flat face up), with surgical gloves placed over
their hooves. The hind legs were both secured to the operating table with rope, shaved,
and cleaned thoroughly using 10 % povidone-iodine (betadine) solution followed by 2%
chlorhexidine gluconate solution. Each sheep was then covered with sterile drapes such
that only the surgical sites were exposed. Longitudinal incisions (10 cm in length) were
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made centred over the palpable bony protuberances located on the medial sides of the
medial femoral condyles of each leg (Figure 4.1A shows the location the condyle defect was
drilled), with careful dissection through subcutaneous tissue, fascia, muscle, and periosteum
to expose the underlying bone. A customised 8 mm drill bit was then used to create a hole
with a consistent depth of 15 mm into the underlying cancellous bone (Figure 4.1B). After
the hole was drilled a reamer was used to give the hole a flat bottom. Scaffold was packed
into the holes on either side, one with scaffold only (control), one with scaffold + MSCs,
as per the randomisation for each sheep. Scaffolds were packed into each hole such that
they were filled (Figure 4.1 D&E). Two guide wires were placed superior and inferior to
the holes for radiographic location purposes at a later stage. The periosteum and other
layers were then closed over the filled holes using 2/0 Vicryl in order to contain the scaffold,
and the skin was closed with interrupted sutures using 2/0 Ethilon and op-site spray. The
wounds were subsequently covered with betadine soaked gauze, wool, and crepe bandage.
The sheep received a five day post-operative antibiotic regime (Ceporex 5 ml OD) with
fentanyl patches and buprenorphine (0.6 mg) for 72 hours after application of the patches
(for analgesia) and regular wound checks. After surgery the sheep were housed individually
in pens for 5 days, followed by group housing in pens for the remainder of the study. The
sheep were fed according to standard practice, with free access to water from troughs.
4.2.1.6 Radiographic analysis
Miss G. Hughes collected the x-ray radiographs at both timepoints.
Craniocaudal radiographs were taken using a portable x-ray unit (PLH Medical Ltd,
U.K.). Radiographs were taken directly after the surgical procedure, after 6 weeks, and
after 13 weeks. Under general anaesthesia, the sheep were placed in appropriate positions
for antero-posterior (AP) and lateral radiographs with the hip and knee fully extended.
The radiographic plate was positioned dorsal with the x-ray source ventral and then the
radiographic plate was placed lateral with source medial using standardised distances (80
cm) and exposure times.
4.2.1.7 Retrieval of specimens
The sheepwere euthanasedwith barbiturate overdose (0.7 mg kg−1) 13 weeks post implanta-
tion of the specimens. The femoral condyles were harvested along with the popliteal lymph
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Figure 4.1: Images of steps of the femoral condyle defect implantation. The arrows in image
(A) show the location the femoral defect was drilled in the femur. B) shows
drilling into the condyle; C) shows the drilled, reamed, defect; D) shows milled
chips of scCO2 seeded with ovine MSCs; E) shows the condyle defect filled with
implanted polymer scaffold.
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nodes.
4.2.1.8 Peripheral quantitative computed tomography (pQCT)
Retrieved femoral condyles were scanned using a pQCT scanner (XCT 2000, Stratec Biomed-
ical, U.K.) by Miss G. Hughes. The bone mineral density within the condyle defect sites was
calculated by manufacturer’s software.
4.2.1.9 Preparation of condyles
Post pQCT scan the femoral condyles were were prepared and mechanically tested within
6 hours of harvest. The condyles were placed in a jig and carefully orientated via the use
of the radiographs and marker wires, such that when cut with a diamond-edged EXAKT
band saw (EXAKT, Hamburg, Germany), the polymer scaffold filled cylindrical defect drill
holes were transected longitudinally in the coronal plane at the midpoints. One half of each
specimen was subsequently taken for immediate mechanical testing and µCT evaluation,
and the other half was prepared for histological staining.
4.2.1.10 Mechanical testing
One half of each of the femoral condyles was used for mechanical indentation testing. The
specimens were position onto the stage of a Z005 static materials testing machine (Zwick/
Roell, Leominster, Herefordshire, U.K.), and the metal indentation rod (diameter 4 mm) was
placed in opposition to the desired test area, and a preload of 10 N applied with a speed
of 5 mm min−1. The test areas are shown in Figure4.6, where areas 1 and 2 correspond
to the superficial and deep areas of the scaffold within the drill hole, and areas A and B
correspond to proximal and distal areas of normal cancellous bone. The test was started and
the indentation rod was advanced at a rate of 10 mmmin−1, and the force measured at each
time point recorded via a load cell.
The data was transferred to a spreadsheet (Microsoft Excel 2007) and graphs of force
against strain plotted (load deformation curve). From these graphs a peak was visible, which
corresponded to the failure of the test area. The force required at this peak was recorded for
each area under test. Mean stress values (along with standard deviations) were calculated
for each area of the femoral defects filled with the scaffold alone, and those implanted with
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the scaffold + MSCs, and they were compared using Student’s unpaired t test.
4.2.1.11 Micro x-ray computed tomography
After indentation testing the specimens were frozen until µCT scanning and analysis could
be performed. They were individually defrosted and scanned using a SkyScan 1176 µCT.
Samples were focused, calibrated, and adjusted to prevent x-ray saturation. The scans were
at an 18 µm voxel resolution. Data reconstruction was performed using NRecon (Skyscan,
Belgium) and saved as 8 bit bitmaps (BMP). Analysis of the reconstructed images was per-
formed using CTAn (Skyscan, Belgium). The region of interest (corresponding to the volume
within the original drill hole) was extracted manually using the software, and via compar-
ison with standard phantoms, new bone was deemed to correspond to all density values
over 0.25 g cm−3. Mean volume of new bone within the region of interest was calculated for
the femoral condyle defects implanted with the scaffold alone, and those implanted with
the scaffold + MSCs, and they were compared using Student’s unpaired t test.
4.2.1.12 Histological examination
The half of each the femoral condyles not used for indentation testing was used for histo-
logical analysis. The samples were fixed in buffered formal saline for one week followed
by dehydration through an ascending alcohol series over a three week period. The sam-
ples were then de-fatted in chloroform for one further week, followed by infiltration and
embedding in LR White methacrylate resin (London Resin Co Ltd, Berks, U.K.). Using the
band saw, longitudinal slices measuring 5 mm thick were taken through specimens, and
from these slices thinner sections measuring between 50 and 80 µm thick were made. The
sections were attached to an acrylic slide using U.V. curable cyano-acrylate glue, before
being grinded and polished on an EXACT grinding machine. Sections were stained with
toluidine blue to stain the soft tissue followed by hematoxylin and eosin (H&E) to stain the
bone, before being viewed by light microscopy.
Histological staining of femoral condyle defects was performed by Prof. G. Blunn at
Stanmore. Imaging of histologically stained samples was performed by the author and by
Mr. E. Tayton at Stanmore.
Histological staining of femoral condyle defects was performed by Prof. Gordon Blunn at
Stanmore. Imaging of histologically stained samples was performed byMr. Matthew Purcell
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and Mr. E. Tayton at Stanmore.
The lymph nodes were fixed in formaldehyde, and dehydrated in graded ethanol solu-
tions prior to wax embedding on a mounting plate. Sections were cut (7 µm thick), trans-
ferred to a water bath, and mounted on slides, prior to transfer to an oven set to 37 ◦C for 4
hours. They were subsequently stained using a standard Haematoxylin and Eosin (H + E)
stain, and assessed by a consultant pathologist for the presence of abnormal inflammatory
cells.
Histological staining of lymph nodes was performed at Southampton University by Mr.
E. Tayton.
Histological staining of lymph nodes was performed at Southampton University by Mr.
E. Tayton and thanks go to Dr. Darren Fowler, a consultant pathologist, for help with analysis
of stained samples.
4.2.2 Parallel in vitro study
Polymer scaffold seeded with ovine MSCs and unused to fill the femoral condyle defects
was kept for a parallel in vitro study. Approximately 1 g of seeded scaffold was placed into
individual wells of 24 well plates and incubated under standard cell culture conditions (37
◦C and 5% CO2) in osteogenic media.
4.2.2.1 WST-1 assay
Three samples for each sheep were assessed for cell viability after 2 week in vitro incubation
(first day of ovine in vivo incubation) and 8 week in vitro incubation (6 week of ovine in vivo
incubation/mid-point of in vivo study). Each sample was submerged in 1 ml 1:10 dilution
WST-1 substrate (Roche Ltd., U.K.). Polymer scaffolds not seeded with MSCs were used
as negative controls. After 4 hours, ×3 100 µl of substrate solution were taken from each
sample well and analysed via a Bio-Tek KC4 microplate fluorescent reader (Bio-Tek, U.S.A)
at 410 nm. Section 2.6.1 contains details of the WST-1 assay used.
4.2.2.2 ALP/DNA assay
Similarly to the WST-1 assays, ovine MSCs were assessed in triplicate for each sheep at 2
week and 8 week in vitro incubation time-points, which corresponded to the first day of
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ovine incubation and to the mid-point of ovine incubation, respectively. Identical protocols
to those detailed in Sections 2.6.2 and 2.6.3 were used; the only difference is that, rather than
referring to the contents of an impaction chamber, portions of seeded scaffold cultured in
individual wells of 24 well plates were used.
4.2.2.3 Immunohistochemical staining
Two samples of milled polymeric scaffolds seeded individually with MSCs collected and
expanded from the bone marrow aspirate different sheep were immunohistochemically
stained for collagen-1 and imaged as described in the procedure detailed in Section 2.7.
4.2.3 Production scale-up
The production of scCO2 foamed scaffolds was scaled up through the utilisation of a custom-
made (School of Chemistry, The University of Nottingham, U.K.) 1 L vessel. The 1 L vessel is
shown in Figure 4.2A while the smaller scale 60 ml autoclave used to produce the scaffolds
for the cell studies within the thesis is shown in Figure 4.2B. While the vessel is scaled up,
the piping, control valves, and back-pressure regulator used to control the pressure within
the vessel, were identical to those used for the 60 ml autoclave as described in Section 2.1.
Custom-made (School of Chemistry, The University of Nottingham, U.K.) PTFE moulds
with a diameter smaller than the internal diameter of the 1 L vessel were used. Each mould
was circular and contained 36 cylindrical wells of identical dimensions to those in themoulds
used in the 60 ml autoclave (11.2 mm × 10.4 mm). Stainless steel base plates and lids were
also made for the moulds, with PTFE sheets to fit between the base plates and the mould and
the lid and the mould. This was to prevent polymer scaffolds bonding to the stainless-steel
and to aid removal of the scaffolds post-scCO2 foaming. Moulds for the 1 L vessel are shown
in Figures 4.2 C, E, & F; and a mould for the 60 ml autoclave is shown in Figure 4.2D. Figure
4.2 C shows the gas inlet ports for the large rig mould. In Figure 4.2D the arrow points to a
gas inlet port in a mould for the 60 ml autoclave. Small channels act as gas inlet ports in the
top and bottom of the mould for each individual well.
The protocol used for scCO2 foaming of PDLLA scaffolds in the 1 L vessel is identical
to that used in the 60 ml autoclave as detailed in Section 2.1. When foaming using one
mould, for practical and safety reasons, PTFE spacers were used to fill the volume of the 1
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Figure 4.2: Images of the 1 L vessel (A) and 60 ml autoclave (B) used for scCO2 foaming.
Moulds for the 1 L vessel (C, E, & F) and 60 ml autoclave (D) are also shown.
Arrows indicate gas inlet port locations in moulds.
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L vessel to lower the volume of stored energy in the form of pressurised fluid within the
vessel. Both the orientation of the moulds and the position within the moulds were tracked
to provide a spectrum of scaffolds from different locations within the vessel. Additionally,
the PTFE spacers were used to vary the height of the moulds within the 1 L vessel in different
batches. Scaffolds from different batches and different locations within the vessel during
scCO2 foaming were used for comparison with scaffolds produced in the 60 ml autoclave,
and to determine the variation in scaffold properties produced using the 1 L vessel.
4.2.3.1 Supercritical CO2 foaming in large vessel
The protocol for scCO2 foaming in the 60 ml autoclave is detailed in Section 2.1. Scaffolds
from different batches were used for comparison with those produced in the 1 L vessel.
4.2.3.2 Supercritical CO2 foaming in small vessel
The protocol for scCO2 foaming in the 60 ml autoclave is detailed in Section 2.1. Scaffolds
from different batches were used for comparison with those produced in the 1 L vessel.
4.2.3.3 Structure characterisation
Scanning electron microscopy
The protocol used for SEM is detailed in Section 2.2.
Micro x-ray computed tomography
The protocol used for characterising scaffolds using µCT is detailed in Section 2.3.1.
4.3 Results and discussion
4.3.1 In vivo ovine study
The aim of the ovine critical sized condyle defect study was to establish the bone regenera-
tion potential of scCO2 foamed PDLLA + HA scaffolds in a larger, more clinically relevant
(similar body weight, long bone size suitable for human protheses [209]) animal model than
the previous murine studies. Additionally, the bone regenerative potential of scaffold and
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MSCs composites was compared to scaffold only controls. This was to determine the im-
portance of implanting MSCs, which were hypothesised to provide osteogenic properties in
scaffold + MSCs composites over the scaffold only controls.
The ovine in vivo incubation was initially due to end after 6 weeks. X-ray radiographs
taken at this point showed limited radiopacity (radiation opacity) within the defect sites
(Figure 4.3) which indicated limited new bone formation and repair. The in vivo incubation
time was therefore extended to 13 weeks. Radiographs taken after 13 weeks (Figure 4.4)
demonstrate less radiopacity in the defect volumes filled with milled scCO2 foamed PDLLA
+ HA + MSCs than the defects filled without cells. This implied defects filled without cells
formed more dense new bone or a greater quantity of new bone.
Following removal, the ovine femoral condyles were analysed on-site using peripheral
quantitative computed tomography (pQCT). This technique measures bone mineral density
(BMD) and was utilised for comparison of BMD within the defects to surrounding can-
cellous bone within the same condyles. Comparison of BMD between defects filled with
milled scCO2 foamed PDLLA + HA (10 wt.%) + MSCs and controls without MSCs was
also performed (Figure 4.5). A difference in mean bone density, between defects filled with
milled scCO2 foamed PDLLA + HA (10 wt.%) + MSCs and controls with no cells, of 29% was
observed, but was not statistically significant at the P<0.05 level.
Two surrounding areas of cancellous bone were used as controls for BMD measured
by pQCT. There was a significant difference in BMD between cancellous bone area one
and defects filled with PDLLA scaffold + MSCs of 58% (P<0.01) and a smaller significant
difference in BMD between bone area one and defects filled with PDLLA scaffold alone
of 38% (P<0.01). The BMD in bone area two was ≈ 24% less than that of bone area one
(P<0.05). Comparison of BMD between the defect sites and bone area two was therefore
more favourable with a significant difference of 44% (P<0.01) between bone area two and
defect filled with PDLLA scaffold + MSCs, and 20% (P<0.01) between bone area two and
defect filled with PDLLA scaffold alone.
Bone strength and BMD vary significantly within the knee. Behrens et al. [234] reported
values of bone strength in rheumatoid or osteoarthritic knees varying from 2.9 - 29.4MPa and
BMD varying from 0.3 - 1.0 g cm−3. This variation was found across ten different (human)
autopsy patients, with eleven sampling sites across the femoral and tibial condyles for each
patient. Given the reported 3-fold variation in human condyle BMD, the variation (≈ 24%)
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Figure 4.3: Representative lateral x-ray radiographs of femoral ovine condyles thirteen
weeks post implantation of: (A) milled scCO2 foamed scaffold and (B) milled
scCO2 foamed scaffold. Black arrows indicate implanted metallic guides for lo-
cating defect. White arrows indicate defects.
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Figure 4.4: Representative medial (A, C, E, & G) and lateral (B, D, F, & H) x-ray radiographs
of a sheep’s knees six weeks post implantation of: (A) milled scCO2 foamed
scaffold + MSCs and (B) milled scCO2 foamed scaffold.
118
CHAPTER 4 : INVE S T I GAT ION OF THE SCALAB I L I T Y OF MANUFACTUR ING
SCCO2 FOAMED SCAF FOLD S AND THE I R UT I L I SAT ION in vivo
in BMD between ovine control areas of bone (bone area one and two) for pQCT analysis
was anticipated. The ovine BMD values are low compared to reported ovine values [235]
but within the lower range of human BMD reported by Behrens et al. [234]. Armstrong et al.
measured BMD values from volumes that included cortical and cancellous bone. Cortical
bone is more dense than cancellous bone [236] and this may account for the lower values of
BMD recorded here in control regions.
The ovine femoral condyles were halved vertically down the centre of the cylindrical
defect using a diamond bandsaw as detailed in Section 4.2.1.9. Indentation tests were per-
formed on one half of the condyles for each sheep leg on two areas within each defect and
two areas in the surrounding cancellous bone as shown in Figure 4.6. The stress at failure
was recorded for each area and the mean of these values is displayed in Figure 4.6. The mean
strength at failure of defects filled with milled scCO2 foamed PDLLA + HA +MSCs was mea-
surably less than that of defects filled with milled scCO2 foamed PDLLA + HA controls. In
position one the difference was 41% while in position two the difference was 72%; however,
these differences were not statistically significant.
Indentation testing results have been found to correlate well (correlation values of 0.823 -
0.952) with compressive tests [232, 237]. Eitel et al. [232] reviewed recorded literature values
of the ultimate strength of cancellous bones and reported a range of 38 - 71 MPa (or N mm2).
The ultimate strength reported here for ovine cancellous bone remains within this range with
40 - 70 MPa (Figure 4.6). This range of values within the same region of bone is not unusual
[232]. It is clear the strength of PDLLA scaffold and new bone within the defect volumes
is less than surrounding bone and less than the minimum strength we would expect for
cancellous bone (38 MPa).
When implanted the milled PDLLA was pushed into the defect and not impacted. The
degree of compaction of loose chips of material affects the ultimate strength due to the
innate weaknesses built in by lack of bonding. More compact chips of material will display
a higher ultimate strength, up to the ultimate strength of the material itself, compared to
less compact chips of the same material (assuming identical properties of the chips, such
as roughness, size distribution, and porosity). Had the chips of scCO2 foamed PDLLA been
more forcefully impacted into the defects a higher ultimate strengthmay have been observed.
The indentation test results showed some strength in the defect volumes (>10 MPa), but this
had yet to reach that of cancellous bone.
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Figure 4.5: Bone mineral densities measured by pQCT post 13 week in vivo incubation of
defect areas and surrounding bone. No statistical significance at P<0.05 level.
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Figure 4.6: Indentation test mechanical stress at failure for test areas (n=6). Positions 1 and
2 on defect and positions A and B surrounding cancellous bone. No statistical
significance at P<0.05 level.
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Figure 4.7: Post ovine implantation (13 week) axial µCT slices of defect sites and surround-
ing bone structure of: (A) milled scCO2 foamed scaffold + MSCs and (B) milled
scCO2 foamed scaffold. Inset images show 3D reconstructions from which dis-
played slices were taken. Scale bars = 4 mm.
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The femoral condyle halves that underwent indentation testing post ovine incubation
were further analysed with µCT. Scans of the defects were reconstructed and representative
axial slices of the 3D reconstructions are displayed in Figure 4.7. In the reconstructions the
defect sites remained discernible from surrounding cancellous bone following 13 week ovine
incubation. Due to in vivo degradation times of PDLLA and PDLLGA of high MW reported
as >13 weeks [238] this was anticipated. Defects filled with milled scCO2 foamed PDLLA +
HA + MSCs were observed to have a sclerotic margin (bony rim) around the outer surface
of the defect volume, with little in-growing bone. Defects filled with milled scCO2 foamed
PDLLA + HA alone (no implanted MSCs) appeared to have a sclerotic margin around the
outer surface of the defect volume, with evidence of bony in-growth/new cancellous bone
within the defect volume (Figure 4.7).
A sclerotic margin refers to a complete or incomplete rim of bone at the interface of, in
this work, defect site and cancellous bone interface. The presence of a sclerotic margin and
little in-growing bone for defects filled with polymer and MSCs implies the bone repair
process sealed off the wound. In turn this implies polymer and MSCs composites were
less osteoconductive than polymer alone: defects filled with polymer alone demonstrated
increased bony in-growth.
The mean percentage bone volume within the defects was calculated from the µCT scan
data for defects filled with milled scCO2 foamed PDLLA + HA + MSCs and the controls
without cells (Figure 4.8). A higher mean percentage of bone formation within defects filled
with milled scCO2 foamed PDLLA + HA (no MSCs) was calculated than defects filled with
the same + MSCs. These results were not significant at the P<0.05 level. The porous nature
of normal cancellous bone would result in a bone volume of ≈40% following µCT scan and
analysis.
The calculation of mean percentage bone volume within defects by µCT includes the
volume taken up by HA incorporated within the PDLLA through scCO2 foaming. The HA
loadings should not be significantly different for defects filled with polymer scaffold and
cells or scaffold alone. The scaffolds were produced following the same protocol and milled
and sterilised as a batch. The volume of MSCs was significantly less than the volume of
the polymer scaffolds at implantation and did not noticeably impact the implanted scaffold
volumes. Due to the presence of HA within the scaffolds the absolute value of bone volume
within defects calculated from µCT scans is not accurate. However, the method is suitable
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Figure 4.8:Mean percentage bone (density ≥0.25 g cm−3) formation within condyle defects
post 13 week ovine implantation. No statistical significance at P<0.05 level.
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to provide a comparison of the bone growth in the defects with and without the presence of
MSCs. Histological analysis was used to assess the regeneration of normal bone within the
defect site.
Each femoral condyle was halved and one half from eachwas used for indentation testing
and µCT analysis; the second half from each condyle was histologically stained. Histological
staining showed similar results to µCT analysis with visible sclerotic margins around the
outer edge of the defects, limited bony in-growth evident in defects filled with polymer and
MSCs, and evidence of bony in-growth into defects filled with polymer scaffolds alone (no
MSCs) (Figures 4.9 and 4.10).
The popliteal lymph nodes receive the lymphatic vessels from the knee joint and were
removed with the femoral condyles. Hematoxylin and eosin (H&E) histological stains were
used on each lymph node and examined for evidence of inflammatory reaction (Figure
4.11). Evidence of inflammatory response would be important to note prior to further in
vivo studies or clinical trials. Some small circular spaces were revealed from examination
of the stained lymph nodes with no observable inflammatory response. These spaces likely
represent scaffold material lost as polymer was implanted. In the fat adjacent to one lymph
node a larger number of roughly circular spaces surrounded by fibrous tissue were observed.
This resembled histology previously seen around biodegradable implants and is of limited
concern [239–241].
4.3.2 Parallel in vitro study
In parallel to the in vivo study MSCs were also cultured in vitro. In vivo implantation and
6 weeks in vivo correspond to the in vitro time points of 2 weeks and 8 weeks, respectively.
The cells in the in vivo study were cultured in vitro for 2 weeks prior to implantation. Cell
viability on milled scCO2 foamed PDLLA + HA (10 wt.%) in vitro was assessed using WST-1
assays carried out after incubation for 2 weeks and 8 weeks (Figure 4.12). A large change
in optical density over the assay period indicated good cell viability at both time points. A
significant (P<0.05) drop from 2 weeks to 8 weeks suggests either a drop in total viable cell
number, or reduced cell metabolic activity by week eight.
In the previous murine study, cells implanted in vivo were labelled with Vybrant (a
fluorescent dye) prior to implantation and were imaged post 5 week in vivo incubation. This
confirmed the presence of cells implanted with the scaffolds at the end of the study period.
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Figure 4.9: Histological staining (H&E) at x2.5 magnification post ovine implantation of: (A)
and (B) normal bone, (C) and (D) defect filled with scaffold control, (E) and (F)
defect filled with scaffold + MSCs.
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Figure 4.10: Histological staining (H&E) post ovine implantation of: (A) and (B) defect filled
with milled scCO2 foamed PDLLA + HA (10 wt.%) + MSCs, (C) and (D) defect
filled with milled scCO2 foamed PDLLA + HA (10 wt.%.
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Figure 4.11: Ovine popliteal lymph nodes collected post study and H&E stained. (A) shows
normal lymph node appearance (x25 magnification). (B) (x25 magnification)
and (C) (x400 magnification) show circular spaces with no surrounding inflam-
mation. (D) shows fibrous tissue containing macrophages, lymphocytes, and
plasma cells, within the peri-lymphatic fat (x50 magnification). A + B scale bars
= 1000 µm. C+ D scale bars = 500 µm.
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Figure 4.12:WST-1 assay readings showing optical density at 450 nm for ovine MSCs cul-
tured on milled scCO2 foamed PDLLA + HA (10 wt.%) scaffolds for two (day
1 in vivo) and eight weeks (textitin vivo midpoint) in osteogenic medium (n=6,
*P<0.05).
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This staining was not carried out for implanted cells in the ovine model. Hence, we are
unable to confirm that cells implanted on scaffolds in the ovine model survived the length
of the study within the defect site. Cell apoptosis or migration away from the defect site
may have occurred. This may limit the conclusions that can be drawn from the in vitro study
that ran in parallel to the ovine in vivo study. Despite this limitation the cells for both studies
(ovine in vivo and in vitro) came from identical sources and in vitro behaviour may shed light
on in vivo results.
Osteoblastic differentiation assays were carried out in addition to cell viability assays in
vitro. Alkaline phosphatase assays were used to assess osteoblastic differentiation follow-
ing 2 weeks and 8 weeks in vitro culture in osteogenic medium on milled scCO2 foamed
PDLLA + HA (10 wt.%) (Figure 4.13). A significant increase (P<0.05) was detected in ALP
specific activity after 8 weeks compared to 2 weeks. However the mean ALP specific ac-
tivities measured at both time points are very low and suggest low levels of osteoblastic
differentiation.
Following 8weeks in vitro incubation in osteogenic medium, samples were immunohisto-
chemically stained for osteoblastic differentiation markers (collagen-1, osteocalcin, and bone
sialoprotein). The confocal microscopy images (Figure 4.14) indicated the presence of bone
sialoprotein (BSP), but limited levels of collagen-1 and osteocalcin expression. Differentiated
osteoblasts express high levels of collagen-1, which forms 90% of total protein by weight
in osteoblastic ECM [242]. While BSP is used as a marker of osteoblast differentiation its
role in function is unclear [242] although it has been implicated as a nucleator of HA crystal
formation [243]. Additionally BSP is expressed by osteoclasts, chondrocytes [244, 245], and
tumor cells [246], as well as, osteoblast and osteoblast progenitors. Osteocalcin is considered
a specific marker for osteoblasts and is not expressed in other ECM-producing cell types
[247, 248].
The limited levels of collagen-1 and osteocalcin expression indicated in Figure 4.14 im-
ply limited osteoblastic differentiation of MSCs over 8 weeks of in vitro incubation. This is
despite some BSP expression. Human and ovine bone marrow derived MSCs are known to
undergo osteoblastic differentiation under osteogenic conditions [249] and [250]). McCarty et
al. [250] established osteoblastic differentiation of ovine MSCs using a procedure for human
MSC differentiation reported earlier by Gronthos et al. [249]. This protocol used a 100 nM
concentration of dexamethasone, compared to the protocol employed here, which required
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Figure 4.13:Mean ALP specific activity for ovine MSCs cultured on milled scCO2 foamed
PDLLA + HA (10 wt.%) scaffolds in osteogenic medium two (day 1 in vivo) and
eight weeks (textitin vivo midpoint) in osteogenic medium (n=3). No statistical
significance at P<0.05 level.
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Figure 4.14: Confocal images of immunostained (AlexaFluor 594, green) ovine MSCs post
8 week in vitro culture on milled polymer scaffolds of: (A) secondary antibody
only control, (B) collagen-1, (C) osteocalcin, and (D) bone sialoprotein. Nuclear
counterstains (DAPI) in red.
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10 nM concentration of dexamethasone. The protocol utilised here to stimulate osteoblastic
differentiation had been optimised for human bone marrow derivedMSCs and was not opti-
mised for ovine bone marrow derived MSCs. This may have resulted in limited osteoblastic
differentiation of ovineMSCs prior to implantation for the in vivo study. Implantation of cells
other than osteoblasts/osteoblast progenitors could account for the reduced levels of new
bone observed through x-ray radiograph, µCT analysis, and histological staining in the in
vivo study. If the implanted MSCs had differentiated along a different lineage then they may
have impeded bony in-growth from the host. Interestingly however, van der Pol et al. [230]
observed fibrous tissue formation at 2 and 4 months in ovine femoral and tibial defects did
not preclude long-term application of a scCO2 foamed PLLA + βTCP scaffold, demonstrated
by osteointegration after 12 months. If the study had been extended, osteointegration of
scaffolds implanted with MSCs may have been observed at a later time point.
A variety of studies similar to the ovine in vivo model established that greater levels
of new bone formed in bone repair studies with the use of MSCs compared to implanted
scaffolds without cells. Korda et al. [196] performed ovine hip replacements and implanted
femoral stems with grooves on the stem that were filled with allograft + MSCs or allograft
alone as a control. Niemeyer et al. [251] implanted mineralized collagen sponges unseeded,
seeded with ovine MSCs, and seeded with ovine adipose-tissue derived stem cells (ASCs)
into critical sized ovine tibia defects. After 12 weeks both of these studies demonstrated
increased new bone formation when comparing implants seeded with MSCs compared to
unseeded implants. Similarly, Cao et al. [252] reported autologous MSCs seeded on β-TCP
and implanted into a femoral condyle defect formed more new bone and demonstrated
greater repair of the defect compared to implanted β-TCP after 16 weeks in a goat osteo-
porotic model.
4.3.3 Supercritical CO2 foaming scale up study.
Commercially viable tissue engineering scaffolds typically require the ability to be produced
on a clinical scale. To demonstrate scale-up of scCO2 foaming of PDLLA a 1000 ml vessel
was utilised and moulds produced in house as detailed in Section 4.2.3. The 12 mm x 11.2
mm cylindrical foams produced in the 60 ml autoclave were easy to handle and suitable
for milling using a standard bone-mill as would typically be found within hospitals that
perform surgeries requiring impaction bone grafting. Rather than produce larger foams,
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Figure 4.15: Representative SEM images of PDLLA scaffolds scCO2 foamed in a 60 ml au-
toclave (small rig, images: (A), (C), and (E)) and a 1000 ml vessel (large rig,
images: (B), (D), (F)). Images (A) and (B) at x50 magnification and images (C),
(D), (E), and (F) at x200 magnification.
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which would change the diffusion times of CO2 out of the polymer upon depressurisation
of the vessel, more PDLLA foam scaffolds of an identical size to those produced in the 60
ml autoclave were produced in the 1000 ml vessel. This enabled direct comparison of the
foams produced in each vessel. Representativemicrographs displayed in Figure 4.15 showed
that there is an extremely similar pore size and distribution between scaffolds produced in
the different vessels. The degree of pore anisotropy was not analysed quantitatively, but
qualitatively through observation of the micrographs the pores in foams manufactured in
the large rig appear slightly more irregular.
The quantitative differences between foams produced in each vessel were assessed
through µCT. Representative images and reconstructed axial slices (400 slices) are displayed
in Figure 4.16. Analysis of the µCT scans calculated the mean porosity of scCO2 foamed
PDLLA produced in the 60 ml autoclave as 51.9 ± 0.9 % (n=4), and produced in the 1000 ml
vessel as 50.0 ± 1.4% (n=13), with a significant difference between the two (P<0.05). Each
foam produced in the 60 ml autoclave and analysed was produced in a separate batch. The
foams produced in the 1000 ml vessel and analysed were taken from three separate batches
and from different locations within the mould; the moulds were placed at different heights
within the vessel for each batch. The standard deviation in the porosity of scaffolds produced
in the 1000 ml vessel is < 3% and even less for those produced in the 60 ml autoclave, which
indicated limited variance between batches. The mean pore size calculated was 79.3 ± 5.2
µm for foams produced in the 60 ml autoclave, and 59.2 ± 5.2 µm for foams produced in
the 1000 ml autoclave, which represented a significant difference (P<0.01). The variance in
mean pore size was <10% for scaffolds produced in both vessels.
The importance of a uniform pore size in scCO2 foamed scaffolds for bone tissue engi-
neering and impaction bone grafting has not been established and was not the purpose of
this study. The difference in pore size observed through µCT analysis demonstrated that
despite identical polymer sources and foaming conditions some differences were noted in
the scaffolds produced from the different vessels. Heating in the 1000 ml vessel may result
in the observed difference, or differences in the moulds used in each vessel may significantly
affect how the scaffolds foam. Many factors that affect how polymers foam in scCO2 have
been studied [97]. These factors represent control of the scCO2 foaming process enabling a
wide variety of porosity, pore sizes, and interconnectivity to be achieved.
Scale-up of porous scaffold production by scCO2 foaming has received very limited
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Figure 4.16: Representative µCT images ((A) and (B)) and reconstructed axial µCT slices
((C) and (D)) of PDLLA scaffolds scCO2 foamed in a 60 ml autoclave (small rig,
images: (A) and (C)) and a 1000 ml vessel (large rig, images: (B) and (D)).
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Figure 4.17:Mean porosity values calculated from µCT data of scCO2 foamed PDLLA scaf-
folds foamed in a 60 ml autoclave (small rig, n=4) and a 1000 ml vessel (large
rig, n=13) (* P<0.05). Error bars show standard deviation.
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Figure 4.18:Mean pore diameters calculated from µCT data of scCO2 foamed PDLLA scaf-
folds foamed in a 60 ml autoclave (small rig, n=4) and a 1000 ml vessel (large
rig, n=13) (** P<0.01). Error bars show standard deviation.
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discussion within the literature [253]. Here we have demonstrated the scCO2 foaming of
thirty six scaffolds per mould in a 1000 ml vessel that holds five moulds; one hundred and
eighty scaffolds can be foamed in one batch. The scaffolds produced had a similar porosity
(within 1%) to scaffolds foamed in a 60 ml autoclave, but had a different mean pore size.
While it is possible to scCO2 foam many more scaffolds in the large vessel compared to the
small vessel further study is required to match the two processes.
The moulds for the large vessel required small holes in the lid and base of each well
within the moulds to allow CO2 to reach the polymer. The location of these holes differed in
the moulds for the large vessel compared to the moulds for the small vessel. For the small
vessel moulds these holes were in the side of each, at the top and the bottom; they were
located in the centre of each well in the large vessel moulds. New lids and bases with CO2
access holes in the centre of each well could be produced for the small vessel, which may
reduce the differences observed in the scaffolds foamed in each vessel. However, it is still
likely that some optimisation will be required through variation of temperature, pressure, or
vent time to more closely match scaffolds produced in the 1000 ml vessel to those produced
in the 60 ml autoclave.
4.4 Conclusion
The work presented in this chapter demonstrated new bone formation within an ovine
femoral condyle defect filled with scCO2 foamed PDLLA + HA 10% (wt%). Limited new
bone formation was demonstrated in defects filled with the same seeded with ovine MSCs.
The apparent detrimental effect of seeding scaffolds with MSCs before implantation contra-
dicts findings reported in the literature and parallel in vitro work indicated MSCs had not
differentiated along the osteolastic lineage. Future work with ovine MSCs should confirm a
working osteoblastic differentiation protocol. Defects filled with scaffolds without MSCs for
12 weeks in vivo incubation showed good osteoconductive and osteoinductive properties,
and while not fully healed, the new bone formed gave good indication that the defect would
heal over time.
Proof-of-concept of the scale-up of scCO2 foaming process has been demonstrated with
the production of 10.8 g of foamed scaffolds in a 1000 ml vessel in a single batch compared to
1.8 g in a batch foamed in a 60 ml autoclave. Furthermore, the 1000 ml vessel has a volume
that allows for scCO2 foaming 54 g of PDLLA per batch. The scaffolds produced in each
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vessel were foamed using an identical protocol and significant differences in the porosity
and pore size of the resulting scaffolds were observed. While significantly different, the
porosities were similar for scaffolds produced in different vessels. Further work is required
to scCO2 foam scaffolds with matching characteristics in each vessel. PDLLA was scCO2
foamed in different locations within the 1000 ml vessel and at different heights, and the
standard deviation in porosity values was <3%. While the standard deviation in mean pore
size matched that for PDLLA scaffolds foamed within the 60 ml autoclave. This is evidence
that scCO2 foaming porous biodegradable scaffolds is possible on a large scale.
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CHAPTER 5
Investigation of factors affecting
scaffold performance
This chapter investigates the reason behind differing performance of PDLLA and PDLLGA
scaffolds that, due to their similarity, was unanticipated. This chapter also investigates HA
particle size and concentration for improvingmechanical strength, important in load bearing
applications, and osteoblastic differentiation of MSCs following observation of new bone
growth concentrated around HA microparticles in the earlier murine model.
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5.1 Introduction
Results presented in Chapter 3 demonstrated that the osteogenic differentiation of MSCs
differed between cells cultured on PDLLA and PDLLGA scaffolds, both scCO2 foamed and
non-foamed. This was observed through ALP assays and collagen-1 immunohistochemical
stains after 2 weeks in vitro culture in osteogenic medium. A significantly higher ALP spe-
cific activity was observed for MSCs cultured in vitro on scCO2 foamed PDLLA compared
to MSCs cultured on scCO2 foamed PDLLGA scaffolds. The same result was observed in
the study that incorporated 10% HA microparticles; significantly higher ALP specific ac-
tivity was reported for MSCs cultured on PDLLA scaffolds (with and without 10 wt.%HA
microparticles) than MSCs cultured on PDLLGA scaffolds (with and without 10 wt.% HA
microparticles) (Figure 3.12). The differences in MSC osteoblastic differentiation observed
were unexpected because the polymers had extremely similar properties (high MW , amor-
phous, random chirality), the lactide:glycolide ratio was high (85:15) for PDLLGA, and both
had been used in scaffolds promoted for bone tissue engineering [254–257]. Additionally on
PDLLGA matrices, osteoblasts had been reported to produce significantly higher levels of
ECM proteins than on PDLLA matrices [258].
This chapter investigates the differentiation of MSCs in vitro on PDLLA, PDLLGA, and
PDLLA:PDLLGA (50:50) films produced by spin-coating and dip coating. Establishing dif-
ferences in the differentiation of MSCs on these films was required to elucidate the results
reported in chapter 3; specifically, to establish that the differences in MSC osteoblastic dif-
ferentiation observed on scCO2 foamed scaffolds were primarily due to morphological dif-
ferences in the foamed structures. The use of flat films removed micro-scale morphological
variation between the polymers. Films of a 50:50 blend of PDLLA and PDLLGA were used
in addition to 100% PDLLA and 100% PDLLGA films to provide a midpoint, and establish if
any trends observed were linear.
There are many variables that may have affected the MSC osteoblastic differentiation in
the earlier experiments reported in Chapter 3 , such as: scaffold pore size, scaffold porosity,
polymer degradation rate, polymer wettability, polymer stiffness, surface (any surface cells
adhered to including inner pore walls) topography, and surface roughness. The differences
in MSC osteoblastic differentiation on different polymer scaffolds (PDLLA and PDLLGA)
observed may not be limited to a single cause, but could arise due to a combined effect of
several variables. However, studies have reported that substrate nano-scale and micro-scale
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structures have a significant effect on the osteogenic differentiation of MSCs [168, 259–270].
Both Oh et al. [271] and Dalby et al. [259] demonstrated that nanotopographical cues can
guide MSC osteogenic differentiation in the absence of chemical cues commonly used (such
as dexamethasone or BMP2). In a 1:1 adipogenic induction:osteogenic induction medium
different microtopographical cues induced MSC differentiation towards different lineages
[262]. Additionally, MSCs cultured on 10 µm deep squares and 30 µm deep grooves demon-
strated enhanced osteocalcin (a specific osteoblast marker [247]) expression, establishing
that microtopographical cues enhance osteoblastic differentiation. The strong effects on
MSC differentiation of topographical cues reported in the literature ensured that establish-
ing if scaffold morphological features affected the osteogenic differentiation of MSCs in the
studies reported in Chapter 3 was a priority over other possible variables to investigate.
In the murine study reported in Chapter 3, µCT analysis revealed the formation of bone-
like matrix in PDLLA:HA composite scaffolds (scCO2 foamed, then milled and impacted,
PDLLA + 10 wt.% HA microparticles) was focused primarily around the HA microparticles.
Increasing the specific surface area of HA particles within the scaffolds may provide more
sites for osteogenesis to occur and improve the bone regeneration rate in vivo. Many bone
tissue engineering scaffolds reported in the literature comprise composite materials that
incorporate HA nanoparticles [186, 198, 208, 254, 272–283]. Nanoparticles are defined as
particles where at least one dimension is on the nanoscale, i.e. <1 µm.
Various authors have demonstrated the efficacy of nanocomposite scaffolds for bone
repair, both in vitro [198, 208, 273, 277, 279, 281] and in vivo. [186, 198, 254, 275, 280]. Nejati et
al. [278] and Eslaminejad et al. [281] compared PLLA + nanorods (NRs) composite scaffolds
to PLLA and PLLA + HA microparticle composite scaffolds; bone related gene expression
(collagen-1, osteocalcin, and RunX2 (Runt-related transcription factor 2)) in MSCs cultured
on the scaffolds was significantly higher (P<0.05) than in MSCs cultured on the microcom-
posite or pure PLLA scaffolds. Additionally, the nanocomposite scaffolds demonstrated
increased compressive strength (8.46 MPa) compared to plain PLLA (1.79 MPa) and micro-
composite (4.61 MPa) scaffolds [281]. Mechanical properties of nanocomposite scaffolds are
reportedly greater than pure scaffolds. Kothapalli et al. demonstrated a linear increase in
compression modulus (from 5 MPa, 0wt.% HA, to 10 MPa, 50% HA) and yield strength
(from 0.3 MPa, 0 wt.% HA, to 0.4 MPa, 50 wt.% HA) with increasing HA content (10 wt.%
increments) in PLA porous scaffolds (chirality not reported). Similarly, Wei et al. reported
an increase in compression modulus from 4.3 MPa (0 wt.% HA) to 8.3 MPa (50 wt.% HA)
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in PLLA scaffolds. Further increases in the strength of PLA:HA nanocomposite scaffolds
were demonstrated through modification of surface grafting of the HA particles. Hong et
al. reported higher bending strengths, impact energies, and moduli for 4% and 20% PLLA:
surface grafted nano HA to PLLA:nano HA scaffolds.
The reported improvements in nanocomposite scaffolds within the literature provided
motivation to investigate the effect of HA nanoparticles compared to HA microparticles on
scCO2 foamed PDLLA scaffolds. In this chapter milled scCO2 foamed PDLLA scaffolds con-
taining nanorods (NRs) and nanoplates (NPs) are investigated in vitro with scCO2 foamed
pure PDLLA and PDLLA + 10 wt.% HA microparticles controls for comparison. Two con-
centrations of nanoparticles were used, 1 wt.% and 10 wt.%, corresponding to the weight
and volume (of powder) of microparticles used in the control scaffolds containing 10 wt.%
microparticles. Cellular compatibility and differentiation experiments were carried out in
vitro with human MSCs. Scaffolds were characterised with mechanical compression and
SEM.
5.2 Materials and methods
5.2.1 Cell differentiation studies on PDLLA and PDLLGA films
5.2.1.1 Spin coated polymer films
Polymer films were spin coated onto 22 mm× 22 mm glass coverslips for cell differentiation
studies on different polymers: PDLLA, and PDLLGA. PDLLA with a MW of 108 kDa, inherent
viscosity of 0.71 dL g−1, polydispersity index of 1.6, and Tg of 49.1 ◦C was used. PDLLGA
(85:15 lactide:glycolide) with a MW of 110 kDa, inherent viscosity of 0.71 dL g−1, polydis-
persity index of 1.5, and Tg of 50 ◦C was used. Glass coverslips were washed in acetone
and air dried prior to spin coating. Solutions of PDLLA, PDLLGA and 50:50 PDLLA:PDLLGA
were made at a concentration of 5% polymer in acetone by dissolving 50 mg ml−1. Solutions
were agitated to ensure that the high MW polymers fully dissolved to create homogeneous
solutions. A 5 ml syringe was used to collect the polymer solution and a coverslip placed in
the spin coater (400 Lite Spinner, model WS-650SX, Laurell Technologies Corporation, PA,
U.S.A.). Under vacuum, 800 µl of polymer solution were dispensed onto the surface of the
coverslip which was then spun at 1000 rpm for 1 minute. Coated coverslips were then stored
in individual wells of six well plates.
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5.2.1.2 Film washes
Two methods were used for washing of spin coated polymer films: washing with hexane,
and washing with scCO2.
Hexane washing
Hexane (1 ml) was pipetted onto each film ×3. This was repeated in triplicate with fresh
hexane and the samples were vented in an extraction hood.
scCO2 washing
For washing with scCO2, glass coverslips were carefully positioned within a 60 ml autoclave
which was heated to 35 ◦C and filled with pressurised CO2 to a pressure of 23 MPa. The
autoclave was held under these conditions for 1 hour and then vented at a constant rate over
30 minutes back to atmospheric pressure. The thin films allowed rapid diffusion of absorbed
scCO2 which prevented scCO2 foaming of the films from occurring.
5.2.1.3 Water contact angle measurement
Statis water contact angle measurements were taken for unwashed films and films washed
using both hexane and scCO2. Ultrapure water droplets were dispensed onto the surface of
each film and images were recorded at 1 s intervals using a CAM 200 Optical Contact Angle
Meter (KSV Instruments Ltd., KSV NIMA, Finland). Manufacturer’s software was used to
calculate the contact angle for each image after the initial image using a Young Laplace fit.
The water contact angle for each film at time = 0 was determined using linear regression
analysis of the angles calculated. The measurements were taken in triplicate for each film
and the mean water contact angles of each film at time = 0 recorded.
5.2.1.4 X-ray photoelectron spectroscopy
X-ray photoelectron spectroscopy was performed by Emily Smith (School of Chemistry, The
University of Nottingham).
Polymer films both unwashed and hexane washed were analysed using x-ray photoelec-
tron spectroscopy (XPS). In XPS the surface of a substrate is irradiated with x-rays which
transfers energy to electrons in the surface (0-10 nm) elements of the substrate. Excited
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electrons are ejected via photoemission. An ultrahigh vacuum is used to prevent ejected elec-
tron scattering via collision with gas molecules. A spectrometer is used to detect the kinetic
energies of ejected electrons and electron binding energy is calculated using the Einstein
equation (EB = hν - EK - W, where EB is binding energy, hν is photon energy, EK is kinetic
energy, andW is the spectrometer work function). The spectra output can be used to identify
elements present and are usually reported as signal intensity plotted against binding energy.
Polymer films were fractured and mounted on a sample bar. A Kratos AXIS ULTRA
instrument (Kratos Analytical Ltd., U.K.) configured with a monochromated Al Kα (1486.6
eV) was used to collect XPS data for the films. CASAXPS (Casa Software Ltd.) was used to
analyse the XPS data.
5.2.1.5 Dipcoated polymer films
Dipcoated polymer films of PDLLA, PDLLGA, and PDLLA:PDLLGA (50:50) were produced.
Polymer solutions using the same polymers for spin coated films (described in Section
5.2.1.1) were made at a 10% concentration in acetone. Solutions were agitated to ensure the
polymers were fully dissolved. Glass coverslips 22 mm × 22 mm were washed in acetone
and air dried prior to dip coating. The dipcoating procedure for a single coverslip is detailed
as follows. Tweezers were used to hold the coverslip by an edge and to dip the coverslip into
the polymer solution. After dipping, excess solution was allowed to drain from the coverslip
by contacting one corner of the coverslip with the container of the polymer solution. The
coverslip was then held and allowed to air dry prior to being placed into an individual well
of a six well plate.
5.2.1.6 Cell culture
Immortalised human MSCs expressing green fluorescent protein (GFP) were gifted by Dr
Hassan Rashidi (School of Pharmacy, The University of Nottingham). These cells were ex-
panded in T175 flasks until confluent and stored in cryo-vials in a liquid nitrogen storage
tank until required for in vitro cell experiments.
For cell expansion and cell seeding, basal mediumwas used, which was Dulbecco’s Mod-
ified Eagle’s Medium (DMEM) supplemented with 10 vol.% fetal bovine serum (FBS), 2mM
L-glutamin, 100 µg ml−1 penicillin and 100 µg ml−1 streptomycin (Pen-Strep, Invitrogen).
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For expansion, cells were cultured in T175 flasks and at 80-90% confluence the cells were
washed in phosphate buffered saline (PBS) and treatedwith trypsin in EDTA for 2 minutes to
detach cells from tissue culture plastic (TCP). An equal volume of serum-containingmedium
was used to deactivate the trypsin and the cell suspension transferred to a universal tube
and centrifuged for 5 minutes at 180 g. Supernatant was aspirated and cells resuspended
in FBS + 10% DMSO to a concentration of 1 million cells ml−1. Cells were stored in 1 ml
cryo-vials at -80 ◦C for one week and then transferred to liquid N2 storage.
Polymer films were sterilised under U.V. light for 1 hour prior to cell seeding. For each
study a cryo-vial of cells was reanimated by thawing and suspension in 20 ml of basal
medium. Then they were seeded in a T175 flask and grown until 90% confluent. Media
changes were performed every 3 days. At 90% confluence cells were released with trypsin in
EDTA for 2 minutes and an equal volume of basal medium was added. The cell suspension
was centrifuged for 5 minutes at 180 g. The supernatant was aspirated and the cells re-
suspended in basal medium. Cell concentration was determined using a haemocytometer
and appropriate dilution with basal medium to reach a final concentration of 1 × 106 cells
ml−1. Cells were seeded onto polymer films in non-TCP six well plates at a concentration of
10,000 cells cm2 (i.e. ≈48,000 cells per film). Cells were cultured on polymer films in basal
medium for 24 hours prior to media change. The cell media was changed from basal medium
to osteogenic medium after 24 hours. Osteogenic medium for these experiments was basal
medium + dexamethasone 0.1 µM, L-ascorbic acid 50 µM, and β-glycerophosphate 10 mM.
Cells were cultured on polymer films in osteogenic medium for 2 weeks and incubated
under standard cell culture conditions (37◦C and 5% CO2).
5.2.1.7 WST-1 assay
A WST-1 assay was carried out at 1 week and 2 week time points of in vitro culture. Back-
ground information of the WST-1 assay is included in Section 2.6.1. The cells cultured on
three of each group of polymer films (PDLLA, PDLLGA, and PDLLA:PDLLGA (50:50)) were
assayed at each time point. Media was aspirated from each well and films were washed
with PBS and aspirated ×2. Basal medium was then added to each well (1 ml) and 100 µl of
WST-1 reagent (Roche Ltd. U.K.). Basal medium (1 ml) was added to an empty well of a six
well plate ×2 and used as a negative controls. After 30 minutes of incubation (37◦C and 5%
CO2) 100 µl was taken from each well and transferred to a 96 well plate; this was performed
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in triplicate for each individual sample. Optical absorbance values were quantified at 450
nm using a µQuant 96 well plate reader (Bio-Tek Instruments, U.K.).
5.2.1.8 ALP assay
An ALP assay was carried out at 1 week and 2 week time points of in vitro culture. Back-
ground information of the ALP assay is included in Section 2.6.2. The cells cultured on
three of each group of polymer films (PDLLA, PDLLGA, and PDLLA:PDLLGA (50:50)) were
assayed at each time point. Media was aspirated from each well and the films washed in 0.2
M tris buffer. A solution of pNPP 1 mg ml−1 (Sigma-Aldrich, U.K.) in 0.2 M tris buffer was
prepared through dissolution and vortexing. Within 1 hour of preparation 1 ml of pNPP
solution was added to each film and incubated (37◦C and 5% CO2) for 1 hour. Then 200 µl
was taken in triplicate from each well and transferred into a 96 well plate; optical absorbance
values were quantified for each sample at 405 nm using a µQuant 96 well plate reader (Bio-
Tek Instruments, U.K.). ALP standards were used to derive a standard curve and determine
ALP concentration in the cellular samples.
5.2.1.9 Collagen-1 immunohistochemical stains
After 2 weeks of in vitro incubation the cells cultured on two of each group of polymer films
(PDLLA, PDLLGA, and PDLLA:PDLLGA (50:50)) were immunohistochemically stained for
the presence of collagen-1. The media in each well was aspirated and cells on each film were
fixed in 4% paraformaldehyde for 5 minutes. After fixing samples were stored under PBS at
3◦C until immunohistochemical staining was performed. Immunohistochemical staining in-
volved permeabilisation of samples using 400 µl of 0.1% TYriton X-100 in PBS for 30 minutes
followed by × washes in PBS. Blocking of non-specific proteins was performed using 400 µl
per film of 3% donkey serum in 1% BSA in PBS. Overnight incubation of samples was per-
formed in a primary antibody solution (1:200 dilution in 1% BAS in PBS); 400 µl per film. The
primary antibody solution was then removed and samples washed ×3 using PBS. Samples
were then incubated at room temperature under secondary antibody solution (1:200 in 1%
BSA in PBS) for 2 hours. Subsequently, the secondary antibody solution was removed and
samples washed ×3 using PBS. Hoechst nuclear counterstaining was used with incubation
for 20 minutes under 500 µl per film of Hoechst solution (1:1000 dilution in 1% BSA in PBS)
followed by further washing in PBS (× 3). Samples were mounted under Pro-fade and stored
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at 3◦C until imaged using fluorescent microscopy. An inverted-microscope (Leica DM-IRB,
Leica, Germany), a Hamamatsu digital camera, and Volocity imaging software (Improvision,
U.K.) was used for imaging of immunohistochemically stained films. The primary antibody
used was collagen-1 (rabbit host, Millipore, MA, U.S.A.). The secondary antibody used was
anti-rabbit IgG (AlexaFluor546, Life technologies, U.K.).
5.2.2 Studies of HA particle size and morphology effect on cell differentiation
5.2.2.1 Supercritical carbon dioxide foaming
Supercritical CO2 foamed polymer scaffolds were prepared as detailed in Section 2.1 using
PDLLA. Briefly, 300 mg of ground polymer powder was loaded into cylindrical wells of a
PTFE mould and foamed in scCO2 at 35 ◦C and 23 MPa for 1 hour with a 30 minute constant
rate vent back to atmospheric pressure. For scaffolds containing HA, 270 mg of polymer
and 30 mg of HA (either microparticles, nanorods, or nanoplates) were used for 10 wt.% HA
containing scaffolds. For scaffolds containing 1 wt.% HA, 297 mg of polymer and 3 mg of
HA (either nanorods or nanoplates) were used.
5.2.2.2 Preparation of polymer:HA composite scaffolds
Once the scaffolds were formed they were milled in a standard bone mill (Tessier Osseous
Microtome, Stryker Leibinger, Freiberf, Germany), sterilised, seeded with primary human
MSCs, and impacted into open ended impaction chambers. The milling and sterilisation
process is detailed in Section 2.5.1.3.
5.2.2.3 Scanning electron microscopy
Scanning electron microscopy was used on scaffolds prior to the milling process to charac-
terise the internal porous structure. Obtaining SEM images was a destructive process. The
protocols used for SEM are detailed in Sections 2.2; SEM was used both for imaging and
elemental mapping.
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5.2.2.4 Mechanical compression testing
A TA.HD plus texture analyser (Stable Micro Systems Ltd., Surrey, U.K.) was used for com-
pression testing of whole scCO2 foamed scaffolds (not milled). A 20 mm aluminium head
and a 50 kg load cell was used to apply a compressive load at a rate of 0.02 mm s−1 to scCO2
foamed scaffolds in a chamber at 37 ◦C. Stress strain curves were recorded for each scaffold
and average compressive failure points for each scaffold type were calculated. The yield
stress was determined by the initial peak of the stress-strain plot. The compressive mechani-
cal strength of the scaffolds was utilised as an additional indicator to compare the scaffolds
with different HA contents to identify those with the most potential for use. The targetted
application of scaffolds (impaction into the femur) is a loaded environment, and hence com-
pressive strength is relevant. Compression testing should not replace shear testing, which is
required because it is a common mode of failure for implanted femoral stems.
5.2.2.5 Cell culture
The isolation of primary human MSCs and their expansion and storage prior to use is de-
tailed in Section 2.5.1.1. The subsequent seeding and impaction of seeded scaffolds is de-
tailed in Sections 2.5.1.4 and 2.5.1.5, respectively. Cells were incubated in vitro for 2 weeks
under standard cell culture conditions (37 ◦C and 5% CO2).
WST-1 assay
The WST-1 assays were carried out for samples following the protocol described in Section
2.6.1.
ALP/DNA assay
The ALP and DNA assays were carried out using the protocols described in Sections 2.6.2
and 2.6.3, respectively.
Immunohistochemical staining
Collagen-1, osteocalcin and bone sialoprotein immunostaining was carried out utilising the
protocol described in Section 2.7.
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5.3 Results and discussion
5.3.1 Cell differentiation studies on PDLLA and PDLLGA films
The aim of the studies investigating osteogenic differentiation of immortalised humanMSCs
on PDLLA and PDLLGA films was to establish whether the difference in osteogenic differen-
tiation observed in Chapter 3 was intrinsic to the properties of the polymers by removing
morphological differences. The results from the studies in Chapter 3 demonstrated greater
specific ALP activity (P<0.001) and collagen-1 expression after 2 weeks in vitro culture in
osteogenic medium for MSCs cultured on PDLLA scaffolds, compared to MSCs cultured on
PDLLGA scaffolds. The characterisation of the scaffolds used in those studies demonstrated
a difference in porosity and pore size between the scCO2 foamed PDLLA and PDLLGA
scaffolds. Scaffold porosity and pore size are both known to influence osteogenesis (the
formation of bone) [180, 181]. Removing differences in scaffold morphology by utilising
flat films allowed any osteogenic differentiation differences observed to be attributed to
differences between the polymers (PDLLA and PDLLGA). Polymer films formed from a 50:50
(wt./wt.) blend of PDLLA and PDLLGAwere also utilised as midpoints, and glass coverslips
as controls.
Initially, spincoated polymer films were utilised. These were characterised by initial
water contact angle and XPS analysis as shown in Figure 5.1 and Table 5.1, respectively. Mea-
surement of water contact angles on different polymeric films indicated surface wettability,
which is known to affect cellular behaviour (e.g. cell adhesion, spreading, and migration)
[284–286], was not significantly different between PDLLA and PDLLGA polymer films. The
behaviour of MSCs cultured on PDLLA and PDLLGA films may have been affected by dif-
ferences in surface wettability between the films. These studies were carried out to remove
morphological differences, which were present in the investigations presented in Chapter 3.
These studies were not carried out to investigate the effect of differences in surface wettabil-
ity on osteoblastic differentiation of MSCs. Water contact angle characterisation for PDLLA
and PDLLGA films confirmed that surface wettability was not significantly different between
the films, and hence that it had a limited effect on the osteoblastic differentiation of MSCs
cultured on different polymer films.
Surface characterisation of polymer films by XPS analysis was carried out to identify
surface contamination and to confirm coverage of the glass substrate upon which the films
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Figure 5.1: Initial water contact angle results for polymer films spincoated onto glass cov-
erslips (n=3). (A) Shows results for unwashed films. (B) Shows results for films
washed with supercritical CO2 or hexane.
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Table 5.1: XPS results for polymer films spincoated onto glass coverslips, shown as percentages of total elemental signal.
Sample C 1s% O 1s% Si 2p% Ti 2p% Zn 2p% B 1s% K 2p% Na 1s%
Glass 15.19 59.13 15.37 0.84 1.48 2.01 2.23 3.75
PDLLA 60.73 36.02 3.25
PDLLA:PDLLGA (50:50) 59.94 37.26 2.81
PDLLGA 59.79 37.98 2.23
Hexane washed PDLLGA 61.45 38.49 0.05
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were spincoated or dipcoated. This increased confidence that osteogenic differentiation dif-
ferences observed in MSCs cultured on the films were due tothe properties of the polymers
being studied.
In Figure 5.1A the initial water contact angles are shown for spincoated films with no
washing steps prior to production. These were measured in triplicate for three different
samples of each polymer film type and the means plotted as shown. Similarly, in Table 5.1
the percentage of total elemental signal for carbon, oxygen, and silicon peaks are shown for
spincoated films of each polymer film type with no washing steps. The carbon:oxygen ratio
was similar for each polymer film type (PDLLA 1.69, PDLLA:PDLLGA 1.61, PDLLGA 1.57) as
expected due to the similarity between the polymers; while lactide has a C:O ratio 3:2 and
glycolide a ratio 1:1 the PDLLGA used was 85:15 lactide:glycolide.
The presence of silicon peaks in the XPS analysis of the polymer films (Table 5.1) indi-
cated a contaminant source. The absence of titanium, zinc, boron, potassium, and sodium
peaks in the polymer films indicated the silicon contamination was not from the glass sub-
strate. The equipment used to spincoat films was previously used to produce poly (dimethyl-
siloxane) (PDMS) films and this was identified as a likely source of contamination. In Figure
5.1B the initial water contact angle is shown for spincoated polymer films washed either with
scCO2 or with hexane. The initial water contact angles were unchanged for films washed
with scCO2: with 87.8±1.9◦ unwashed and 81.8±5.5◦ washed for PDLLA, and 80.5±1.0◦ un-
washed and 82.4±3.4◦ washed for PDLLGA. The films washed with hexane however, had
lower initial water contact angles than the unwashed films with reductions to 70.0±2.3◦
for PDLLA, to 70.3±2.6◦ for PDLLA:PDLLGA (50:50) (from 88.5±2.8◦), and to 70.4±0.7◦ for
PDLLGA. Cai et al. [287] reported similar values for PDLLA films of 69±3◦. XPS analysis of
hexane washed PDLLGA films confirmed a 98% reduction in the percentage total elemental
signal for silicon compared to unwashed PDLLGA films. This confirmed hexane washing
as an effective method of removing the suspected PDMS contaminant from the polymeric
films.
As in Chapter 3, WST-1 assays were used to assess cell viability and ALP assays were
used to assess osteogenic differentiation. Immortalised human MSCs were cultured in vitro
on hexane washed, spincoated polymer films for 4 weeks in osteogenic medium. An increase
in measured optical density over the WST-1 assay period indicated good cell viability on
all films after 1 week and 2 weeks in vitro culture (Figure 5.2. The assay results indicated
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significantly greater metabolic activity for cells cultured on PDLLGA films compared to
cells cultured on PDLLA:PDLLGA (50:50) films after 1 week. (P<0.05). After culture for 2
weeks there were indications of significantly greater metabolic activity in MSCs cultured
on PDLLA:PDLLGA (50:50) films compared to cells cultured on PDLLA films (P<0.01) and
PDLLGA films (P<0.05) (Figure 5.2B).
The osteogenic differentiation assays indicated an increase in ALP expression from 1
week to 2 weeks culture forMSCs on all films. Osteogenic differentiation after 1 week culture
was significantly less for MSCs on polymer films compared to tissue culture plastic (TCP)
controls (P<0.01) (Figure 5.3A. However, after 2 weeks there was no significant difference
in ALP expression between cells cultured on TCP, or on PDLLA and PLGA films. There
was significantly greater ALP expression in cells cultured on PDLLA:PDLLGA (50:50) films
compared to on PDLLA films and TCP (P<0.05) (Figure 5.3B. Due to failure of the DNA
assay the ALP assay results do not refer to specific activity as in Chapters 3 and 4. Therefore
the higher ALP expression evident in PDLLA:PDLLGA films may be due to increased cell
number indicated by higher metabolic activity measured by the WST-1 assays (Figure 5.2B).
Some spincoated polymer films changed shape during cell culture; film edges pulled
away from the glass coverslips and stretched towards the centre of the film. This reduced
the surface area of the films and resulted in samples that could not be used for analysis.
Even though spare samples were created, too many of each polymer type were lost, which
prevented assays being taken at 4 weeks and samples being immunohistochemically stained
and imaged. When the films are created through spincoating the forces acting on the poly-
mer molecules due to the high rotation speed likely orientates the molecules to stretch out
towards the film edges. When the rotation halts and the films are placed in cell culture
medium the stretched polymer molecules will return to a lower energy shape rather than
remain stretched out, which may cause the shrinkage of the spin coated films and formation
of the creases.
Various solutions were considered to prevent films pulling away from the edges of the
glass coverslips. Fixing the edges of the films to the coverslips with a cyanoacrylate was
considered but proved toxic to the cells. An alternative method for creating polymer films
was utilised, which involved dipping the glass coverslips in an acetone:polymer solution,
hence referred to as dipcoating. Dipcoating was theorised to cover the entire coverslip in a
polymer film rather than the upper surface only, as with spincoating. The advantage in this
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Figure 5.2:MeanWST-1 assay readings showing optical density at 450 nm for immortalised
human MSCs cultured in vitro on hexane washed spincoated polymer films for
(A) one week, and (B) two weeks in osteogenic medium (n=3). Statistically signif-
icant differences shown (* P<0.05, ** P<0.01). Error bars show standard deviation.
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Figure 5.3:Mean ALP activity for immortalised human MSCs cultured in vitro on hexane
washed spincoated polymer films for (A) one week, and (B) two weeks in os-
teogenic medium (n=3). Statistically significant differences shown (* P<0.05, ***
P<0.001). Error bars show standard deviation.
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was to prevent water ingress between the underside of the polymer films and the surface
of the glass coverslips, and prevent the film edges detaching from the glass. Unfortunately
some of the polymer films produced using the dipcoating method still pulled away from the
coverslips and crumpled inwards, which reduced the surface area and prevented the use of
the samples. This stopped assay results being collected after 4 weeks in vitro culture. Repeats
of WST-1 metabolic assays at 1 week and 2 weeks, and ALP osteogenic differentiation assays
at 2 weeks were collected for MSCs cultured on dipcoated PDLLA, PDLLA:PDLLGA (50:50)
and PDLLGA films. The results are presented in Figures 5.4 and 5.5, respectively. Highest
results for cell metabolic activity and ALP expression at 2 weeks were for cells cultured on
PDLLA:PDLLGA (50:50) films, although there were no statistically significant differences in
WST-1 and ALP assay results between cells cultured on the different polymer films in the
study.
Additionally, MSCs cultured on dipcoated polymer films for 2 weeks were immunohis-
tochemically stained for collagen-1 and imaged using fluorescence microscopy, as shown in
Figures 5.6 and 5.7. In Figure 5.6 cells cultured on areas of the polymer films that were flat
against the glass substrate (not raised away from the glass substrate/ridged) are shown.
Cells appeared to be confluent demonstrated by GFP expression (green) and DAPI nu-
clear counterstains (blue). Presence of collagen-1 (red) was indicated on glass coverslip
controls, PDLLA, and PDLLA:PDLLGA (50:50) films while negligible collagen-1 was observed
on PDLLGA films. The secondary-only control samples confirmed specificity of the fluores-
cent secondary antibody. The polymer films did not remain flat and formed creases/ridges.
Cells grew to confluency over the entire film exposed surface area, which included these
creases and raised regions. The films for the samples imaged and displayed in Figure 5.6
were not uniformly flat and cells growing on polymer film ridges in the samples are shown
in Figure 5.7. In these raised areas there was positive staining for collagen-1 on all polymer
films, including PDLLGA. This confirmed evidence of osteogenic differentiation indicated
by cellular expression of ALP.
The fluorescent images shown in Figures 5.6 and 5.7 gave qualitative results of a lim-
ited number of samples with varying surface morphology. They appeared to indicate that
osteogenic differentiation of MSCs cultured in vitro in osteogenic medium on flat areas of
PDLLA films expressed higher levels of collagen-1 than MSCs cultured on PDLLGA films,
under the same conditions after 2 weeks. They also indicated that MSCs that grew on ridged
areas of PDLLA films and PDLLGA films both express collagen-1 after 2 weeks. Lack of a
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Figure 5.4:Mean WST-1 assay readings showing optical density readings at 450 nm for im-
mortalised humanMSCs cultured in vitro on dipcoated polymer films for (A) one
week, and (B) two weeks in osteogenic medium (n=3). Statistically significant
differences shown (** P<0.01). Error bars show standard deviation.
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Figure 5.5:Mean ALP activity for immortalised humanMSCs cultured in vitro on dipcoated
polymer films for two weeks in osteogenic medium (n=3). No statistically signif-
icant differences (one-way ANOVA , Tukey’s multiple comparisons). Error bars
show standard deviation.
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Figure 5.6: Fluorescent microscope images of immortalised human MSCs cultured in vitro
on dipcoated polymer films for two weeks at ×20 magnification. Collagen-1
(red) immunostaining andHoechst nuclear counterstains (blue) were used. Scale
bars signify 100 µm. Collagen-1 was positively stained on all films other than
PDLLGA films. Secondary antibody only controls demonstrate the specificity of
the stain.
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Figure 5.7: Fluorescent microscope images of immortalised human MSCs cultured in vitro
on dipcoated polymer films for two weeks at ×20 magnification. Images show
MSCs on raised/ridged areas where films pulled away from the glass substrate.
Collagen-1 (red) immunostaining andHoechst nuclear counterstains (blue) were
used. Scale bars signify 100 µm. Collagen-1 was positively stained on all films.
Secondary antibody only controls demonstrate the specificity of the stain.
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statistically significant difference in ALP expression between cells cultured on PDLLA films
to cells cultured on PDLLGA films may have resulted from osteogenic differentiation of
MSCs on ridged areas of PDLLGA films. This differentiation may have masked differences
in differentiation on flat areas of the PDLLGA films compared to MSCs cultured on PDLLA
films, which expressed collagen-1 in both flat areas and creased areas of the films. These
results are not conclusive evidence that there are no differences in osteogenic differentiation
of MSCs cultured on PDLLA and PDLLGA flat films. The experiment should be repeated
in the future with films clamped with sterilised clips to limit changes in morphology and
prevent the raised ridges from forming. Additionally, the study would ideally be extended
to 28 days for full osteogenic differentiation and further differentiation markers stained for,
such as osteocalcin and/or osteopontin.
5.3.2 Studies of HA particle size and morphology effect on cell differentiation
The incorporation of HA particles in scCO2 foamed polymer scaffolds described within this
thesis was initially limited to microparticles at 10 wt.(%) concentration. In Chapter 3 MSCs
cultured on scCO2 foamed PDLLA and PDLLGA scaffolds with 10% HA expressed higher
levels of ALP in comparison to cells cultured on respective scCO2 foamed 100% polymer
controls. Additionally, the formation of bony matrix within milled scCO2 foamed PDLLA +
10% HA scaffolds cultured in vivo (murine) for 5 weeks appeared to be concentrated around
HA microparticles within the scaffolds. The action by which bony matrix formed around
the HA microparticles in vivo was not elucidated in Chapter 3; HA may be a nucleation
site for mineralisation to occur and/or osteoinductive properties of the HA microparticles
may prompt osteogenesis. Bony matrix within the scaffolds was desirable and it would
be regarded as an improvement to increase the rate at which it forms. To achieve this, an
increased specific surface area of HA within the scaffolds was investigated; a larger spe-
cific surface area would provide a greater number of sites around which bony matrix may
form. Smaller HA particles at the same weight concentration increased the specific surface
area. Nanoparticles of HA with two different morphologies were used: nanorods (NRs) and
nanoplates (NPs). Loosely packed HA nanoparticles occupy a larger volume than the same
weight of HA microparticles. While scaffolds containing 10% HA nanoparticles were inves-
tigated, concentrations of 1 wt.% HA NRs and NPs were also investigated that occupied
similar volumes to 10 wt.% HA microparticles within the PTFE scCO2 foaming moulds.
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Representative micrographs displayed in Figure 5.9 demonstrate the pore size and distri-
bution of scCO2 foamed PDLLA scaffolds with 10%HA (microparticles, NRs, and NPs), with
1% HA (NRs and NPs), and without HA. Scanning electron microscopy commonly detects
secondary electrons emitted by atoms excited by the electron beam of the microscope. In
the micrographs produced from secondary electron detection HA particles were difficult to
discern from the background PDLLA.
In Figure 5.9 BSE micrographs are displayed of the same areas shown in the secondary
electron beam (SB) micrographs for samples containing HA particles. Bright spots can be
seen in the BSE images that are absent in the SB images, these represent the HA particles.
This was confirmed with energy dispersive x-ray spectroscopy (EDX) as shown in Figure
5.10. Calcium and phosphorus peaks were detected when EDX was used on bright spots
identified by BSEs; these peaks were absent in areas of the images corresponding to areas
of PDLLA. Carbon was used to coat the samples imaged in Figures 5.9 and 5.10 to prevent
interference with BSE and EDX that platinum or gold (high atomic numbers: 78 and 79,
respectively) coatings may have introduced.
The micrographs in Figure 5.9 show a similar porous structure in scCO2 foamed PDLLA,
PDLLA + 10%HAmicroparticles, PDLLA + 1%NRs, PDLLA + 1%NPs scaffolds. The internal
structure of scCO2 foamed PDLLA + 10% NRs and PDLLA + 10% NPs contained smaller
pores, thicker interporous walls, and a more closed internal structure. The scaffolds that
contained nanoparticles had aggregated clumps of particles rather than a dispersed homo-
geneous mix throughout.
The compressive yield stresses of scCO2 foamed PDLLA + 10%HAmicroparticles, PDLLA
+ 1% NRs, PDLLA + 1% NPs, PDLLA + 10% NRs, and PDLLA + 10% NPs scaffolds were
recorded (Figure 5.11). One-way analysis of variance and Tukey’s multiple comparisons
revealed no significant differences between the compressive yield stresses of any of the
scaffolds. This contrasts to literature where composite scaffolds of HA nanoparticles and
poly(α-hydroxyacids), such as PLA have demonstrated improved mechanical strength over
poly(α-hydroxyacid) scaffolds alone [186, 198, 208, 254, 272–283].
The aggregation of nanoparticles prevented a homogeneous distribution throughout the
scaffolds which could have limited the strengthening of the polymer by HA particles. Meth-
ods utilised within the literature to mix HA nanoparticles used solutions of polymer in chlo-
roform or 1,4-dioxane; HA nanoparticles were added to these solutions and then sonicated
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Figure 5.8: SEM images of scCO2 foamed PDLLA scaffolds at ×500 magnification. Scaffolds
containing HA particles (indicated by arrow) (microparticles, MPs) are imaged
with both secondary beam (SB) and back scattered electrons (BSE) to highlight
the HA content.
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Figure 5.9: SEM images of scCO2 foamed PDLLA scaffolds at ×500 magnification. Scaffolds
containing HA particles (indicated by arrows) (nanorods, NRs; and nanoplates,
NPs) are imaged with both secondary beam (SB) and back scattered electrons
(BSE) to highlight the HA content.
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Figure 5.10: SEM BSE image (top) and energy dispersive x-ray (EDX) analysis spectra (bot-
tom) of scCO2 foamed PDLLA scaffolds + 10% HA microparticles at ×50 mag-
nification. Spectra taken from top left hand points (arrows) of spectrum boxes
marked on SEM image.
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Figure 5.11:Mean compression yield points for different scCO2 foamed PDLLA:HA scaffold
compositions with SD error bars (n=3). No statistical significance at P<0.05
level.
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and mixed to create particle dispersions [276, 277]. Quantitative assessment of the degree of
particle dispersion within the scaffolds produced was not used. Particle dispersions were
frozen and lyophilized, or polymer and HAwere precipitated in excess of ethanol [277]. The
use of either method could be utilised in the future to create more dispersed PDLLA + HA
nanoparticles scaffolds. The utilisation of solvents is not desirable but may be unavoidable
for desired dispersion and the benefits of nanoparticles may overcome detrimental solvent
residue effects. Additionally, the scCO2 foaming step can double as a solvent extraction step.
A comparison was made between solvent cast and particle leached scaffolds (an alternative
method to scCO2 foaming for producing porous polymeric scaffolds described in Section
1.5) to gas foamed and particle leached scaffolds within the literature [198]. They reported
gas foamed and particle leached scaffolds were more desirable than solvent cast and particle
leached scaffolds as they: exposed HA nanoparticles to a greater extent, exhibited higher
compressive moduli (4.5 MPa compared to 2.3 MPa), and demonstrated higher cell growth
rates, ALP activity, and mineralization [198]. Enhanced bone formation following in vivo
culture was also reported for gas foamed and particle leached scaffolds [198].
The integration of HA particles with PLGA scaffolds was improved within the litera-
ture through surface grafting L-lactide to the particles which resulted in improved strength
compared to the incorporation of ungrafted HA particles [273, 288]. Kutikov et al. [283]
investigated utilising polyethylene glycol (PEG) to improve structural homogeneity and
mechanical integrity in PDLLA:HA composites; a PEG containing triblock copolymer (a
copolymer comprising three distinct homopolymer subunits linked covalently) comprising
PDLLA-PEG-PDLLA was synthesised and mixed with HA particles (particle size not com-
mented on). The triblock composites (25 wt.% HA) exhibited an 8-fold increase in tensile
storage modulus and ≈0◦ water contact angle compared to >100◦ for PDLLA:HA compos-
ites. Surface grafting L-lactide to HA particles and improving the hydrophilic properties of
PDLLA through utilisation of a PDLLA-PEG-PDLLA triblock copolymer has demonstrated
improved integration of HA particles within scaffolds [283]. Investigation of these meth-
ods in scCO2 foamed scaffolds and utilisation of a PDLLA:PEG blend rather than a triblock
copolymer are viable future directions for this work.
In this work the compressive testing of the scaffolds was potentially flawed because
moulded cylindrical foams were tested rather than the polymer and HA composites as a
material. The cylinders formed by scCO2 foaming are known to have an outer skin that
is less porous. This skin was not removed and the compression of the cylinders may have
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been dominated by the compressive strength of this less porous outer skin surrounding
a more porous inner core; the strength of the outer skin may not vary significantly with
incorporation with HA particles at the concentrations used. This is likely given the lack of
statistically significant variations in compressive strength of the scaffolds tested.
The scCO2 foamed scaffolds were milled using a bone mill to produce chips of porous
scaffold onto which primary human MSCs were seeded. These seeded chips were impacted
and cultured for 2 weeks in osteogenic medium in standard cell culture conditions (37 ◦C, 5%
CO2). Cell viability on milled scCO2 foamed PDLLA, PDLLA + 10% microparticles, PDLLA +
1% HA NRs, PDLLA + 10% NRs, PDLLA + 1% NPs, and PDLLA + 10% NPs was assessed us-
ing WST-1 assays (Figure 5.12). The assay results indicated a significantly higher metabolic
activity for MSCs cultured on PDLLA scaffolds containing nanoparticles compared to MSCs
cultured on scCO2 foamed PDLLA + 10% microparticles (P<0.05 for PDLLA + 1% NRs and
1% NPs, P<0.001 for PDLLA + 10% NRs and NPs). This suggested a higher number of cells
was present on scaffolds containing nanoparticles than scaffolds containing microparticles.
There was no significant difference in the metabolic activity of MSCs cultured on scaffolds
that contained 1% nanoparticles (NRs and NPs) to MSCs cultured on PDLLA scaffolds con-
taining no HA. However, MSCs cultured on scaffolds that contained 10% HA nanoparticles
exhibited significantly greater metabolic activity than MSCs cultured on PDLLA only con-
trols. This suggested a larger cell population on scCO2 foamed PDLLA + 10% nanoparticles
(either NRs or NPs) to all other scaffolds after incubation for 2 weeks.
Alkaline phosphatase assays were carried out to assess osteoblastic differentiation (Fig-
ure 5.13). These assays were carried out following culture for 2 weeks in osteogenic medium,
of MSCs seeded onto milled PDLLA scaffolds containing HA particles. There were no sta-
tistically significant differences between the mean values of ALP specific activity results for
MSCs cultured on each of the different scaffolds. The results for MSCs cultured on PDLLA
+ 10% NPs were inconclusive, with both the highest and lowest readings for ALP specific
activity. The HA NPs occupied a large volume of the PTFE mould prior to scCO2 foaming
which affected the foamed structure formed by the PLA. Additionally, a homogeneous dis-
tribution of NPs throughout the scaffolds was not achieved by mixing HA NPs and PDLLA
powder within the PTFE moulds then scCO2 foaming. This was observed by inspection
of the scaffolds and SEM (Figure 5.9). The heterogeneous distribution of HA NPs and the
limited foaming of PDLLA scaffolds with 10% NPs may have resulted in large differences
(morphological and HA concentration) in the scaffolds that the MSCs were seeded onto.
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Figure 5.12:WST-1 assay results showing increase in optical density over 4 hr for MSCs
cultured on different scCO2 foamed PDLLA:HA composition scaffolds for two
weeks. SD error bars (n=4). Two-way ANOVA was carried out and presented
where ∗ signifies statistical significance compared to scCO2 foamed PDLLA
controls and ◦ signifies statistical significance compared to scCO2 foamed
PDLLA:10% HAMPs (∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001).
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This would account for the varied results in ALP specific activity. Disregarding the incon-
clusive results for MSCs on PDLLA + 10% HA NPs, the lowest ALP specific activity results
were for MSCs cultured on PDLLA scaffolds with no HA (0.76 nmol pNPP hr−1 ng DNA
−1) and PDLLA + 10% NRs (0.89 0.758 nmol pNPP hr−1 ng DNA −1). Higher ALP specific
activities were observed for MSCs seeded on PDLLA + 10% HA microparticles, PDLLA + 1%
NRs, and PDLLA + 10% NRs scaffolds with slightly higher results for cells cultured scaffolds
containing nanoparticles.
While the ALP results in this study were not statistically significant at the P<0.05 level,
the trends observed between MSCs cultured on scCO2 foamed PDLLA and scCO2 foamed
PDLLA + 10% HA microparticles match the trends reported in Chapter 3; MSCs cultured
on scCO2 foamed and milled PDLLA + 10% HA microparticles had a higher ALP specific
activity than MSCs cultured on scCO2 foamed and milled PDLLA (Figure 3.12). In the study
within this chapter, cells cultured on scaffolds containing 1 wt.% nanoparticles had slightly
higher ALP specific activity levels than cells cultured on PDLLA + 10% HA microparticles
(not significant at P<0.05 level). The scaffolds containing 1% nanoparticles had a poor distri-
bution of HA, for both NRs and NPs. A homogeneous distribution of HA nanoparticles may
improve the osteoinductive properties of the scaffolds with MSCs cultured on such scaffolds
potentially demonstrating improved osteogenic differentiation compared to PDLLA + 10%
HAmicroparticles scaffolds. The greater metabolic activity and similar ALP specific activi-
ties observed for MSCs cultured on PDLLA + 1% HA nanoparticle scaffolds suggest a minor
improvement based on cellular compatibility compared to PDLLA + 10% HA microparticles
scaffolds.
Following 2 weeks in vitro incubation in osteogenic medium, samples were immunohis-
tochemically stained for osteoblastic differentiation markers (collagen-1, col-1; osteocalcin,
OC; and bone sialoprotein BSP). The confocal microscopy images (Figure 5.14 indicated the
presence of col-1, OC, and BSP (green) on PDLLA + 1% NRs scaffolds. There was limited
evidence of expression of all three markers on PDLLA + 1% NPs scaffolds but BSP stained
strongly positive on PDLLA + 10% HA microparticles scaffolds. Limited staining of col-1 on
PDLLA + 10% HAmicroparticles scaffolds contrasts strong staining after 2 weeks incubation
in osteogenic medium that was observed in previous studies in Chapter 3. Some expression
of all three osteoblastic markers was evident on PDLLA + 10% nanoparticles scaffolds (both
NRs and NPs).
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Figure 5.13:Mean specific ALP activity of MSCs cultured on different scCO2 foamed
PDLLA:HA composition scaffolds for two weeks. SD error bars (n=4). No sta-
tistical significance at P<0.05 level.
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Figure 5.14: Collagen-1, Osteocalcin, and Bone sialoprotein immunostains (green) with
DAPI nuclear counterstain (red) for different scCO2 foamed PDLLA:HA com-
position scaffolds following two week incubation with MSCs viewed under
confocal microscopy. Scale bars = 100 µm.
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The combination of cellular assays and immunohistochemical staining suggested that
PDLLA + 1% NPs scaffolds may be more favourable than PDLLA + 10% HA microparti-
cles. However, the differences observed were minor and the use of nanoparticles in scCO2
foamed PDLLA scaffolds needs further investigation for application as allograft alternatives.
Specifically, the study period should be extended to 4 weeks (the time for full osteoblastic dif-
ferentiation), and mechanical shear testing is required. Additionally, focus should be placed
on producing homogeneous distributions of particles within the scaffolds, and avoiding
particle agglomeration to improve the mechanical strength and provide a greater surface
area of osteoinductive HA.
Compressive dynamicmechanical analysis (DMA) tests were performed on scCO2 foamed
PDLLA:HA composite scaffolds (10 wt.% HA microparticles, 1 wt.%, and 10 wt.% HA NRs
andNPs). However, the results between identical samples variedwidely with large standard
deviations and for this reason the results were not included. The variation was attributed to
heterogeneous distributions of HA particles within the scaffolds. Further DMA tests (dual
cantilever bending) were conducted on PDLLA:HA composite bars (results not included).
The PDLLA:HA composites were created by dispersing HA particles (through sonication
and mixing) in a PDLLA solution in 1,4-dioxane, followed by venting then lyophilization.
Thermogravimetric analysis of the composites confirmed presence of solvent within the
PDLLA:HA composite bars tested and it was for this reason the results were not included.
These tests should be repeated and a scCO2 solvent extraction step added prior to forming
the PDLLA:HA composites into uniform bars for mechanical characterisation.
5.4 Conclusion
Results presented in Chapter 3 demonstrated that the osteogenic differentiation of MSCs
differed between cells cultured on PDLLA and PDLLGA scaffolds, a novel result. The work
presented in this chapter was undertaken to investigate this. Polymer films were used rather
than foamed scaffolds to remove any morphological differences that were present in the
foamed scaffolds in Chapter 3. It was demonstrated that there were no significant quantita-
tive differences in hMSCs cultured in vitro on PDLLA and PDLLGA films. Proliferation and
osteogenic differentiation were assessed with WST-1 and ALP assays, respectively, at one
week and two week time-points.
Qualitative immunohistochemical stains were also used to visualise any differences.
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Collagen-1 immunohistochemical stains after 2 weeks demonstrated absence of collagen-1
in flat areas of PDLLGA films; the same was not observed on PDLLA and PDLLA:PDLLGA
(50:50) films. The presence of col-1 was confirmed on ridged areas of all films, which demon-
strated osteoblastic differentiation of cells on both polymers. Morphology, surface roughness,
degradation rates, and polymer stiffness may all affect osteoblastic differentiation of cells
cultured on these polymers. The wettability of the films was characterised, and there was
no significant difference between PDLLA and PDLLGA films. Both polymers were matched
for MW and inherent viscosity according to manufacturerâA˘Z´s specification sheets.
Throughout the culture period the polymer films pulled away from the glass substrate
and ridges were formed which affected the results. Spincoated films were used initially,
followed by dipcoated films used in an attempt to avoid the formation of ridges. Clamping
edges of the films to prevent changes to polymer film topology throughout culture is advised
for a repeat experiment. Experiments should be extended to four weeks to allow for comple-
tion of osteogenic differentiation protocol and compare differences in MSC differentiation
on PDLLA and PDLLGA scaffolds over this time period.
Within the literature and in Chapter 3 the importance of HA particles in scaffolds for
bone regeneration is established. In Chapter 3 scaffolds incorporating HA microparticles
demonstrated improved performance in vivo, which stimulated further studies. In this chap-
ter human MSCs were seeded on milled scCO2 foamed PDLLA scaffolds containing either
HA NRs or NPs at 1 wt.% and 10 wt.% concentrations, or microparticles at 10 wt.% con-
centration with milled scCO2 foamed pure PDLLA scaffolds as controls. The seeded milled
scaffolds were impacted to mimic IBG and cultured for two weeks in osteogenic medium.
There was evidence of improved MSC proliferation on scaffolds containing HA nanoparti-
cles compared to HA microparticles. No significant differences in the yield stresses of all
scaffold compositions tested were observed.
The osteoblastic differentiation of MSCs appeared enhanced on scaffolds containing
10 wt.% microparticles or 1 wt.% HA nanoparticles (for both rods or plates) compared to
PDLLA control scaffolds. Osteoblastic differentiation of MSCs was comparable between cells
cultured on PDLLA and PDLLA + 10 wt.% NRs scaffolds. The results were inconclusive
for PDLLA + 10 wt.% HA NPs scaffolds. Scaffolds containing 10 wt.% HA nanoparticles
morphologically differed from pure PDLLA and PDLLA + HA (10 wt.% MPs and 1 wt.% HA
nanoparticles) scaffolds due to the high relative volume of HA nanoparticles, which affected
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scCO2 foaming, and the poor dispersion of particles within the scaffolds; morphological
differences will have affected results observed and limit conclusions that can be drawn.
PDLLA + 1 wt.% HA nanoparticles provided equivalent compressive strength to other
scaffolds and demonstrated improved MSC proliferation and differentiation with no quan-
tiative differences between scaffolds containing NRs or NPs. Qualitatively, immunohisto-
chemical stains demonstrated greater evidence of osteocalcin on PDLLA + 1 wt.% NRs.
The use of scCO2 foamed PDLLA scaffolds containing 1% HA nanoparticles appeared
the most promising scaffold formulation, of those tested, for MSC culture on the scaffolds
when used for IBG. The volume of 1 wt.% HA NPs is roughly equivalent to that of 10
wt.% HA microparticles (as loosely packed powders). Greater proliferation and osteoblastic
differentiation of MSCs was observed for cells cultured on scCO2 foamed PDLLA containing
1 wt.% HA NPs than on scCO2 foamed PDLLA foamed controls and those containing 10
wt.% HA microparticles.
Further work is required to improve the dispersion of nanoparticles within the scaffolds,
characterise the mechanical properties of nanocomposites, optimise HA concentration, and
characterise porosity and pore size. Organic solvents (chloroform or 1,4-dioxane) are utilised
within the literature to create HA nanoparticle dispersions. The use of organic solvents in
these scaffolds is undesirable, however scCO2 may be investigated as an extraction process
should nanoparticle containing scaffolds continue to offer improved results.
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The current material used in impaction bone grafting to rebuild bone stock within the
femur, allograft bone, is not ideal; inspite of this it remains the clinical "gold standard".
The increasing number of revision hip arthroplasty procedures, which commonly require
impaction bone grafting, and limited allograft supply, place increasing demand for an alter-
native. The risk of transmission of infectious agents is, however small, a present and real
risk with the utilisation of allograft bone, and indeed all allogeneic tissue grafting. Allograft
bone, unlike autograft bone, has no osteogenic properties, which can be introduced into an
alternative by utilising stem cell populations, specifically MSCs.
The growth of the regenerative medicine field and the investigation of porous polymeric
scaffolds introduced the possibility for alternative materials for bone repair. The proper-
ties of bone vary with location and function and the desired qualities in synthetic scaffolds
for bone repair also change with the desired function. For revision hip arthroplasty a com-
mon prosthesis failure mechanism is femoral stem subsidence, where the implant sinks
further into the femur than was desired with subsequent impairment to joint functionality; a
resistance to the shear forces experienced within the femur is therefore desirable in graft ma-
terials. Material, such as allograft bone, is impacted into the femur and must also resist these
impaction forces. Additionally, when cell populations are impacted with the graft material,
it must be able to protect the cells from the forces to ensure that a viable cell population
survives the implantation procedure.
The work presented within this thesis describes the performance of supercritical CO2
foamed polymer scaffolds in experiments designed to determine the suitability of these scaf-
folds for impaction bone grafting. Allograft bone is milled in a bone mill to create small
chips of bone for impaction bone grafting and scCO2 foamed scaffolds were milled in this
way for both in vitro and in vivo experiments contained within this thesis. In Chapter 3, me-
chanical shear experiments demonstrated the superiority of scCO2 foamed scaffolds (PDLLA
and PDLLGA) over non-foamed scaffolds of the pure polymers and allograft bone. Cellular
studies within the same chapter determined superiority in terms of proliferation and differ-
entiation of MSCs on scCO2 foamed scaffolds over non-foamed scaffolds and higher levels
of osteoblastic differentiation after two weeks of MSCs on PDLLA scaffolds over PDLLGA.
The inclusion of 10 wt.% HAmicroparticles demonstrated no significant differences in shear
resistance of milled scCO2 foamed scaffolds of both polymers, and higher levels of osteoblas-
tic differentiation of MSCs. These experiments also demonstrated survival of MSCs seeded
on scCO2 foamed scaffolds through a simulated impaction procedure.
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The most promising formulation at this stage was scCO2 foamed PDLLA scaffolds con-
taining 10 wt.% HA microparticles. This was established through in vitro cellular experi-
ments and a subcutaneous murine model. For the small-scale murine in vivomodel scCO2
foamed scaffolds were milled, sterilised, seeded with MSCs, and then impacted into open
ended pots which were implanted for 5 weeks. Controls without MSCs were also used. The
presence of bony matrix was detected within the implanted pots using µCT and significantly
higher levels were observed within the pots containing scCO2 foamed PDLLA scaffolds with
10 wt.% HA microparticles. Scaffolds containing HA implanted without MSCs showed sig-
nificantly higher levels of new bony matrix than PDLLA scaffolds without HA implanted
withMSCs. This demonstrated a high level of osteoinduction for PDLLA scaffolds containing
HA.
In Chapter 4 scCO2 foamed PDLLA scaffolds containing 10 wt.% HAmicroparticles were
investigated in a large animal in vivo model. Autologous ovine MSCs were seeded on the
scaffolds prior to implantation and controls without cells were also used. Histological stain-
ing and µCT analysis demonstrated the formation of new bone within the condyle defects.
This was far more pronounced within condyles filled with milled scCO2 foamed scaffolds
without MSCs. This result was unexpected as results reported within literature demonstrate
improved bone regeneration when MSCs are utilised. Parallel in vitro studies suggested
limited osteoblastic differentiation of the MSCs and the ovine cells likely required different
differentiation media to human cells which were used in the investigations prior to the ovine
in vivo study. In vivo incubation of scCO2 foamed PDLLA + 10 wt.% HAmicroparticles for 12
weeks within an ovine condyle defect demonstrated formation of new bone and indicated
over time full healing of the defect site may be anticipated. There is potential for further
improvement of the scaffolds through inclusion of osteoinductive factors such as BMP-2 that
can be incorporated within the scaffolds through the scCO2 foaming process. Additionally,
further in vivo studies that utilise an optimised ovine osteoblastic differentiation procedure
for MSCs of the appropriate animal (e.g. sheep) are likely to demonstrate greater healing
and improvement in line with findings reported within the literature.
Chapter 4 also contained studies that demonstrated the potential scale-up of manufac-
turing scCO2 foamed scaffolds. The potential to produce one hundred and eighty scCO2
foamed scaffolds (54 g) within a single vessel in a single batch was shown in a 1000 ml vessel.
This represents a scale-up of 3000% compared to the six scaffolds per batch (1.8 g) capable in
the 60 ml lab-scale autoclave used to produce the scaffolds utilised in the in vivo and in vitro
180
CHAPTER 6 : F I NAL CONCLUS IONS
studies within this thesis. The scaffolds produced in the 1000 ml vessel had little variation in
porosity and mean pore size based on their location within the vessel when foamed. While
the porosities of scaffolds produced in the larger vessel matched those produced in the 60
ml autoclave their internal structures differed; optimisation of the scCO2 foaming protocol
to match scaffolds produced in the larger vessel to those produced in the smaller vessel is
required. Furthermore, a repeat of experiments performed with scaffolds produced in the
60 ml autoclave with scaffolds produced in the 1000 ml vessel would further confirm the
potential scale-up of scCO2 foamed scaffolds. The evidence presented here provides proof-
of-concept of the potential to scale-up the scCO2 foaming process. This scale-up potential is
necessary for scCO2 foamed scaffolds to be a viable synthetic alternative to allograft bone.
The work in Chapter 5 investigated differences observed in MSC osteoblastic differentia-
tion when cultured on PDLLA scaffolds to PDLLGA scaffolds. Utilisation of polymer films
rather than foamed scaffolds removed morphological differences in the scaffolds that were
present in the foamed scaffolds. These experiments were inconclusive due to the polymer
films lifting away from the glass substrates and becoming crumpled. There was evidence of
collagen-1 on both PDLLA and PDLLGA films in crumpled regions, demonstrating osteoblas-
tic differentiation on both films. The collagen-1 expression observed on PDLLA films in flat
regions was not observed on PDLLGA films. Differences in the osteoblastic differentiation
may be due to several variables that include morphology, surface roughness, degradation
rates, polymer stiffness. The wettability of the films was characterised, and there was no
significant difference, while the polymer MWs and inherent viscosities were matched for
PDLLA and PDLLGA for these studies.
The importance of HA particles demonstrated in Chapter 3 through superior perfor-
mance in vivo of scCO2 scaffolds PDLLA scaffolds + 10 wt.% HA microparticles stimulated
further studies. The incorporation of HA nanoparticles was investigated in scCO2 foamed
PDLLA scaffolds. While aggregation of nanoparticles was a problem, MSCs cultured on scaf-
folds containing 1 wt.%HA nanoparticles, a similar volume to 10 wt.%HAmicroparticles (of
loosely packed powder), demonstrated greater proliferation and osteoblastic differentiation
to MSCs cultured on scCO2 foamed PDLLA containing 10 wt.% HA and no HA. To overcome
aggregation of nanoparticles and create homogeneous dispersions of nanoparticles within
scCO2 foamed scaffolds methods in the literature utilise organic solvents such as chloroform
or 1,4-dioxane. This is not desirable, however, and the scCO2 foaming process may also be
investigated in the future as an extraction process, should nanoparticle containing scaffolds
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continue to offer improved results over microparticles.
Overall, the work presented in this thesis has demonstrated that scCO2 foaming has the
potential to create polymeric scaffolds suitable for impaction bone grafting and production
on an industrial scale would be possible. Optimisation of specific formulations to be utilised
remains to be performed. From the studies presented here PDLLA (MW ≈ 110 kDa) scaffolds
containing HA microparticles (10 wt.%) have the potential to regenerate bone in vivo both
with and without MSCs.
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Appendix 1
Supercritical CO2 foaming standard operating procedure
The standard operating procedure of the high pressure foaming rig is detailed as follows:
Please refer to Figure 2.1 for equipment layout. The inlet valve is valve 1 and the outlet
valve is valve 2.
Preparations
• Ensure the external thermocouple is attached to the band heater.
• Ensure the rig is at atmospheric pressure by checking valve 1 is closed, valve 2 is open,
and the safety key is unscrewed.
• Switch on the power supply of the pressure indicator, back pressure regulator, and
temperature controller.
• Select the temperature for the pressure vessel at the temperature controller. The tem-
perature may overheat during the initial 5 minutes of heating.
• Wait for a stable temperature to be obtained.
• Place the prepared and closed foamingmould into the pressure vessel. Close the vessel,
tighten the clamp, and screw in the security key.
• Open outlet valve (valve 2).
Starting the procedure
• Start the program FlowDDE. Select "open communication" in menu " communication".
Wait for response "server is active and ready for any client".
• If temperature recording is desired start PLWRecorder. Click "new file", select directory
and filename and click "save". Click "start recording" to start temperature log.
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• Start the program FlowPlot. Click "setpointscript" in menu "extra". Click "load" and
open filename (e.g. 20 60 30 program HY.txt) (switch "files of type" to "all files".
• Close menu "setpointscript". Click "script" buttion (NOT "start" button). Three lines
will be displayed: red indicates the pressure setpoint, green indicates the measured
pressure, yellow indicated the BPR opening in %.
• Wait for the pressure set-point (red) to reach the value 5. Carefully open the inlet valve
(valve 1). The Pickel pump will begin pumping.
• Ensure with the Pickel pump operating there is no blocking between the inlet valve
and the BPR through obersvation of an increase in the internal pressure (green line).
• Keep the valve opening line (yellow) between 25–35% by regulating inlet valve (valve
1). During the vent phase valve 1 may be almost closed.
Shutting down
• If the program has finished completely close the inlet valve (valve 1). If desires save a
screen shot of the flow plot window.
• Switch off temperature controller.
• Click "stop recording" on PLW Recorder. Select "close communication" in men "com-
munication" of FlowDDE. Exit all programs.
• Ensure the pressure has reached atmospheric pressure (pressure indicator). Unscrew
safety key and open pressure vessel. Remove the sample.
• Switch off pressure indicator and back pressure regulator.
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